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Summary 
p53 is among the most thoroughly studied proteins to date. Its tumour suppressor 
activity and the consideration that inactivation of the p53 pathway is a common, if not 
universal, feature of all human cancers, have gained it the interest of a multitude of 
researches seeking new therapies against this disease. As a consequence, p53 is at the 
centre of a feverish research and nowadays is reported to be involved in most cellular 
processes. Despite the vast amount of data published, much is yet to be unravelled about 
the mechanisms regulating the p53 signalling network. Indeed, the p53 network is 
extremely intricate and complex, and from a system biology point of view it can be seen 
as a series of interconnected negative and positive feedback loops, which can give rise to 
complex dynamics such as oscillations. In the combined effort to understand more of the 
biological meaning of these oscillations and to study the properties of this network motif 
from an engineering perspective, a synthetic p53 network has been built in budding yeast 
with the aim of studying the network in isolation while being embedded in living cells. 
p53 and most proteins in the network are absent from the budding yeast genome. This 
diminishes the likelihood of interferences on the engineered module from the cellular 
environment. Surprisingly, despite the evolutionary conservation of the ubiquitin 
pathway from yeast to humans, p53 ubiquitylation by the E3 ubiquitin ligase Mdm2 - an 
event central to the oscillatory dynamics of the system - does not appear to take place in 
budding yeast, even when the human E2 enzyme UbcH5B is exogenously expressed. p53 
is instead sumoylated by Mdm2 and sumoylation dictates the co-localization of p53 and 
Mdm2 to a nuclear body reminiscent of human PML bodies. In conclusion, attempting to 
rebuild from scratch a simplified version of the intricate p53 network, isolating it from its 
natural context, has proven to be a very powerful means leading to unexpected findings, 
testifying the usefulness of the synthetic biology approach.  
 
 
 Zusammenfassung 
p53 gehört zu den bislang am häufigsten untersuchten Proteinen. Seine Rolle als 
Tumorsupressor und die Tatsache, dass der p53 Signalweg in den meisten, wenn nicht 
gar allen, menschlichen Krebsarten blockiert ist, weckte das Interesse zahlreicher 
Forscher auf der Suche nach neuen Therapien. Infolge seiner fieberhaften Erforschung 
findet man dieses Protein inzwischen an den meisten zellulären Vorgängen beteiligt. 
Trotz dieser enormen Datenmenge ist die Regulation des p53 Signalnetzwerkes aber noch 
keineswegs verstanden. Tatsächlich ist das p53 Netzwerk extrem verschlungen und 
komplex. Aus Sicht der Systembiologie stellt es sich als eine Aneinanderreihung 
miteinander vernetzter positiver und negativer Rückkopplungsschleifen dar, deren 
komplexe Dynamik zum Beispiel zur Ausbildung von Oszillationen führen kann. Um 
einerseits die biologische Funktion dieser Oszillationen zu verstehen, sowie andererseits 
die Eigenschaften des Netzwerkes unter systembiologischen Aspekten zu untersuchen, 
habe ich ein synthetisches p53 Netzwerk in Sprosshefe eingeführt. Dies erlaubte die 
Untersuchung des Netzwerkes in lebenden Zellen bei gleichzeitiger Entkopplung von der 
natürlichen Umgebung; p53 und die meisten der mit ihm verbundenen Proteine fehlen im 
Genom der Sprosshefe. Dies verringert die Gefahr von Wechselwirkungen zwischen dem 
synthetischen Modul und der Wirtszelle. Erstaunlicherweise, trotz der evolutionären 
Erhaltung des Ubiquitin-Signalwegs zwischen Hefe und Menschen, wird p53 in 
Hefezellen nicht von der E3 Ubiquitin Ligase Mdm2 ubiquitiniert. Diese Reaktion spielt 
im menschlichen System eine Schlüsselrolle bei der Ausbildung von Oszillationen. In 
Hefezellen bleibt sie jedoch selbst dann aus, wenn das menschliche E2 Enzym UbcH5B 
zusätzlich exprimiert wird. Stattdessen wird p53 von Mdm2 sumoyliert, und diese 
Sumoylierung führt zur Co-Lokalisierung von Mdm2 und p53 in einem Kernkkörper mit 
Ähnlichkeit zu menschlichen PML-Körpern. Der Versuch, eine vereinfachte Version des 
p53 Netzwerkes ausserhalb seiner natürlichen Umgebung aufzubauen, erwies sich 
schliesslich als hervorragender Weg zu neuen Erkenntnissen und bestätigt den 
Forschungsansatz der synthetische Biologie. 
 
Aim of this study 
The aim of this study was to build a synthetic p53-Mdm2 module in isolation 
from its natural genomic and proteomic environments, ascertain its sufficiency in 
generating oscillations, determine whether the properties of these oscillations (e.g. period, 
amplitude) would be translated into the preferential activation by p53 of genes involved 
in apoptosis or cell-cycle arrest and investigate the robustness of the design, since 
synthetic oscillators are typically noisy as compared to natural ones (Elowitz et al., 
2000). Taking advantage of the minimal design of the network, we also aimed at better 
understanding the relation between p53 and Mdm2 in the absence of other proteins that 
constitute the intricate p53 regulatory network in human cells. 
We chose Saccharomyces cerevisiae as a host because it is a eukaryote for which 
homologues for p53 and Mdm2 have not been identified so far, making it a perfect model 
organism to study the p53-Mdm2 system “in isolation”; the term “isolation” does not 
mean that the synthetic module is cut out from any endogenous cellular processes, rather 
that its communication with the environment comes in a well-defined manner so that in 
the end the relations among the components of the circuit are only the designed ones 
(Kobayashi et al., 2004).  
Working with p53 in yeast has several advantages. First, one can over-express it in the 
absence of Mdm2 without incurring in undesirable outcomes such as cell-cycle arrest or 
apoptosis. For several key regulators in the p53 network (e.g. p300, p14ARF, 
promyelocytic leukemia protein (PML)) yeast homologues have not been identified so 
far, giving us more confidence in interpreting the results in view of p53 and Mdm2 action 
only. Notably, in human cell lines, even if RNAi is used to selectively eliminate certain 
proteins from the cell in order to study the effects of a single cellular factor on p53,  the 
observed behaviour could still be due to some other protein(s) present in the network, 
whose contribution to p53 regulation is yet to be uncovered. Furthermore, yeast has a 
number of features (beyond rapid growth, ease of handling, etc.) which make it 
particularly suitable for our purposes; mainly the availability of several studies that 
compare specifically yeast and human cellular processes or machineries (Vijay-Kumar et 
al., 1987; Yasugi et al., 1996; Huang et al., 2001), easy retrieval of information on yeast 
homologues of human proteins and finally a highly versatile DNA transformation system 
which gives us flexibility in the number of components of the p53 network we wish to 
include in our circuit.  
The idea of expressing p53 and Mdm2 in yeast is not novel. Back in 1993, the Vogelstein 
laboratory used S. cerevisiae to prove that Mdm2 is able to bind the p53 transactivation 
domain thus blocking p53-dependent transcription (Oliner et al., 1993). Several other 
laboratories have been exploiting the ability of p53 to interact with the yeast transcription 
machinery to study aspects of p53 transcriptional activation (Ishioka et al., 1993; Flaman 
et al., 1995; Pearson et al., 1998; Waddell et al., 2001; Kato et al., 2003).  
Mdm2-mediated p53 degradation in yeast, though, was never shown and, if we exclude 
the pioneering work of the Vogelstein laboratory, no other work was ever published on 
p53 and Mdm2 dynamic interaction in yeast.  
Inspired by the work carried out in the Alon laboratory, where by fluorescence 
microscopy they studied the p53-Mdm2 oscillations in single human cells (Lahav et al., 
2004), we decided upon using the fusion proteins p53-ECFP and Mdm2-EYFP to obtain 
single-cell data, which would be useful in studying the noise of our synthetic circuit.  
Being mathematical modelling an important aspect of a synthetic biology project, we also 
planned to model the synthetic p53-Mdm2 circuit. To pave the way towards building a 
sound model, we first wanted to investigate and compare different mathematical 
formalisms and modelling approaches. 
In summary, the aims of this project lied on two different levels: a) the engineering level, 
which consisted of building a synthetic circuit using both transcription and post-
translational modifications to generate oscillations and studying its robustness to noise, 
while at the same time identifying the most suited mathematical formalism to model the 
synthetic network; b) the biological-biochemical level, which consisted in taking 
advantage of an over-simplified interaction network to better understand the p53-Mdm2 
regulatory dynamic interactions.   
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Synthetic biology 
 
“Practise what you know, and it will help to make clear what now you do not know” 
 
Rembrandt Harmenszonn van Rijn 
 
Synthetic biology is a striking term: it’s the juxtaposition of contradictory words 
and therefore it grabs people’s attention. Synthetic refers to something artificial, 
something that is being created from scratch often as an imitation of a natural 
counterpart. Biological is, on the contrary, a synonym for genuine, unaffected. Although 
this effectual expression isn’t new in that it dates back to the 1980’s, when it referred to 
the use of recombinant DNA technology, it is only recently that synthetic biology has 
gained recognition as a new branch of molecular biology, with its own goals and 
strategies. The idea of inferring the properties of a system through the analysis of its 
reaction to perturbations has been used from the beginning of times in biology as in other 
sciences and the advent of a technology allowing the manipulation of the genetic code 
has indeed widen the horizons for such perturbation analysis (e.g. inserting an additional 
copy of a certain gene, putting a gene under a different promoter, expressing 
heterologous genes in a host species). The ascertainment that in any molecular biology 
enterprise unnatural situations are forced to occur leads many scientists to believe that 
synthetic biology is nothing more than a term, misused and abused by a group of people 
(mainly engineers converted to biology) trying to attract public opinion’s interest. Several 
characteristics distinguish, in my opinion, modern synthetic biology from other molecular 
biology approaches:  
1. the will to construct organisms that have never appeared before 
2. the will to manipulate organisms to function in a way they never did before 
3. the combination of analysis and synthesis to understand biological processes and 
extract general “design rules” which have emerged from evolution 
4. the use of rational design, typical of engineering disciplines, which implies 
cycling between definition of system specifications, mathematical modelling and 
simulation, prototype building and testing before reaching the final functional 
implementation 
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5. the interdisciplinarity which brings biologists, engineers, physicists, chemists and 
mathematicians together. 
 
Constructing new organisms fulfilling a set of man-posed requirements sounds very 
much like science fiction and brings about long philosophical discussions on the timeless 
desire of human kind to create life, possibly immortal. Despite their falling into the 
synthetic biology category, I will not discuss these fascinating attempts to make 
organisms from scratch using minimal genomes (Kobayashi et al., 2003) or totally 
artificial ones (Smith et al., 2003), or to make synthetic vesicles capable of supporting 
protein production (Noireaux et al., 2004) and, as final goal, division.  
More practical social impact have, instead, those synthetic biology endeavours dealing 
with the modification of organisms in order to obtain benefits like low-cost drug 
production (Martin et al., 2003; Herrera, 2005), ecological welfare (Gilbert et al., 2003) 
and biomedical discoveries (Benner et al., 2003).   
Synthetic biology, in this context, is a reverse engineering exercise: there is a product out 
there, that someone else has built, and you want to understand how it works, with the 
final aim to change the specifications and implement your own design. What you need to 
do is dismantle the product, take each part and understand it well, as a single entity first; 
then, use the parts as building blocks to interconnect in search of a complex function. The 
advantage of this approach is that, while building your own product using the parts 
extracted from the pre-existing one, you are very likely to learn much more about this 
latter than you would if you stopped once reduced the object to pieces. A beautiful 
example of how synthesis can lead to new discoveries and paradigm shift is offered by 
the Watson-Crick model of the DNA. The model was so simple that nobody ever doubted 
that the pairing rules for the nucleobases were the only essential feature of this incredible 
molecule. Only when attempts to create synthetic self-replicating molecules started, did it 
become clear that the repeating-charged backbone, thought to be dispensable up to that 
moment, was in fact an essential characteristic to make DNA the genetic code carrier 
(Hutter et al., 2002).  
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Synthesis of unnatural nucleobases also allowed proving that the pairing rules were 
indeed as simple as predicted by the model and, as a matter of fact, twelve additional base 
pairs were artificially introduced (Geyer et al., 2003). 
For a synthetic biologist, the final product could be the cell for instance, and the building 
blocks the so-called network motifs. The latter are cross-species recurrent functional 
modules comprising a stand-alone “body” (i.e. genes and proteins, characterized by their 
own biochemical properties and kinetics, connected according to a certain topology), 
which performs a specific function (the output) in response to external stimuli, sensed by 
the module through a well-defined interface (Yeger-Lotem et al., 2004).  
The concept of module is well-known in computer science, where it represents a piece of 
software that groups cohesive subprograms and data structures, can be independently 
compiled and provides a separation between interface – defining the objects required and 
supplied by the module – and implementation – the actual working code referring to the 
objects defined in the interface. Modularity is a highly desirable quality for complex 
software, because it means the possibility to reuse modules in different contexts (instead 
of writing dedicated programs each time), to hide information, which makes the software 
friendlier to anyone approaching it, finally allowing a very efficient tasks distribution 
among several programmers. Modularity is turning out to be just as good in molecular 
biology for synthetic purposes (Hartwell et al., 1999). In fact, only thanks to the 
modularity of biological processes it is now possible to extract such circuits, test their 
context-free functionality, and then assemble them in new ways which never occurred 
inside a cell. Until recently, despite the evidence of its existence, modularity wouldn’t 
come out as an emergent property of in silico evolved circuits. Only with the introduction 
of a modularly varying goal (i.e. each goal is made of a different combination of sub-
goals), did Kashtan and Alon find that networks are selected to be modular (Kashtan et 
al., 2005); and modularly varying goals seem to be a reasonable assumption requiring 
that the environment changed so that new functions could be obtained by different 
combinations of a set of basic biological functions.  
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The isolation and characterization of biological modules have been the obligatory starting 
points of the nascent synthetic biology field, since, as previously mentioned, in a reverse 
engineering approach it is essential to know the behaviour of each individual building 
block before assembling many blocks in any desired way (Becskei et al., 2000; Gardner 
et al., 2000; Becskei et al., 2001; Kobayashi et al., 2004; Kramer et al., 2004).  
Extracting a network motif, plugging it again inside a cell, isolating it from the other 
cellular processes, is probably the trickiest part of a synthetic biology project, first of all 
because the concept of isolation is somewhat cryptic. Isolating a module does not mean 
putting it into an air bubble with no connections to the cellular environment! Indeed, the 
module becomes “alive” only provided it can successfully interact with endogenous 
machineries that will transcribe genes, translate mRNAs into proteins, transport them to 
the right cellular locations, degrade them when needed, etc. Communication with the 
environment has to come in a well-defined manner, though, via specific predictable 
inputs, so that in the end the relations among the components of the circuit are only the 
designed ones (Figure 1.1) (Kobayashi et al., 2004).  
It should be noted that, although it is in principle possible to connect modules in any 
desired way, the resulting networks have not been optimized by evolution and it is likely 
that a considerable amount of work needs to be done in order to obtain a functional 
circuit out of this assembly. Still, the number of examples of successful construction of 
complex networks from simpler modules is increasing (Pourquie, 2003; Blatten, 2004; 
Guido et al., 2006).   
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Figure 1.1 | Example of a synthetic module with its interface and output. The 
interface represents the communication channel between the module itself and the 
cellular environment acting upon the module, which ensures the isolation of the module 
from the remaining cellular processes. The separation between these entities (represented 
by dashed lines) is only for explanatory reasons, because there is no physical separation 
inside the cell between module and endogenous components. To show some of the 
interactions which are required for the module to function, I depicted cellular machineries 
(like the transcriptional, translational and proteolytic - pacman - ones) in colour, while 
the synthetic network is shown in black and white. DNA damage is the external stimulus 
to which the circuit responds. Once RecA gets activated upon damage, it cleaves cI 
making it inactive and therefore inhibiting its repressor activity on the PL* promoter. 
Transcription from this promoter leads to the expression of lacI, which represses 
transcription of cI, and to the expression of traA, which induces biofilm formation 
(output of the network). Adapted from (Kobayashi et al., 2004) 
 
 
Mathematical modelling and simulation offer to synthetic biologists the opportunity to 
validate their designs before realizing them, which is common practise in any engineering 
discipline. Mathematical models can be derived for any biological process, synthetic or 
not; the advantage of modelling a synthetic network resides in the fact that the network 
components are chosen among well-characterized ones, and also they are connected in a 
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predefined way, so that the topology of the network, as well as at least an idea of the 
parameters ranges, are available (mathematical modelling is discussed in more detail in 
the paragraph “Mathematical modelling of biological networks”).  
Mathematical modelling of biochemical networks is not an easy task and there are many 
pitfalls that could lead to false predictions (see Results Part One). Moreover, noise in 
biological processes like transcription and translation – due to small numbers of 
molecules as well as events that fire rarely – makes it more difficult to predict the output 
of a circuit. In this respect, synthetic networks have been extremely useful in the study of 
noise properties (e.g. noise reduction, amplification, and propagation; distinction between 
intrinsic and extrinsic noise) (Becskei et al., 2000; Hooshangi et al., 2005; Pedraza et al., 
2005; Rosenfeld et al., 2005; Dublanche et al., 2006; Hooshangi et al., 2006), mainly 
because of the degrees of freedom they offer in respect to endogenous networks.  
Despite all their limitations, modelling and simulation offer great benefits to the 
experimentalists, as beautifully exemplified by several synthetic biology efforts which 
are proving the symbiosis between theory and bench work possible (Elowitz et al., 2000; 
Atkinson et al., 2003; Kobayashi et al., 2004; Fung et al., 2005).  
Synthetic networks can also be used to study natural circuits. Most of the times, only a 
simplified version can be obtained (either due to technological limitations - length of 
DNA that can be inserted into a plasmid, number of plasmids that can be simultaneously 
introduced in a cell, possibility to separate different wavelengths to follow many proteins 
at the same time in vivo, etc - or due to incomplete knowledge), but there are many 
advantages in using synthetic networks to study natural ones.  
First, the synthetic circuit can be more freely modified, thanks to the use of inducible 
promoters, re-wiring of regulatory proteins for them to act upon uncommon targets, 
manipulation of proteins’ half-life, engineering of receptors to bind unnatural ligands and 
start signalling cascades upon unnatural inputs, etc. The fact that the synthetic network is 
in principle isolated from the rest of the cell means that the manipulations can be carried 
out without incurring into downstream side-effects (e.g. that an over-expressed 
transcription factor started several signalling pathways, some of which might lead to cell 
death).  
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Also, making slightly different versions of the same circuit can help elucidate the 
importance of a design detail, for instance the impact of the length of a signalling cascade 
on noise and timing of response (Hooshangi et al., 2005). 
Although studying natural circuits with a synthetic biology approach is indeed very 
fruitful for the above mentioned reasons, it is clear that this is an application-oriented 
discipline, its strongest motivation being the desire to build something - from scratch or 
reassembling what’s already out there -, rather than simply contemplating what Mother 
Nature has done. From the first examples of synthetic circuits, which can be honestly 
described as beautiful toys with little relevance to anything of practical use, but which 
represent the steps towards acquiring the necessary skills, we are now witnessing a shift 
towards more and more complex networks that are actually achieving something. For 
instance, the production of artemisin, the precursor of an anti-malaria drug currently 
present on the market, through a synthetic pathway engineered in Escherichia coli 
(Martin et al., 2003), or the coordination of cellular behaviour in cell populations using 
engineered cell-cell communication networks, which would benefit diverse 
biotechnology applications like fermentation processes, biomaterial production and tissue 
engineering (Chen et al., 2005). 
Just like the advent of recombinant DNA technology raised many doubts and questions 
about the ethics of pursuing genetic modifications on organisms, with unknown 
consequences for the society, synthetic biology carries the fear that these engineered 
organisms (e.g. nasty viruses which never existed before and therefore are dreadful more 
than any other) can escape the laboratories and infect the world. On the contrary of what 
happened in the past, though, nowadays a good communication between science and 
society on these delicate issues is being pursued and synthetic biologists are trying to 
device ways to prevent abuses of these newly acquired skills (Ball, 2004). For example, 
“control networks” can be used to keep population density of modified organisms under a 
certain threshold, or to kill the cell once the function it has been designed for is fulfilled. 
Also, it is noteworthy that most of the modified strains engineered up to now are less fit 
than the wild type already in the laboratory, so it is not very likely that they could survive 
in the wild and take over the existing populations. Still, risks are to be taken into account, 
especially considering that carrying on with synthetic biology can be so rewarding.  
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Synthetic oscillators  
Among the network motifs that are being studied using a synthetic biology 
approach, oscillators are of particular interest because of their intriguing dynamics and 
because many cellular processes, such as cell cycle progression (Pomerening et al., 
2005), circadian rhythms (Naef, 2005), somite segmentation (Pourquie, 2003), are 
characterized by oscillatory protein levels. Usually natural oscillators are made of 
intricate regulatory networks; however, simpler modules have been shown to produce 
oscillations in different biological contexts (Hoffmann et al., 2002; Lewis, 2003). 
Studying these simple architectures can help discover common properties of oscillators, 
as well as determine their contribution to the dynamics of modularly assembled more 
complex networks.  
The first synthetic oscillator to be built was the so-called repressilator, where three 
repressors are connected in a daisy-chain (Elowitz et al., 2000). The network was built in 
E. coli using components which do not belong to any natural biological clock. The read-
out of the system is the fluorescent protein synthesized in each cell. Since the period of 
the synthetic oscillations is of hours, while E. coli divides faster, the state of the system is 
passed on to the next generation. Notably, the repressilator is rather noisy as compared to 
the robust performance of natural clocks.  
Few years later, a more complex design was shown to generate oscillations, as well as 
toggle switch behaviour (Atkinson et al., 2003). The beauty of this work consists in the 
use of a purely theoretical analysis prior to the effective construction of the network.  
These two circuits are made only of transcriptional elements, such as transcription factors 
and genes, but are independent of metabolism. The most recent synthetic oscillator to 
appear is called the metabolator to stress the fact that metabolism is coupled to 
transcription to obtain oscillations (Fung et al., 2005). This design uses glycolytic flux to 
generate oscillations through the signalling metabolite acetyl phosphate. Two enzymes 
which interconvert two metabolite pools are placed under the (positive and negative) 
transcriptional control of acetyl phosphate in a way that when glycolytic flux exceeds a 
critical value the passage between one metabolite pool and the other takes place and so 
do the oscillations.  
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Although not coupled with mathematical modelling – which was done separately by other 
researchers (Takigawa-Imamura et al., 2006) – another beautiful example of how 
reconstructing a system from scratch can help study modularity and complex dynamical 
behaviours comes from the in vitro cyanobacterium circadian clock (Tomita et al., 2005). 
The authors show that temperature-compensated, robust circadian cycling can be 
obtained independently of de novo transcription and translation processes. This discovery 
is very important, since it disproves the general belief that transcription-translation 
feedback loop is necessary to generate circadian rhythms.  
Design able to generate oscillations, as well as the properties of the oscillations, are the 
focus of intense research, not only experimental, but also theoretical (Lewis, 2003; 
Blatten, 2004; Guantes et al., 2006; Wong et al., 2006). These theoretical studies can 
teach us a lot about oscillators and make us long for new exciting synthetic oscillators to 
be developed. 
 
 
The p53 natural oscillator 
 
To live or to die, that is the question. Unfortunately existence is not so straightforward. 
To arrest or to propagate? And so the cell speaks, hiding its secrets in a mass of 
protoplasm. 
Anonymous blogger on the internet 
 
Despite its unassuming name, p53 is an essential protein for the cell and it is 
evolutionarily conserved from worm to human (Slee et al., 2004). Acting as a sensor of 
DNA damage, p53 dictates life or death to the cell, dependently on its ability to cope with 
the damage and repair it. The fundamental role of p53 in ensuring genomic integrity is 
better reflected in its nickname, “guardian of the genome”. This and other epithets, such 
as “good cop/bad cop” or “heavily dictated dictator”, emphasize not only the centrality of 
p53 in keeping proliferating cells under control, they also suggest that p53 activation can 
have contradicting effects on the organism (like cancer prevention and aging) and it is 
therefore itself subject to a tight regulation achieved by a complex network of cellular 
proteins (Sharpless et al., 2002; Kohn et al., 2005; Lu, 2005). p53 is mainly a sequence-
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specific DNA-binding transcription factor which, under normal growth conditions, is kept 
latent in various ways (see below). When necessity calls, i.e. upon some stress signal – 
such as damages to the DNA, hypoxia, oncogenic expression – p53 is rapidly activated 
and starts its gene expression program. p53 target genes mediate a plethora of cellular 
functions, including cell cycle arrest, senescence, apoptosis, differentiation and DNA 
repair, to name but a few (Liu et al., 2006; Matoba et al., 2006; Roger et al., 2006). 
Inactivation of the p53 pathway – being it through mutations on the p53 gene itself, 
mutations on genes encoding key p53 regulators and/or binding partners, or  other means 
– is a common, if not universal, feature of human cancers. p53 is therefore considered the 
perfect candidate to develop new drugs for this disease. If on the one hand this has 
considerably boosted research on p53 – so that we now know a lot more about the 
mechanisms underlying its regulation and functions – on the other hand it has given rise 
to an explosion in the number of publications involving p53, making it difficult at times 
to discern reality from artefacts. Artefacts can arise, for instance, from putting together 
results obtained with different cell lines, under different experimental conditions, in 
different organisms. At least some of the contradictions found in the field could very 
probably be explained considering that using a lymphocyte instead of a hepatocyte, or a 
healthy cell instead of a cancer one can radically affect the results.  Through the years, to 
the processes somehow historically related to p53 (like cell cycle arrest, DNA repair and 
apoptosis), many more have been added – as diverse as cytokinesis (Scoumanne et al., 
2006), mitochondrial respiration (Matoba et al., 2006), Golgi complex integrity (Jung et 
al., 2006), bone organogenesis (Lengner et al., 2006), exosome secretion (Yu et al., 2006) 
and cell migration (Roger et al., 2006) – as proofs of the multifaceted role of p53. It is 
interesting to note that a similar trend is involving another protein in the p53 network, 
Mdm2. Mdm2 has been first shown to form a complex with p53 and inhibit its 
transcriptional activity (Momand et al., 1992). Years later, Mdm2 was shown to have 
ubiquitin ligase activity towards p53, regulating its levels by targeting it for proteasomal 
degradation (Fuchs et al., 1998). Although Jun-N (amino)-terminal kinase (JNK) was 
soon after proved to also target p53 for degradation (Fuchs et al., 1998), Mdm2 has 
monopolized the attention of researchers, and has been considered (wrongly, see below) 
the one and only p53 negative regulator. As a consequence, much effort has been 
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invested in discovering Mdm2 functions and mechanisms of action. No wonder if it is 
now found to be involved in almost as many cellular processes as p53 itself (cell cycle 
control, differentiation, cell fate determination, DNA repair, basal transcription, and other 
processes) and to be regulated just as much (Ganguli et al., 2003; Meek et al., 2003).  
 
The p53-Mdm2 feedback loop  
A very fascinating aspect of the p53-Mdm2 interaction, from a systems biology 
perspective, is that it can lead to oscillations. While Mdm2 is negatively acting on p53 
(concealing its activation domain and targeting it for degradation), p53 is positively 
acting on Mdm2, which is in fact a p53 target gene. To use an engineering terminology 
(which has indeed become of common use in biology as well), p53 and Mdm2 form a 
negative feedback loop. This motif recurs often in the p53 network. The recently 
discovered E3 ligases Pirh2 and COP1, in fact, also target p53 for proteasomal 
degradation while being at the same time transcriptionally activated by p53 (Leng et al., 
2003; Corcoran et al., 2004; Dornan et al., 2004). Mathematical analysis of negative 
feedback loops tells us that oscillations can arise if there is a delay in the production of 
Mdm2 (Lewis, 2003; Bratsun et al., 2005). This assumption is sufficiently realistic 
considering that there are several time-consuming steps involved in the production of a 
functional protein, such as mRNA splicing, translation and protein folding, with nuclear 
transport playing an important role in the case of nuclear proteins such as Mdm2. Also, it 
has been shown that, in certain circumstances, Mdm2 transcription is induced later than 
that of other p53 target genes (Perry et al., 1993; Knippschild et al., 1995). Oscillations in 
the p53-Mdm2 network have been observed both at the population level (Lahav et al., 
2004) and at the single cell level (Lahav et al., 2004; Geva-Zatorsky et al., 2006). In the 
first case, the oscillations were dumped and the explanation given by the authors was 
rather logical: p53 levels increase upon stress so that the cell can try to repair the damage 
to its DNA before committing suicide. After several trials of repair (each corresponding 
to a peak in p53 levels), p53 goes back to its low basal concentration, either because 
repair has been successfully accomplished or because the cell undergoes apoptosis. The 
results coming from single cell studies (Lahav et al., 2004; Geva-Zatorsky et al., 2006), 
carried on with the fusion proteins p53-ECFP and Mdm2-EYFP for visualization in living 
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cells, revealed that the oscillations are sustained rather than damped (dampening being 
the effect of averaging over many cells), with some cells exhibiting oscillations that last 
several days. This time, the authors do not offer an explanation for this observation and 
simply conclude that, since oscillations are found also in other systems like the SOS 
DNA damage response in E. coli and the NF-KB system, oscillations likely play a 
general role in stress or damage response. It would be extremely interesting to find out 
whether oscillations in the p53 and Mdm2 protein levels occur in normal cells as well as 
in cancer ones, and whether they do have a physiological relevance or not.   
 
p53 regulation 
p53 is subject to a very tight regulation, which ensures that the protein is scarce 
and dormant when the cell is unstressed. This is achieved in various ways, for instance by 
keeping p53 in the cytoplasm, by targeting it for proteasomal degradation, or by 
inhibiting p53 binding to its DNA target sites (Gohler et al., 2002; Liu et al., 2006). 
When exposed to some source of stress which damages its DNA, the cell invokes p53 to 
take action. p53 is quickly stabilized and its transcriptional activity is strongly enhanced 
as a result of the nuclear accumulation of the protein and modifications within both its N- 
and C-termini. For instance, such modifications allow p53 to recruit more efficiently 
components of the transcription machinery through its transactivation domains (Figure 
1.2) (Espinosa et al., 2003; Liu et al., 2006). Although for many years regulation of p53 
at the level of transcription has received little attention, different transcription factors 
have been found to activate and repress p53 gene expression and the deregulated 
expression of p53 appears to be a central feature of malignant transformation (Nayak et 
al., 1999). p53 mRNA levels change during the cell cycle – p53 gene transcription is 
induced prior to DNA synthesis – and also rise substantially upon serum stimulation and 
excess of c-Myc (Reisman et al., 1993; Boggs et al., 2006). At first sight, up-regulation 
of an anti-proliferative gene such as p53 by serum and growth factors might seem 
contradictory. As a matter of fact, extensively proliferating cells are at a higher risk of 
acquiring DNA damage and generating cancer-prone progeny than quiescent cells. 
Therefore, they enter into a state of anticipation characterized by high levels of p53 
mRNA which guarantee a rapid and effective response in case of necessity, without 
Chapter One  Introduction 
 14
otherwise interfering with normal cellular processes in the absence of DNA damage or 
other stresses. When the cell is exposed to p53-activating signals, p53 protein levels rise 
rapidly and, although this is partially due to a higher translational rate of p53 mRNA, the 
major players in p53 stabilization are post-translational modifications (Figure 1.2). Apart 
from preventing the association of p53 with its negative regulator Mdm2 and from 
making it a more potent sequence-specific DNA binding transcription factor, post-
translational modifications can influence which downstream pathway is initiated by p53. 
For instance, p53 phosphorylation at serine 46 has been shown to be required for p53-
induced apoptosis, while cell cycle arrest does not depend on this modification (Oda et 
al., 2000).  
 
 
Figure 1.2 | Protein domains, post-translational modification sites, and proteins that 
interact with human p53. The 393 amino acid human p53 polypeptide is represented 
schematically with postulated functional regions and domains indicated. Residues ~1-40 
(TAD1) and 41-83 (TAD2) comprise independent tandem transactivation domains; 
residues ~63-97 also is a Src homology 3-like (SH3, not shown) domain that overlaps 
with a poorly conserved proline and alanine rich segment (33-80); residues ~102-292 
contain the central, sequence-specific, DNA binding core region; residues 305-321 
contains the primary bi-partite nuclear localization signal (NLS); residues 324-356 
comprise the tetramerization domain (TET) which contains a nuclear export signal within 
residues 339-350; residues 363-393 (REG) negatively regulate DNA binding by the 
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central core to consensus recognition sites in oligonucleotides and interact in a sequence-
independent manner with single- and double-stranded nucleic acids but contribute 
positively to chromatin binding and transactivation in vivo. Posttranslational modification 
sites (P, phosphorylation; Ac, acetylation; Me, methylation, N8, neddylation; Ub, 
ubiquination) are indicated together with enzymes that can accomplish the modifications 
in vitro. Interaction regions for selected proteins are indicated below the polypeptide. The 
C-terminal six lysines (K370, K372, K373, K381, K382, and K386) can be ubiquinated; 
K373, K372, and K373 are likely sites of attachment for the ubiquitin-like protein 
NEDD8; Lys386 may be modified by conjugation with SUMO1, a ubiquitin-like peptide. 
Adapted from (Appella, 2003) 
 
 
Mdm2 
As mentioned above, Mdm2 is one of p53 main negative regulators, whose 
critical role in preventing p53 apoptotic function when unnecessary is manifested by the 
lethality of mice embryos deprived of Mdm2; a phenotype which can be rescued by the 
simultaneous inactivation of p53 (Jones et al., 1995; Montes de Oca Luna et al., 1995). 
Mdm2 is, like p53, a multi-domain protein (Figure 1.3). The N-terminus is characterized 
by the p53 binding domain, which binds on p53 to the N-terminal transactivation domain. 
In this way, Mdm2 is able to inhibit p53 transcriptional activity independently of its 
ubiquitin ligase function, which is to be ascribed to the RING-finger domain. This 
characteristic distinguishes Mdm2 from the other p53 ubiquitin ligases (COP1, Pirh2, 
ARF-BP1), that can target p53 for proteasomal degradation, but do not conceal its 
transactivation domain.  
 
 
Figure 1.3 | Mdm2 protein motifs. NLS, nuclear localization signal; NES, nuclear 
export signal; Zn-finger, zinc-finger domain; NoLS, nucleolar localization signal; RING-
finger, ring-finger domain. The numbers above the drawing denote amino acid numbers. 
Adapted from (Iwakuma et al., 2003) 
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Mdm2 nuclear export signal (NES) was long thought to be essential for Mdm2-mediated 
p53 degradation, in that Mdm2 would shuttle nuclear p53 out into the cytoplasm, where 
ubiquitylated p53 would be degraded by cytoplasmic proteasomes (Freedman et al., 
1998). It was later discovered that this shuttling does not require the NES on Mdm2, but 
rather the NES on p53 and an intact RING-finger domain on Mdm2 (Geyer et al., 2000). 
Furthermore, it has been recently shown that nuclear export is not an obligatory step in 
p53 degradation, which occurs on cytoplasmic and nuclear proteasomes in the down-
phase of a successful stress response, when the cell has repaired its DNA and needs to 
rapidly eliminate p53 to return to normal homeostasis (Joseph et al., 2003). Also recent is 
the discovery of a cryptic nucleolar localization signal (NoLS) at the C-terminus of 
Mdm2, whose biological significance is yet to be clarified (Lohrum et al., 2000). The 
central acidic domain of Mdm2 is necessary for interaction with the ribosomal protein L5 
and with p300, thus contributing to p53 degradation since this requires the chain-
elongation enzymatic activity of p300 (see below).  
 
Mono- versus polyubiquitylation 
In order to be degraded, p53 – like any other protein – needs to carry a 
polyubiquitin chain, which is the signal that will recruit the proteasome (see below for 
more details on ubiquitylation). Monoubiquitylated p53 is exported into the cytoplasm 
where it can function in a transcription-independent manner (Moll et al., 2005) or where 
it can be stored in a monomeric form (Li et al., 2003). Mdm2 has been shown to mediate 
both mono- and polyubiquitylation of p53 depending on its abundance: low levels of 
Mdm2 result in p53 monoubiquitylation and subsequent nuclear export, while high levels 
of Mdm2 cause p53 polyubiquitylation and degradation inside the nucleus (Li et al., 
2003). These distinct activities of Mdm2 towards p53 are likely exploited under different 
physiological conditions. For instance, p53 needs to be quickly eliminated when the cell 
has terminated its response to DNA damage and wants to go back to normal conditions 
and this correlates well with the fact that Mdm2 levels are found to be higher at this 
stage. On the other hand, it would be advantageous for an unstressed cell to keep inert 
forms of p53 into the cytoplasm, so that if necessity calls, these p53 molecules can be 
rapidly activated (via post-translational modifications) without the need to start from 
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scratch, and this correlates with the fact that in unstressed cells Mdm2 levels are also kept 
low – mainly through autoubiquitylation. Despite the ability of Mdm2 to polyubiquitylate 
p53 when at high levels, additional cellular factors are likely needed to foster p53 
degradation in its natural context with endogenous Mdm2. One such protein is p300, 
whose role in p53 regulation is rather complex. In fact, on the one had, p300 acetylates 
p53 thus enhancing its transcriptional activity (Liu et al., 1999); on the other, it acts as an 
E4 in the ubiquitin pathway, i.e. it transforms single ubiquitins on p53 into polyubiquitin 
chains which will recruit the proteasome and lead to p53 destruction (Zhu et al., 2001; 
Grossman et al., 2003).   
 
Redundancy in the p53 network 
The conventional model for p53 regulation sees Mdm2 as the only E3 ubiquitin 
ligase in charge of p53 destruction. Recent data prove this model wrong, as p53 lacking 
the major ubiquitylation sites for Mdm2 has a normal half-life and is stabilized and 
activated upon stress like wild type p53 (Feng et al., 2005; Krummel et al., 2005). This 
does not come as a surprise, though, since the discovery of other E3 ligases for p53 
preceded the work by Feng, Krummel and colleagues (Corcoran et al., 2004). Actually, at 
least four classes of E3 have been reported to recognize p53 as a target for ubiquitylation, 
including RING, U-box, HECT (homology to E6AP C-terminal domain), and 
cullin/ROC1–containing ubiquitin ligase complexes (Figure 1.4) (Dai et al., 2006). The 
authenticity in vivo of some of the newly discovered ligases, though, still needs to be 
proved.  
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Figure 1.4 | p53 is targeted for degradation by several E3 ubiquitin ligases. In the 
diagram, bars indicate ubiquitylation and the functional suppression of p53, while arrows 
indicate the transcriptional activation of the ubiquitin E3 ligase by p53. Adapted from 
(Dai et al., 2006) 
 
 
The physiological role of having many ligases for p53 has been elusive, if we exclude a 
general fail-safe mechanism which relies on redundancy to keep p53 under control were 
the function of one or more ligases impaired at any given time. Some differences between 
these ligases could also turn out to be important under different conditions. For instance, 
Pirh2 inhibits p53 transcriptional activity by binding to p53 central sequence-specific 
DNA-binding domain, instead of binding to its transactivation domains like Mdm2 (Leng 
et al., 2003).Recently, yet another ubiquitin ligase for p53 has been discovered, the 
HECT-domain ligase ARF-BP which, differently from Mdm2, COP1 and Pirh2, is not a 
p53 transcriptional target (Chen et al., 2005). This detail led Christopher L. Brooks and 
Wei Gu to propose a new model for p53 regulation, with Mdm2, COP1 and Pirh2 in 
charge of p53 destruction in response to stress, and ARF-BP1 in charge of keeping p53 
levels low during normal cellular growth (Figure 1.5) (Brooks et al., 2006). In fact, being 
ARF-BP1 independent of p53 transcriptional activity, it can degrade equally well wild 
type and mutant p53, accounting for the observed instability of mutant p53 in tumor cells 
– which are generally under stress, for instance due to oncogene activation. One could 
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think that this model is in contradiction with the observed embryonic lethality of mice 
caused by Mdm2 depletion. On the other hand, the embryos survive until day E5.5 of 
development so, were Mdm2 the primary source of p53 degradation in unstressed cells, 
we would expect the Mdm2 null embryonic cells to undergo some sort of growth arrest 
much before, due to p53 unconstrained activity. It is possible, therefore, that these 
embryos die because p53 is activated by an undefined stage-specific developmental 
stress, and its proapoptotic functions do not find any opposition in the absence of Mdm2, 
although it is unclear why the other E3 ligases (COP1, Pirh2) do not suffice to make up 
for Mdm2’s absence. 
 
 
 
Figure 1.5 | A new model for p53 regulation under stressed and unstressed 
conditions. In unstressed cells, ARF-BP1 might be the major ligase responsible for p53 
ubiquitylation and degradation, with Mdm2, present at low levels in the cell, only 
triggering p53 monoubiquitylation. In response to stress, p53 is rapidly stabilized and 
activated, and as a consequence of its transcriptional activity, the levels of  Mdm2, COP1 
and Pirh2 increase and engage in p53 degradation. Adapted from (Brooks et al., 2006)  
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Indeed, it seems that only lower organisms such as Caenorhabditis elegans and 
Drosophila melanogaster can cope with having a fully functional p53 gene and no 
Mdm2. Considering that ARF-BP1 gene is instead conserved in both C. elegans and D. 
melanogaster, one could speculate that ARF-BP1 is present in all species encoding p53 
and that the other ligases (e.g. Mdm2, COP1, Pirh2) emerged in evolution to regulate p53 
under different cellular conditions (Brooks et al., 2006). It is interesting to note that p53 
function itself evolved, since in C. elegans and D. melanogaster cells p53 can only 
trigger apoptosis, with growth arrest entering into play only in mammals. It is possible, 
then, that Mdm2 and the other ubiquitin ligases evolved to give stressed cells the 
opportunity to undergo a transient growth arrest before committing to a death response 
(Brooks et al., 2006).   
 
 
Other players in p53 regulation: HAUSP, MdmX, p14ARF and nucleolar proteins  
One of the defining characteristics of post-translational modifications is that they 
are very dynamic (see below). p53 is no exception and much of the regulation of its 
degradation is exerted through the fine-tuning of ubiquitylation and deubiquitylation 
reactions. In particular, the ubiquitin hydrolase HAUSP seems to play a critical role in the 
control of the stabilities of both p53 and Mdm2 (Li et al., 2004). On the one hand, 
HAUSP over-expression leads to the activation of p53-dependent transcription and 
growth arrest, while partial reduction of HAUSP levels by RNAi induces p53 
destabilization. On the other hand, complete ablation of HAUSP causes indirectly p53 
activation because Mdm2 autoubiquitylation is not counterbalanced anymore and Mdm2 
is too unstable to degrade p53. The regulation of the p53-Mdm2 feedback network 
involves also many other players, among which MdmX and p14ARF are of note. MdmX 
is, like Mdm2, a RING-finger protein, whose N-terminus contains a p53 binding domain 
which makes of MdmX a perfect candidate for being a ubiquitin ligase for p53 (Shvarts 
et al., 1996). Until recently, though, MdmX was believed to be unable to ubiquitylate p53 
and to not affect Mdm2-mediated p53 ubiquitylation. At the same time, MdmX was 
shown to stabilize both p53 and Mdm2, the first by preventing its nuclear export and 
subsequent degradation, the second by heterodimerization of the respective RING fingers 
and inhibition of Mdm2 autoubiquitylation (Stad et al., 2001). Since Badciong and Haas 
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reported that MdmX has in vitro E3 ligase activity and that it can ubiquitylate itself and 
p53 synergistically with Mdm2 (Badciong et al., 2002), there is the urge for further 
experiments that can better delineate MdmX role in the p53 network. p14ARF is a tumor 
suppressor which inhibits cell proliferation by activating p53 and the retinoblastoma 
protein Rb. Lately, p14ARF is gaining the interest of the scientific community for its p53-
independent activities which seem to correlate with the sumoylation, and subsequent 
inactivation, of several transcription factors by p14ARF (Sherr et al., 2005). p14ARF has 
been shown to promote Mdm2 rapid degradation, regardless the presence of p53 (Zhang 
et al., 1998) and to block Mdm2-dependent p53 degradation by anchoring Mdm2 into the 
nucleolus thus keeping Mdm2 from shuttling p53 out of the nucleus into the cytoplasm 
where it can be degraded (Tao et al., 1999).  Similarly to blocking Mdm2, p14ARF also 
suppresses ARF-BP1-mediated p53 degradation (Chen et al., 2005). Interestingly, p53 
down-regulates expression of its positive regulator p14ARF, giving rise to another 
feedback loop in the p53 network (Stott et al., 1998).   
Finally, nucleolar proteins, such as the ribosomal proteins L11, L23 and L5, have also 
been implied in p53 regulation, for their ability to inhibit the action of Mdm2 on the 
tumour suppressor (Dai et al., 2004; Dai et al., 2004; Dai et al., 2006). These proteins act 
as sensors of ribosomal stress (i.e. any situation in which rRNA synthesis, rRNA 
processing and ribosome assembly is impaired) upon which they are released from the 
nucleolus into the nucleoplasm where they can directly associate with Mdm2 and block 
p53 degradation. The precise mechanism underlying such regulation is not clear. It has 
been suggested that these proteins bind to Mdm2 in its central acidic region, which has 
been implicated in p53 ubiquitylation (Argentini et al., 2001; Kawai et al., 2003; 
Meulmeester et al., 2003; Zhang et al., 2003; Dai et al., 2004; Dai et al., 2004; Dai et al., 
2006). Also, different ribosomal proteins seem to use different mechanisms, in that L26 
was found to bind the 5’UTR of the p53 mRNA and enhance its translation (Takagi et al., 
2005).   
 
p53 sumoylation 
To the long list of post-translational modifications influencing in a way or another 
p53 activity, sumoylation has been lately added (Gostissa et al., 1999; Rodriguez et al., 
1999) (see below for more details on protein sumoylation). The initial suggested 
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enhancement of p53 transcriptional activity by such modification has been questioned 
though, so much that at the moment the biological function of sumoylated p53 is rather 
contradictory (Watson et al., 2006). Also under debate is the effect of sumoylation on 
p53 localization, since on the one hand it has been reported that the p53 mutant protein 
that cannot be sumoylated (p53K386R) shows unchanged cellular distribution as 
compared to wild type p53 (Fogal et al., 2000; Kwek et al., 2001); on the other hand, p53 
sumoylation seems to be related to the association of the protein with nuclear organelles 
such as the nucleolus (Muller et al., 2001; Chen et al., 2003). The speculation that p53 
association with nuclear bodies is a prerequisite for p53 sumoylation comes rather 
naturally when putting together the following observations: a) p53 recruitment to the 
PML bodies triggers activating modifications on p53 (Gostissa et al., 2003); b) nuclear 
bodies seem to stimulate SUMO conjugation and proteins that bind transiently to nuclear 
bodies are often SUMO targets (Jackson, 2001; Seeler et al., 2001); c) p53 is itself a 
SUMO target and the major site for sumoylation lies into the C-terminus of p53, which is 
known to regulate p53 transcriptional activity (Gostissa et al., 1999); d) p73, another 
member of the p53 protein family, is also sumoylated and its sumoylation might be 
involved in the re-localization of p73 into nuclear bodies (Minty et al., 2000). 
Indeed, sumoylation affects p53 directly or indirectly, because several of its 
regulators – Mdm2, MdmX, and PML for instance – are found to be modified by SUMO. 
Nonetheless, the current data available on the SUMO system in the p53 pathway still fail 
to give a unified model and more work is needed to uncover the network of protein-
protein interactions and the interplay of post-translational modifications that may play a 
role in the SUMO-mediated regulation of p53.  
 
 
Regulation of protein function through post-translational modifications 
A cell is a very dynamic entity: in order to survive, it has to continuously interact 
with its environment and be able to rapidly respond to external changes with internal 
ones. To do this, cells can count, among other things, on an army of modifications which 
proteins undergo depending on the circumstances.  An important characteristic of these 
modifications is their reversibility (not all modifications are reversible, but those involved 
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in signalling mostly are) and their possible coexistence, which dramatically increases the 
number of functions that very cell can perform with a limited number of proteins encoded 
by a limited number of amino acids. These modifications are called post-translational 
modifications (PTMs) because they occur after protein synthesis; this, together with the 
fact that a modified protein can be brought back to its original unmodified status, make 
PTMs a fast, efficient way for the cell to regulate its functional units without the need to 
re-synthesize proteins from scratch. The way in which PTMs work is sometimes by 
inducing a new conformational state of the protein, which brings an altered function 
about. Alternatively these modifications constitute anchoring points for other proteins 
resulting in complex formation and therefore new functionalities. Recently, a very 
elegant, evolutionary sound model has been proposed. The task of decoding the status of 
the proteins inside the cell is assigned to the modular protein interaction domains that 
proteins are made of. These domains are dedicated to the recognition of specific 
modifications and combinations of them in a way that is general and does not require 
molecular interactions tailor-made to a particular polypeptide (Seet et al., 2006) . Despite 
their being all fascinating, in the following sections only two of these modifications will 
be discussed: ubiquitylation and sumoylation.     
 
Eukaryotic protein degradation and the ubiquitin pathway 
Proteins exist as a chain of amino acids which can degrade over time being this 
reaction thermodynamically favourable in aqueous solution. Protein turnover (i.e. 
degradation), together with protein synthesis, determine the concentration of each protein 
inside the cell. The great majority of proteins are long-lived, abnormal proteins and key 
regulatory proteins representing an exception with their very short half-lives. Rapid and 
specific degradation of regulatory proteins in charge of the activation of one or more 
pathways is indeed an essential feature for cells, because it means blocking these 
pathways (when needed!) without hesitation or mistake. Mistakes could arise, in fact, 
were the regulatory protein simply inhibited in its function - via a conformational change, 
for instance -, since such inhibition could be accidentally removed (being a reversible 
process).  
Chapter One  Introduction 
 24
Degrading regulatory proteins instead of inhibiting them is therefore a much safer option 
which, despite its high cost (proteins need to be synthesized from scratch!), ensures that 
processes, potentially lethal to the cell if executed in the wrong circumstances, are kept 
strictly under control. Starting from a rather dark past, when it received little attention 
compared for instance to protein synthesis, protein degradation slowly gained ground, 
finally granting Aaron Ciechanover, Avram Hershko and Irwin Rose the Nobel Prize in 
Chemistry in 2004 for their major contributions to the elucidation of the mechanisms 
regulating the highly specific breakdown of intracellular proteins through the ubiquitin 
pathway. Together with lysosomal proteolysis, the ubiquitin-proteasome pathway 
represents the major pathway mediating protein degradation in eukaryotic cells. 
Lysosomes (membrane-enclosed organelles that contain an array of digestive enzymes) 
are used by the cell to dispose of extracellular proteins - taken up by endocytosis - as well 
as cytoplasmic organelles and cytosolic proteins. Alternatively, in order to quickly 
degrade cytosolic and nuclear proteins, cells adopt a tightly regulated process which 
requires to first put a tag on those proteins which need to be eliminated, and then proceed 
to their destruction. The tagging process is called ubiquitylation (ubiquitination in earlier 
publications) from the name of the protein (ubiquitin, precisely) which is covalently 
attached to a substrate to signal that its time has come. The destruction is carried out by 
the multisubunit ATP-dependent protease called proteasome. Ubiquitylation is actually 
more complex than what emerges from this description, as one might guess considering 
its being involved in many cellular processes, as diverse as cell cycle progression (Krek, 
1998) and immune response (Liu, 2004). It requires, in fact, the coordinated action of at 
least two, but most of the times three, different enzymes (many more if we consider the 
newly described chain elongation factor E4 and the de-ubiquitylating enzymes DUBs): 
the E1, ubiquitin-activating enzyme, an active cysteine residue of whom forms a thioester 
bond with ubiquitin C-terminus, thus activating it for the next step in the cascade; an E2, 
ubiquitin-conjugating enzyme, onto which ubiquitin is passed from the E1, again through 
the formation of a thioester bond between a cysteine on the E2 and ubiquitin C-terminus.  
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The E2 can either directly catalyse the conjugation of ubiquitin to the substrate or 
cooperate with one of the so-called ubiquitin-ligase E3 enzymes, which recognize the 
substrate and, by binding simultaneously to it and to the E2, facilitate the passage of 
ubiquitin from this latter to the substrate. Sometimes there is no other substrate than the 
E3 itself, which can mediate its own degradation through a mechanism called 
autoubiquitylation, term that does not distinguish between inter or intramolecular modus 
operandi (this latter is being demonstrated in some cases (Banerjee et al., 1993). This 
three-step mechanism initiates all known ubiquitylation reactions, independently of 
whether the substrate-bound ubiquitins will signal proteosomal degradation or some other 
fate. Contrary to what was believed until recently, in fact, ubiquitylation regulates other 
cellular functions than protein degradation, like protein localization (d'Azzo et al., 2005), 
transcription (Dhananjayan et al., 2005), endocytosis (Rotin et al., 2000), ribosomal 
function (Panasenko et al., 2006), postreplicational DNA repair (Baarends et al., 2000) 
and budding of retroviruses from the plasma membrane (Kikonyogo et al., 2001). 
Whether or not an ubiquitylated protein will be degraded depends on the number of 
ubiquitin molecules it carries and, when many, on the type of linkage between them; 
degradation being triggered only by the presence of a long polyubiquitin chain, attached 
at a single site on the substrate, where at least four molecules are linked pair-wise via an 
isopeptide bond between the ε-amino group of a lysine of one ubiquitin and the C-
terminal carboxyl group of the next ubiquitin in the chain (Thrower et al., 2000). 
Monoubiquitylation, multiubiquitylation characterized by single ubiquitins attached at 
different sites on the same protein, or a polyubiquitin chain with a different type of 
linkage between ubiquitins, are instead the signal recognized by the array of cellular 
processes regulated by ubiquitin in a proteasome-independent way (Figure 1.6). 
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Figure 1.6 | Schematic representation of the difference between mono and 
multiubiquitylation. a, monoubiquitylation is characterized by a single ubiquitin 
covalently attached to a lysine residue on a target protein. b, Multiubiquitylation 
characterized by several single ubiquitin attached at different lysines on the protein. c, 
Multiubiquitylation characterized by a chain of ubiquitins where the C-terminal glycine 
76 of one ubiquitin is linked to lysine 48 of the next ubiquitin. This chain signals the 
destruction of the protein by the proteasome. d, Multiubiquitylated proteins can also have 
a different type of chain, the best known being characterized by a bond between lysine 63 
of one ubiquitin with the C-terminus of another ubiquitin. Adapted from (Haglund et al., 
2005) 
 
 
The mechanism(s) of ubiquitin-chain assembly is still somewhat controversial. The 
textbook version holds that ubiquitin molecules are added on at a time, first to the 
substrate and then to the most distal ubiquitin of the growing chain (Figure 1.7). This 
model, called the “sequential addition model”, is a natural extension of a 
monoubiquitylation reaction, in which the most distal ubiquitin in the chain provides the 
lysine residue to which the next molecule can be attached.  
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Figure 1.7 | Schematic representation of the sequential addition model. In this model, 
the most distal ubiquitin in the chain provides the lysine residue to which the next 
molecule can be attached. Adapted from (Hochstrasser, 2006) 
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This model becomes less intuitively appealing when we consider that a polyubiquitin 
chain can be very long and therefore the free end of it becomes structurally remote from 
the original substrate. A way to justify this would be to consider that the chain is looped 
out between the substrate and the E2 binding sites on the E3. Given the discovery that E1 
and E3 binding sites on the E2 overlap and their binding to E2 is mutually exclusive 
(Eletr et al., 2005), if the chain is assembled on the substrate by a sequential addition 
mechanism, then multiple cycles of E2-E3 binding and release are necessary if 
continuous E3-substrate binding is required for processive ubiquitylation (Reiss et al., 
1989; Rape et al., 2006).  An intriguing possibility in this respect would be that the E2 
dimerizes and the E1 and the E3 would each bind to one monomer in the dimer, thus 
avoiding the full release of the E3 from the E2 (Pickart, 2001). Yet another possibility is 
that unanchored ubiquitin chains are assembled in solution, prior to attachment to a 
substrate, which would occur once the E1 fishes the chain and activates the C-terminal 
carboxyl group at its base of the chain, This idea is supported by the observation that 
many cell types have a significant amount of what appears to be “free” ubiquitin chains 
(van Nocker et al., 1993) which are competent intermediates in the ubiquitylation 
pathway. While degradation is irreversible, ubiquitylation is a reversible process; the cell 
can in fact call upon a class of thiol proteases, called deubiquitylating enzymes (DUBs), 
to  hydrolyze the amide bond between glycine 76 of ubiquitin and the substrate protein 
(or another ubiquitin), thus adding another layer of regulation on the amount and identity 
of ubiquitylated proteins.  
 
Ubiquitin 
 Ubiquitin is a heat-stable small protein, comprising 76 amino acids, which can 
exist either in free form or as part of a complex with other proteins. Figure 1.8 shows 
ubiquitin three-dimensional structure, at 1.8 Å resolution, with its characteristic β-grasp 
fold, which is shared by other proteins as well, also referred to as the ubiquitin-like fold 
due to ubiquitin popularity. Its name eloquently signifies its ubiquitous presence all over 
the cell and throughout all eukaryotes, from yeast to humans.  
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Figure 1.8 | Three-dimensional structure of ubiquitin Adapted from (Gumbart, 2006) 
 
 
The conservation of the amino acid sequence of ubiquitin becomes obvious when 
comparing plants and animals, for there is just a two amino acid difference between 
ubiquitin of the two groups (Figure 1.9). This high degree of conservation strongly 
suggests that each amino acid is extremely important for ubiquitin’s proper functioning, 
which, being essential to the survival of any eukaryotic cell, pressed for its fine-tuning 
before the appearance of multi-cellular organisms. 
 
 
Figure 1.9 | Sequence alignment of ubiquitin from different organisms. The colours 
represent different degrees of amino acid conservation. In blue are identical residues, in 
green are conserved substitutions, in light brown are semi-conserved substitutions. Red 
means no conservation among residues. In the far-right column, protein accession 
numbers to the NCBI database are given. Adapted from (Gumbart, 2006) 
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E1, the ubiquitin-activating enzyme  
All E1s known so far share a common homology domain, which contains a 
nicotinamide adenine dinucleotide  (NAD) binding site. This domain assumes a fold 
found in many NAD binding proteins and can be traced back to bacteria (Begley et al., 
1999; Unkles et al., 1999). Interestingly, E1s harbouring two NAD domains like yeast 
Uba1 and human UBE1 act as monomers, while those with a single copy need to be in 
complex with a protein containing a second NAD-binding domain (Huang et al., 2004). 
Figure 1.10 shows a comparison between the E1 enzymes of budding yeast and humans. 
Although the E1 concentration is usually less than the total E2 concentration, E1 is a very 
efficient enzyme producing enough activated ubiquitin for all downstream conjugation 
reactions. While the connection between structure and function remains to be elucidated, 
the mechanism of ubiquitin activation is known in great detail. The reaction starts with 
the binding of MgATP followed by the binding of ubiquitin; a ubiquitin adenylate 
intermediate is thus formed which serves as the donor od ubiquitin to a cysteine in the E1 
active site. A fully loaded E1 carries two ubiquitins, one as a thiol ester, which is further 
transferred onto the next enzyme in the cascade, and one as an adenylate. E1 has a rather 
weak binding affinity for ubiquitin prior to ATP binding, suggesting an ATP-dependent 
conformational change that helps increase the accessibility of a ubiquitin binding site.  
 
 
Figure 1.10 | Domain structure of budding yeast (UBA1 sc) and human (UBE1 hs) 
ubiquitin activating enzymes. The name of each domain is written on top of the box 
representing the domain. Type-I repetitive domain following a UBA_NAD domain 
contains the active cysteine. Adapted from (Scheel, 2005) 
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Currently, there is no solved crystal structure for the ubiquitin-activating E1, but 
inferences can be made using the crystal structures for the E1 enzymes that catalyze the 
attachment on substrate proteins of so-called ubiquitin like proteins (Ubls), among which 
the most studied are SUMO (small ubiquitin like modifier) and NEDD8.  
Based on weak sequence similarity to these proteins, the structure of ubiquitin-E1 is 
thought to consist primarily of the adenylation domain and the catalytic cysteine domain, 
plus a ubiquitin-like domain at the C terminus of the protein (Figure 1.11).  
 
Figure 1.11 | Schematic diagram of the likely domain structure of the E1 (1-6) in 
complex with ubiquitin (7). The fragments of ubiquitin-E1 are (1) first adenylation half-
domain, (2) first catalytic cysteine half-domain (FCCH), (3) second adenylation half-
domain, (4) second catalytic cysteine half-domain (SCCH), (5) SCCH poorly conserved 
region and (6) Ubl-domain. The dotted rectangle marks the extent of the first half-domain 
(FH), which consists of the first adenylation half-domain and the FCCH. The yellow star 
marks the location of the catalytic cysteine residue. Adapted from (Szczepanowski et al., 
2005) 
 
 
 
Sequence conservation among Ubl-E1s is highest for the adenylation half-domains, 
which are also homologous to each other. Therefore, it is very likely that the adenylation 
domain of ubiquitin-E1 resembles the pseudodimeric adenylation domains of the 
NEDD8-E1 and SUMO-E1.  
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In contrast, no confident homology model can be built for the catalytic cysteine half-
domains. Both half-domains differ significantly between E1s for different ubiquitin-like 
modifiers (Figure 1.12). 
 
 
 
 
Figure 1.12 | Domain organization mapped to linear sequence for the ubiquitin-E1 
(top), SUMO-E1 (middle), and NEDD8-E1 (bottom). The adenylation half-domains are 
shown in dark and light gray, the FCCH in different shades of red, the SCCH in green 
and blue (representing the well conserved and poorly conserved parts, respectively), and 
the Ubl domain in very light gray. A, adenylation domain; CC, cysteine catalytic domain. 
The catalytic cysteine residue is marked by a yellow star. Adapted from (Szczepanowski 
et al., 2005) 
 
 
E2, the ubiquitin-conjugating enzyme  
Any member of the E2 protein family is characterized by the presence of a 
cysteine into a conserved domain; it is this cysteine to form the thioester bond with the 
ubiquitin coming from the E1, thus conferring the enzyme its catalytic function, which is 
abrogated by substitution of the cysteine residue (VanDemark et al., 2002). Opposite the 
active site poorly conserved residues are found which might have diverged due to low 
selective pressure, but it is likely that they mediate interactions important for the specific 
function of each individual E2. In fact, despite their similarity to one another (similarity 
that holds even between E2s dedicated to ubiquitin and ubiquitin like proteins, as shown 
by the crystal structure of the SUMO-specific yeast E2, Ubc9), different E2s have distinct 
biological functions, probably consequence of their highly specific interaction with E3s.  
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Although it would seem plausible that the binding of an E3 would reposition residues in 
the E2 active site, the currently available crystal structure of E2-E3 complexes do not 
show any alteration in the E2 conformation.  
This suggests that the residues responsible for the passage of ubiquitin from the E1 onto 
the E2 mainly sit in the E1 active site, while those responsible for conjugation of 
ubiquitin to a substrate mainly sit in the E3 active site.   
Free E2s bind tightly to the loaded E1 molecule as well as to their cognate E3s, but 
weakly to free ubiquitin and free E1. Like ubiquitin activation by E1, ubiquitin transfer to 
E2s is rapid relative to downstream reactions of substrate ubiquitination. There are eleven 
E2 enzymes in the budding yeast genome (Pickart, 2001) and approximately fifty in the 
human genome (Jiang et al., 2004).  
A comparison between yeast Ubc4 and human UbcH5B is shown in Figure 1.13. When 
one considers that the molecular character of the E2-E3 interaction is well conserved 
across several E2-E3 pairs, it is natural to wonder what the need to have many E2s for 
each E3 might be. Plausibly, having various E2s ensure that the pool of activated 
ubiquitin is appropriately distributed among different E3s, although the discovery of new 
interacting E2 partners could shed some light on the reasons behind the need of 
specialized E2s.  
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Figure 1.13 | Comparison between the yeast E2 enzyme Ubc4 and the human E2 
enzyme UbcH5B. a, Sequence alignment of human UbcH5B and yeast UBC4 
encompassing the _α1 helix and the L1 and L2 loops. Conserved residues are displayed 
in bold. b, X-ray structure of Ubc4 and ensemble of UbcH5B models as predicted by 
(Dominguez et al., 2004). These enzymes have been chosen since UbcH5B is the E2 
responsible for p53 ubiquitylation together with the E3 enzyme Mdm2 (Saville et al., 
2004). Adapted from (Dominguez et al., 2004) 
 
 
E3, the ubiquitin ligase 
Ubiquitin ligases are divided into three families: the HECT, the RING-finger 
(Figure 1.14) and the U-Box families. Contrary to what the name suggests, RING-finger 
and U-Box E3s do not catalyse the ligation of ubiquitin onto the substrate, rather they act 
as scaffolds to bring the E2 and the protein to be modified together (Figure 1.15). The 
HECT E3s, instead, do perform the ligation step, since ubiquitin is first temporarily 
transferred to a cysteine of the E3 and then attached to the substrate (Figure 1.15). U-Box 
E3s have been identified recently, therefore details about their catalytic action are not 
known.  
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As previously mentioned, often proteins do not acquire a single ubiquitin but a chain of 
them. It is still not clear how an E3 distinguishes between attaching a ubiquitin to another 
ubiquitin already present on the substrate (thus starting or elongating a chain) or to 
another lysine on the substrate. 
 
 
 
 
Figure 1.14 | RING domain This domain is characterized by a series of histidine and 
cysteine residues with a characteristic spacing allowing the coordination of zinc ions. The 
spacing, rather then any primary sequence, is conserved in the RING finger family. The 
zinc ions and their ligands are catalytically inert, suggesting for the E3s a role as 
molecular scaffolds to bring different proteins together. Adapted from (Pickart, 2001) 
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Figure 1.15 | Outline of the ubiquitin-conjugation payhway. Activation of the 
ubiquitin C terminus by E1 proceeds in two steps: adenylation  (not shown) followed by 
attack by a cysteine side chain to form a thioester bond between the E1 and ubiquitin. 
Ubiquitin is then passed to a cysteine of an E2. Ligation of the ubiquitin to a substrate 
(S), usually to a lysine side chain, follows either directly with the aid of a RING-bearing 
E3 or after an intermediate transthiolation to a cysteine side chain of a HECT-domain E3. 
Both types of E3 interact with their substrates, many of which acquire a polyubiquitin 
chain rather than just a single ubiquitin. Note: The dashed red arrows represent the 
direction of movement of ubiquitin, not the direction of nucleophilic attack. Adapted 
from (Hochstrasser, 2006) 
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The kinetic of the first process could be faster than that of the second, for instance, or 
perhaps conjugation of the first ubiquitin inhibits attachment of other ubiquitins on 
different lysine residues on the same substrate, leaving the door open for chain 
elongation.  
This model is attractive in that it agrees with the evidence that monoubiquitylated 
proteins predominate when ubiquitin self-conjugation is abrogated. It also remains to be 
elucidated whether the E2-E3 pair that executes the first ubiquitin ligation is the same 
that elongates the chain or if there are other pairs dedicated to this (allowing for further 
regulation of polyubiquitylation).  Recently, a new class of enzymes has been identified 
in the ubiquitin pathway - referred to as E4 enzymes or chain elongation factors -  which 
mediates the passage from mono- or oligoubiquitylated (i.e. few ubiquitins) protein to a 
polyubiquitylated one (Hoppe, 2005). E3s appear not to discriminate among the different 
lysines on a substrate, although experimental validation of this is yet to come. Finally, it 
is important to note that productive ubiquitylation depends upon successful interaction of 
the E3 with both the E2 and the substrate, paving the way for regulation of ubiquitylation 
at the level of protein-protein interactions; for instance, the E3 might need to be 
covalently modified before being in the right conformation to bind the E2 or the 
substrate; this latter might also need some modification (often phosphorylation) in order 
to be recognized by the E3; finally, the E2 levels might be a function of time. 
 
Sumoylation 
Despite its name, SUMO is a small protein which is attached to other proteins in a 
very dynamic, reversible covalent way. Indeed, together with ubiquitin, it represents one 
of the biggest tags that a protein can acquire (SUMO and ubiquitin being proteins of 
about ten kilo Daltons). Even if the sequence similarity between SUMO and ubiquitin is 
rather poor, SUMO shares (like the other ubiquitin-like modifiers) with ubiquitin its 
typical fold, to which a C-terminal loop is added, probably conferring to SUMO the 
specificity that distinguishes it from ubiquitylation notwithstanding their surprising 
similarity (Figure 1.16).  
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Figure 1.16 | Comparison between ubiquitin and SUMO three-dimensional 
structures. Adapted from <www.roberts-publishers.com/walsh/chapter9.pdf > 
 
 
The mechanism of SUMO conjugation is the same as for ubiquitin and the enzymes in 
this cascade are also referred to as E1, E2 and E3 (Figure 1.19). First SUMO needs to get 
into its mature form through the action of a SUMO protease that exposes a carboxy-
terminal glycine residue on the protein; then SUMO is activated by temporary attachment 
to the E1 via the formation of a thioester bond between the C-terminal glycine of SUMO 
and a cysteine on the E1. Contrary to the ubiquitin E1, which is a single protein, SUMO 
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E1 is a heterodimer whose subunits are respectively in charge of the adenylation and 
thioesterification reactions (Figure 1.17).  
 
 
Figure 1.17 | Domain structure of budding yeast (AOS1/UBA2 sc) and human 
(UBLE1A/AOS1/SAE1/SUA1/UBLE1B/UBA2/SAE2 hs) SUMO activating enzymes. 
The name of each domain is written on top of the box representing the domain. The 
subunits of the heterodimeric E1s are shown as separate proteins in the same row. 
Adapted from (Scheel, 2005) 
 
 
The structural analogy with the ubiquitin E1 is nonetheless preserved, since the two 
subunits of the heterodimer correspond to its amino and carboxy termini, this solution 
being in addition more suitable for regulation. SUMO then passes onto the E2, again 
through the formation of a thioester bond between a cysteine on the E2 and a C-terminal 
glycine on SUMO. Notably, there exists only one E2 (Ubc9) for SUMO conjugation 
compared to the many E2s in the ubiquitylation pathway (see Figure 1.18 for a 
comparison between the human and the yeast SUMO E2s). Ubc9 can interact directly 
with the substrate leading to its sumoylation; the fact that the target protein carries all the 
necessary information to specify its own sumoylation led to discard the hypothesis of the 
existence of E3 SUMO ligases. Recently, this belief has been shelved since different E3 
ligase types have been identified (Hochstrasser, 2001). This discovery reveals another 
layer of regulation in the sumoylation pathway which adds itself to other regulatory 
mechanisms, like, for instance, the desumoylation responsible of cleaving SUMO off 
target proteins.   
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Figure 1.18 | Sequence alignment of the human SUMO E2 UBE2I and the budding 
yeast SUMO E2 Ubc9. Conserved residues are shown in bold. The numbers indicate the 
position of the respective amino acid. 
 
 
Sumoylated proteins are not targeted for proteasomal degradation. Sumoylation signals 
the re-localization of proteins, as well as regulates nucleocytoplasmic shuttling, genome 
integrity and transcription. The vast majority of sumoylated targets are in fact 
transcription factors, but the effects of sumoylation on such proteins has proven to be 
subtle, bringing some doubts over the role of this modification in the transcriptional 
process.  
Currently, there are two models (which could also be both correct, since they do not 
contradict one another) for the role of SUMO in the regulation of transcription factors 
activity. The most experimentally validated is the “sequestration” model, for which 
sumoylation signals the re-localization of transcription factors to specific cellular 
compartments, often nuclear speckles or bodies (e.g. the PML bodies) (Muller et al., 
2001). The other model, still awaiting clear experimental evidence, is the “promoter” one, 
for which sumoylated transcription factors, as well as components of the sumoylation 
machinery, are bound directly to the chromatin. Supporting this model is the fact that 
sumoylation most often leads to the attenuation or repression of transcriptional activity 
(Seeler et al., 2003).  
Sumoylation appears to be mainly directed towards nuclear proteins, although some 
cytoplasmic targets have been also identified.  
 
Chapter One  Introduction 
 41
Like any other post-translational modifications, sumoylation can be influenced by other 
modifications and in fact it is not rare the finding that the same residue on a certain 
protein can be ubiquitylated, sumoylated or acetylated. Therefore, although sumoylation 
is not directly involved in the degradation of proteins, it can indeed indirectly influence 
their half lives, competing with ubiquitylation for the same lysine residue(s) and therefore 
protecting it from proteasomal targeting. The most striking characteristic of sumoylation 
is its relation with subnuclear structures. All three types of E3 SUMO ligases that have 
been identified up to now are bound to specific subnuclear structures, like PML or other 
nuclear bodies, the nuclear pore complex and so-called Polycomb group bodies (Seeler et 
al., 2003). Regardless of how attractive this can be, it is difficult to assign to sumoylated 
proteins some clear-cut, specific characteristics that distinguish them from their non-
modified counterparts. Apart from few striking cases (Muller et al., 1998; Johnson et al., 
1999), most of the times only subtle effects have been attributed to sumoylation. This is 
fastly changing though and in the literature more and more examples of proteins whose 
function is modulated by SUMO are found. Also, it is likely that SUMO effects are going 
to reveal themselves the closer experimental setups will get to physiological conditions. 
Moreover, from the available data, it is evident that sumoylation often affects many 
components of the same complex (Seeler et al., 2001). This raises the possibility that 
what really matters is the dynamic equilibrium among modified and unmodified 
components, which would explain why mutations of the sumoylation acceptor residues 
on a protein show only subtle effects. There is still room for great discoveries about the 
mechanisms underlying this new exciting post-translational modification, one of which is 
indeed the role in vivo of poly-SUMO chains, which have appeared only recently on the 
scene, having been thought not to exist before.  
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Figure 1.19 | Different steps in the sumoylation cycle. Before being attached to protein 
substrates, SUMO needs to get into its mature form. This is achieved through cleavage by 
a SUMO protease (Ulp in the scheme). The three following steps, namely activation, 
conjugation and ligation, are similar to those int the ubiquitin pathway (see text for 
details). On the target protein, the short consensus sequence ΨΚxE – where Ψ is an 
aliphatic residue – surrounding the acceptor lysine residue is shown. Adapted from 
(Seeler et al., 2003)  
 
 
Mathematical modelling of biological networks 
 Biologists are very familiar with the term ‘model’.  They use it repeatedly to 
designate a verbal or graphical description of a mechanism underlying a certain cellular 
process. Less often do they use it to refer to a set of equations expressing in a formal 
manner relations among variables that characterize the state of a biological system. Yet 
these mathematical models, more rigorous and more potent than the former ones, are 
entering biology at an increasingly rapid pace, pressing biologists to make themselves 
familiar with them. In many cases, concepts derived from engineering can be applied 
directly to graphical models. Thus, a negative feedback loop is expected to diminish the 
noise (Becskei et al., 2000), while a positive feedback loop could produce a switch 
behaviour (Becskei et al., 2001). Although topological models, with their comprehensive 
list of connected parts, can give important insights into the process they represent, 
predicting the behavior of a system just based on its topology is risky (Guet et al., 2002). 
A biological network is in fact a dynamical system and the values of the kinetic 
parameters of the reactions taking place in the network define what the outcome will be 
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(Ronen et al., 2002). Bridging the gap between an oversimplified model of a biological 
process, and a sufficiently detailed one to be useful is not trivial. Equations don’t get 
along well with fuzziness, so having a clear mind about the way things go in the system, 
and by that, knowing what to include in the model and what type of downstream analysis 
to do on the results, is a great benefit if one wishes to write down equations that are to be 
meaningful. Despite the satisfaction that can derive from writing such equations, for a 
mathematical model of a biological system to be useful, more than formally correct 
equations are needed. A successful model should allow predicting the system’s behaviour 
under conditions that were never tested before and that, therefore, were not used during 
the model building process. Ideally, in order to model a biological system one would like 
to make a replica of it in silico, what we could call the “molecular dynamics” of 
modeling. Thus spatial distribution, diffusion parameters, excluded volumes, 
concentrations and rates could be fed into a maximally detailed model to get an accurate 
reproduction of the biological process’ dynamics. Unfortunately, even for the best-
studied fields of research, for which daunting amounts of knowledge have accumulated 
and continue to do so, the variety of elementary processes such as posttranslational 
modification, degradation, or complex formation, as well as spatial information and 
timing of events in relation to the cell cycle are, at best, partially known and, even then, 
rarely in numbers. Nonetheless, insights can often be obtained in the absence of any 
precise quantitative knowledge of the system, using modelling tools unconcerned with 
precisely specified parameter values, but that are instead well suited to incorporate data 
of the type which is by far more readily available at present, i.e. qualitative. 
 
 
Qualitative Modelling 
Qualitative models are simplified models obtained by sacrificing details. In order 
for qualitative models to be useful in gaining an understanding of a biological system, a 
wiring diagram of the network – representing causality relationships between events 
linked to model components – or logical statements need to be given. As is still most 
often the case due to techniques routinely used in labs, the analysis of experimental data 
leads to knowledge of qualitative nature, which integrated with other data allows the 
formulation of statements translated more or less accurately by diagrams. While logical 
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inferences are manageable when the amount of information is small, the fields of model-
checking and model validation within qualitative reasoning have proven invaluable to 
accomplish the same task on much larger amounts of accumulated knowledge, for 
instance by highlighting inconsistencies (Batt et al., 2005).   
Closer to the goals of systems biology, a qualitative modelling approach may be more 
effective in gaining higher-level understanding of the organizational principles of a 
family of processes, through the theoretical study of generic systems. Such mathematical 
investigations lead to conclusions that are valid for the family of systems matching the 
description, stating for instance under which conditions certain behaviours such as 
oscillations can be expected. For modelling gene networks, as step functions are in fact a 
good approximation of gene activity, such qualitative models using Boolean formalism 
are particularly well suited. However, even a rough exploration of parameter space can 
become intractable as the size of the system increases, and therefore methods to 
accelerate the search and access to increasingly powerful computer resources are critical. 
For example, in the sister field of network identification, a task seeking to make out the 
set of reactions carried out during glycolysis (10 reactions and 15 metabolites) took 
several months on a 65 node Beowulf cluster to compute (King et al., 2005).   
Qualitative models can be quite useful when aiming at a quick general description of the 
possible behaviour of a system, but has the risk of leading the user to false conclusions 
(see Results Part One).   
 
 
Quantitative modelling 
Compared with qualitative models, quantitative ones have a natural appeal in that 
they offer greater detail in mimicking reality. Moreover, rich qualitative insights on the 
system are possible using theoretical tools such as bifurcation and stability analysis (Fall 
et al., 2002), which, for example, indicate the precise boundaries of parameter ranges to 
which steady states or sustained oscillations correspond, or reveal the stability of the 
solutions before actually solving the dynamical equations representing the system. 
Quantitative models can be either deterministic or stochastic. The most popular is the 
deterministic formalism of ordinary differential equations (ODEs) which when extended 
to include spatial information is referred to as partial differential equations (PDEs). Each 
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equation in a set typically represents the rate of change of a species’ continuous 
concentration as a sum or product of, more or less, empirical terms (typically law of mass 
action terms, Michaelis–Menten functions, power laws and so on), accounting for the 
effect of biological events on such concentrations. By definition, the initial state of the 
system in a deterministic model uniquely sets all future states. As analytical solutions 
seldom exist, numerical solutions need then to be computed (once for each set of 
parameter values and initial conditions explored). A word of caution: although this step is 
simple in principle, wrong solutions can arise. For instance, the chosen step-length for the 
integration of the ODEs can be sufficiently large to cause divergence of the numerical 
solution from the correct one (numerical instability), making a minimum of experience 
with related issues a strong asset for the user. In general, ODEs are best suited to 
capturing the behaviour of systems where species are abundant and reaction events 
frequent (as is often the case for metabolic pathways, for example), because species 
concentrations are then acceptably approximated as varying continuously and 
predictably. 
Molecular interactions are intrinsically random and cellular behaviour itself sometimes 
seems to reflect this randomness (Liu et al., 2004). Indeed, occurrences of noise have 
been found to be exploited by cells – for instance, to survive a variety of environmental 
changes (Thattai et al., 2004) or to increase sensitivity in signal transduction processes 
(Hanggi, 2002). To model such stochastic systems, two main methods are used. The first 
is using stochastic differential equations (SDEs; derived from ODEs by adding noise 
terms to the equations), the solutions for which can be numerically obtained either by 
computing many trajectories (Monte Carlo methods) or approximating their probability 
distribution and then calculating statistical measures (such as mean and variance). 
Notably, with this method noise is imposed on the system and represented by 
mathematical terms chosen a priori, instead of arising from the underlying physical 
interactions. The second is a very successful and exact method introduced nearly 
30 years ago (Gillespie, 1976; Gillespie, 1977), and recently enhanced to cope with 
different reaction timescales (Haseltine et al., 2002; Rao et al., 2003; Rathinam et al., 
2003) or space (Stundzia, 1996; Ander, 2004). With this approach, molecules are 
modelled individually and reaction events are calculated by the probability of meeting 
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and reacting. The price to pay for having a more physically realistic model is the 
considerable increase in computational time and the need for specialized algorithms 
(Alfonsi et al., 2005; Salis et al., 2005). 
 
 
Space in modelling 
Until recently, the majority of simulations ignored the fact that biological 
processes take place in heterogeneous and highly structured environments. Even 
prokaryotes are now known to possess a cytoskeleton and control the movement and 
location of molecules, so regulating cellular processes in both space and time (Gitai, 
2005). Indeed, spatial segregation underlies many cellular strategies; reactions are 
prevented by physically separating molecules and molecular gradients within or between 
cells are used in pattern formation (Gorlich et al., 2003). Crucial as it may be for 
fundamental processes such as self-organization (Nedelec et al., 2003; Sawai et al., 
2005), morphogenesis (Collier et al., 1996), cell division (Dens et al., 2005) or calcium 
waves (Wu et al., 2005), spatial information is still largely absent from interaction 
databases. Recent technological advances are addressing this dearth of spatial data, and 
theoretical advances are improving computational methods, making it now possible to 
simulate spatio-temporal models of biological processes in coarse-grained or realistic 
geometries (Lemerle et al., 2005). 
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As discussed in the Introduction, mathematical modelling and simulation of 
biological processes represent a powerful means to gain understanding on the 
mechanisms underlying these processes, often suggesting which experiments to do that 
would help corroborating or rejecting a working hypothesis. Although modelling could 
seem simple to an outsider, who might interpret the wealth and user-friendly appearance 
of simulation tools as an insurance of success, there are many conceptual pitfalls for the 
modeller that result in unrealistic predictions. The first step towards the generation of a 
good, informative model consists in understanding the limitations and advantages of the 
different available mathematical formalisms. In the following paragraphs, I give some 
examples of how modelling and simulations can lead to false predictions when the 
limitations of a given approach to represent reality are not taken into account.  
 
 
Mathematical-formalism-independent errors 
The precise order in which a series of reactions occurs can be consequential, yet is 
frequently disregarded. To show the impact that the choice of order of events can have on 
the predictions obtained by the corresponding model, I considered the case in which the 
formation of active dimers of a certain species is known to trigger downstream events, 
and, as an additional assumption, such a dimer is only active when both monomers are 
activated (for example, by phosphorylation). One can formulate a general model 
considering all possible dimerization and monomer activation/deactivation reactions 
derived from these hypotheses. Not knowing the order of events, three extreme 
possibilities can be formulated: two of total dependence (only activated monomers can 
dimerize or dimerization must occur before activation can) and one of total independence 
between activation and dimerization reactions. As Figure 2.1.1 shows, the different 
models lead to different steady-state concentrations of active dimer. If high 
concentrations (e.g. more than 200 molecules) but not low concentrations of this species 
can start a signalling cascade, only the system modelled as in the scheme corresponding 
to  “activate and dimerize” will show a response.  
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Figure 2.1.1 | Example of mathematical-formalism-independent pitfalls in 
modelling.  If protein M is active as a post-translationally modified dimer DAA, the 
formation of DAA can be modelled differently, depending on assumptions made 
regarding the order of events and the nature of the active dimer. Here we assume that 
both monomers must be modified to form an active dimer. a, The scheme shows all 
reactions compatible with the experimental observations. M, monomer; MA, modified 
monomer; D, dimer; DA, dimer with one modified monomer; DAA, active dimer (both 
monomers modified). Each horizontal arrow corresponds to a reversible activation 
reaction and each vertical arrow corresponds to a reversible dimerization reaction. The 
two slanted arrows, together with the central vertical arrow, represent dimerization of a 
modified monomer with an unmodified one. b–d, Simulation runs for three different 
orders of events—respectively, ‘activate then dimerize’, ‘dimerize then activate’ and 
‘dimerize and activate together independently’—showing the deterministic (black) and 
stochastic (cyan) temporal evolution of DAA molecules. (see Materials and Methods for 
parameters used in the simulation and a mathematical derivation of the steady-state 
solution). 
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Mathematical-formalism-dependent errors 
 
Choice of formalism 
Problems can arise from the mathematical formalism used to simulate a system. 
To illustrate the impact of modelling choices, I simulated a simple gene network with 
negative feedback (protein B forms multimers and sequesters the activator protein AP 
responsible for its transcription) using three formalisms with different degrees of 
graininess (Figure 2.1.2): a simple boolean model, a quantitative deterministic model 
with ODEs, and a quantitative stochastic model (Ander, 2004). With the discrete-time 
boolean model, the built-in delay produces oscillations (Figure 2.1.2b). The other two 
models require additional events to be modelled explicitly (for example, degradation to 
balance production), and in contrast to what is observed with the coarser boolean model, 
oscillations do not occur unless multimerization is allowed (Figure 2.1.2c-f). 
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Figure 2.1.2 | Simulation of a simple network using different mathematical 
formalisms.  a, Diagram of the negative feedback network used in the simulations. n, the 
number of B molecules in the active complex. b–f, Time courses of activator protein AP 
(red), B mRNA (blue) and B protein (black). The y axis represents the number of 
molecules, normalized for each species by the maximum value reached, except in b, in 
which it represents presence or absence of the molecules. Simulation of discrete time 
boolean model (b) with synchronous update. Deterministic (c, d) and stochastic (Ander, 
2004) (e, f) simulations using specified parameters (see Materials and Methods), with B 
monomer (c, e) or octamer (d, f). Oscillations predicted by the boolean model are 
obtained in the deterministic/stochastic model only when B oligomerization is included. 
 
 
 
Effect of localization of species on cellular processes 
To illustrate the impact on predictions of accounting for constraints of cellular 
space, I modelled a simple network (Figure 2.1.3a), in which a phosphorylated 
transcription factor triggers the production, in one pole of the cell, of protein A that is 
involved in a positive feedback loop (resulting from mutual repression of species A and 
B). Starting from an initial state corresponding to a high concentration of B and no A, 
when the kinase and the phosphatase freely diffuse in the cell, the positive feedback acts 
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as a switch causing the disappearance of B and the accumulation of A (Figure 2.1.3d). 
When the kinase and the phosphatase are localized to opposite poles of the cell (Figure 
2.1.3b), however, a gradient of the phosphorylated transcription factor is formed (Figure 
2.1.3c), and the amount of A produced is insufficient to trigger the switch (Figure 2.1.3e). 
 
 
 
Figure 2.1.3 | Effect of localization of species on cellular processes.  a, Diagram of a 
simple network in which a phosphorylated transcription factor TFP triggers the synthesis 
of protein A that is involved in a positive feedback loop (resulting from mutual 
repression). Ø → indicates protein production, whereas → Ø indicates protein 
degradation. The behaviour will depend on the spatial constraints imposed on the kinase 
Kn and the phosphatase Ph. When they localize to opposite poles of the cell, switching 
behaviour does not take place. Production of protein A in both simulations (Ander, 2004) 
takes place in the pole of the cell where the phosphatase is localized. b, The model 
geometry (lattice unit is 1 µm). Yellow indicates the longitudinal cell slice along which 
the gradient is observed. c, Gradient of TFP obtained with localization of species. d, e, 
Time course of protein B without (d) and with (e) localization of species (see Materials 
and Methods for parameters used in the simulation). 
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Continuous versus discrete concentrations 
Because molecules are discrete species, continuous representations of molecular 
abundance are another source of artefacts. For example, contrary to what happens with 
discrete-value models, steady states take infinite time to be reached with continuous 
concentrations, a discrepancy that disappears by focusing instead on how fast the steady 
state is approached (that is, by introducing the concepts of half-life, rise-time and others; 
Figure 2.1.4a). Similarly, a probabilistic key is needed to interpret the non-integral values 
generated by the continuous-value deterministic models, as for discrete stochastic 
models. For low numbers, however, this interpretation is not error proof. If we consider a 
single, strictly autocatalytic species, B (Figure 2.1.4b), an ODE model would conclude 
(as would a related SDE model with a noise term that was only multiplicative) that there 
are two steady states: an unstable lower one (with zero molecules per cell) and a stable 
upper one. Simulation runs based on such models show that any non-zero initial state 
evolves asymptotically towards the upper steady state, whereas zero states are absorbing 
(that is, that once reached, they cannot be left). If important downstream events, such as 
cell differentiation or apoptosis, are triggered only by the absence of B molecules, a 
continuous model would lead us to wrongly conclude that these events never occur, 
whereas the more physically realistic, discrete stochastic model would reveal that, for 
each cell, it is only a matter of time before the triggering state is reached (Figure 2.1.4b). 
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Figure 2.1.4 | Example of putative model-dependent pitfalls in modelling: 
continuous versus discrete concentrations.  a, Simulation of a simple system in which 
a species is produced at a constant rate (16×10−3 molecules s−1), and degraded with a first 
order decay rate of 1×10−3 s−1, giving an asymptotic steady-state of 16 molecules per cell 
(plotted as a straight horizontal line). The initial state for all simulations is 8 molecules 
per cell. Two discrete stochastic runs are shown in blue and green. The corresponding 
ODE solution is shown in black, whereas the discrete approximation of it is shown in red 
(rounding each value of the continuous run to the closest integer). A star indicates, for 
each discrete run, when the steady-state value has been reached. Each broken line 
illustrates a geometric construction of the rise-time, as the time taken by the system to go, 
first from 8 to 4 molecules per cell away from steady state, then from 4 to 2. Each unit of 
rise-time is separated by tick-marks on the x-axis, which are identically spaced (as a 
property of exponential curves). The stochastic simulation shows that it is possible to 
reach steady-state values earlier or later than in the deterministic analysis. b, 
Superimposed stochastic (wavy lines) and deterministic (continuous straight lines) 
simulation runs of a system composed of a single autocatalytic species, with parameter 
values (see Materials and Methods) such that the upper steady-state solution is either high 
(black curves) or low (red curves) (respectively, 50 and 10 molecules per cell volume of 
1 µm3). A star indicates when a stochastic run has reached the zero absorbing state. In the 
lower case (red curves), the deterministic solution clearly differs from the average 
stochastic run, because all runs reach zero and stay there. 
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Building the p53/Mdm2 synthetic oscillator in budding yeast (Saccharomyces 
cerevisiae) 
Fundamental pre-requisites for the successful construction of the p53/Mdm2 
synthetic oscillator in yeast are that:  
a) p53 is stable when expressed alone and degraded only in the presence of Mdm2 
b) Mdm2 triggers its own degradation and has a short half life 
c) p53 can induce Mdm2 expression. 
p53 has already been shown to bind in yeast to p53-responsive elements and start 
transcription of downstream genes (Oliner et al., 1993), so we only need to ascertain that 
p53 is not being substantially degraded by some yeast enzyme in an Mdm2-independent 
fashion and that Mdm2 performs its E3 ubiquitin ligase activity in cooperation with the 
endogenous components of the ubiquitin pathway, finally leading to p53 proteasomal 
degradation.  
 
Based on the results published by Lahav et al. (Lahav et al., 2004), we decided upon 
using the fusion proteins p53-ECFP and Mdm2-EYFP, since this allows monitoring 
single cells – with techniques such as time-lapse fluorescence microscopy or FACS.   
 
 
p53-ECFP is stable when expressed alone in yeast  
In order to determine whether p53-ECFP is degraded in yeast cells, I performed a 
pulse-chase-like experiment, in which p53-ECFP expression is triggered with the 
addition of galactose in the culture medium and either it is stopped adding glucose in the 
same medium or all protein synthesis is halted by adding cycloheximide. In the first case, 
we are blocking gene expression, while in the second we are blocking translation of any 
mRNA into protein. If p53 or Mdm2 mRNA is very stable, in fact, adding glucose to the 
medium could still result in accumulation of the protein over time. On the other hand, 
cycloheximide prevents translation of any mRNA in the cell (Emmerich et al., 1975) 
(which makes it toxic in the long run), so it is not suited to study the degradation of p53 
in the presence of Mdm2, since it would prevent formation of Mdm2 as well. In this case, 
in fact, Mdm2 must be kept at constant levels, while p53 must be given a pulse.  
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I therefore used cycloheximide only to check the stability of p53-ECFP and Mdm2-EYFP 
when they are expressed separately, but used glucose when p53-ECFP and Mdm2-EYFP 
are co-expressed, being respectively under the inducible GAL or constitutive TEF 
promoter.  
The pool of molecules produced during the induction stage is then monitored over time, 
collecting samples at fixed intervals. If the protein is not degraded and repression is 
effective, we expect its levels to remain constant when equal volumes of sample are 
loaded on the gel. Figure 2.2.1 shows that p53-ECFP is stable under these conditions. I 
repeated the same experiment several times, monitoring the fusion protein levels for up to 
six hours and no degradation was observed (data not shown)1. 
 
 
Figure 2.2.1 | p53-ECFP is stable in budding yeast. Human p53 wild type gene was 
fused to ECFP and cloned into a yeast plasmid under the inducible GAL promoter. Cells 
harbouring the p53-ECFP fusion protein were grown at 30°C and when they reached 
logarithmic growth phase, protein expression was induced by adding 2% final 
concentration (f.c.) of galactose to the medium. Induction lasted one hour; subsequently 
cycloheximide was added to 100 µg/ml f.c. Samples were collected every half an hour 
starting from the moment in which protein synthesis is stopped (time 0’), for a total 
period of one and a half hours. No significant degradation of the p53-ECFP fusion 
protein was observed in this experiment as well as in several other experiments where the 
protein levels were monitored for longer time.  
 
 
p53-ECFP does not interfere with yeast gene expression under normal growth 
conditions    
In order to proceed with the construction of the synthetic oscillator, we wanted to 
determine whether the p53-ECFP transcriptional activity would interfere with the normal 
                                                 
1 For all results presented in the thesis, I performed at least two independent experiments under the same 
conditions. Each figure shows only one representative experiment.   
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gene expression in yeast cells. Bioinformatics predictions conducted for us by BioBase 
suggested that the yeast genome possesses many putative p53-responsive promoters. To 
eliminate the possibility that p53 could interfere with the normal expression profile of 
yeast cells and to get more confident that our synthetic circuit would not cross-talk with 
endogenous signalling pathways, the EMBL Gene Core Facility performed microarray 
analysis on total RNA extracted from exponentially growing yeast cells (ESM356-1), 
comparing the gene expression profiles of yeast cells containing an empty plasmid and 
cells containing the plasmid carrying the p53-ECFP fusion gene. Since there was no 
significant change in the expression profiles between control and p53-ECFP containing 
cells, we can rule out a significant effect of p53 on yeast transcription, which is a 
prerequisite for our circuit (Figure 2.2.2). 
 
 
 
Figure 2.2.2 | Correlation between expression profiles of control (X axis) and p53-
ECFP harbouring cells (Y axis). Cells carrying an empty plasmid and cells carrying the 
plasmid containing the p53-ECFP fusion protein were grown at 30°C and induced with 
GAL once they reached the exponential growth phase. Induction was carried on for two 
and a half hours, then cells were lysed and total RNA extracted and prepared for chip 
hybridization (see Materials and Methods). Comparing the expression profiles of control 
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and p53-ECFP containing cells, only few genes lied outside the significance threshold 
and they had no apparent relation to p53. Globally, the p53-ECFP transcription factor 
does not interfere with the normal gene expression in budding yeast.  
 
 
 
p53-ECFP is diffused throughout the yeast cell nucleus and can be found at the septin 
ring  
In order to determine the localization of the p53-ECFP fusion protein in budding 
yeast, I used fluorescence microscopy to image living cells. Figure 2.2.3 shows that the 
p53-ECFP fusion protein mainly concentrates in what seems to be the cell nucleus, but 
can also be detected in the cytoplasm, sometimes along a line. Since most Höechst 33352 
fluorescence displays in the ECFP channel, staining the cell nucleus with this dye in the 
presence of a CFP-tagged protein yields ambiguous results if the protein of interest does 
localize in the nucleus. Nevertheless we could speculate that the p53-ECFP fusion protein 
resides in the nucleus by looking, for instance, at budding cells where the nucleus is 
easily detected at the interface between mother and daughter cells (see red arrow in 
Figure 2.2.3).  
In human cells, p53 is found in the cytoplasm and in the nucleus (in a cell cycle 
dependent fashion) (Liang et al., 2001), so the distribution of p53-ECFP in yeast cells 
seems to recapitulate what happens in human cells.   
Interestingly, the protein is also found at the septin ring (Figure 2.2.4) and this 
localization is likely not an artefact, considering that for instance Mdm2 is never found 
there (see below) and that usually exogenous proteins expressed in yeast are either 
cytoplasmic or nuclear (Prof. Ed Hurt, personal communication). 
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Figure 2.2.3 | Localization of p53-ECFP in yeast cells. Cells were grown at 30°C and 
gene expression was triggered by the addition of 2% f.c. galactose in the exponentially 
growing culture. After 1 hour of induction, the cells were imaged using excitation and 
emission filters for CFP (see Materials and Methods). p53-ECFP can be detected in both 
the cytoplasm and the nucleus of yeast cells, with higher nuclear concentration levels as 
compared to the cytoplasmic ones.      
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Figure 2.2.4 | p53-ECFP localizes to the septin ring. Cells were grown at 30°C and 
gene expression was triggered by the addition of 2% f.c. galactose in the exponentially 
growing culture. After 1 hour of induction, the cells were imaged using excitation and 
emission filters for CFP (see Materials and Methods). p53-ECFP localizes to the septin 
ring of yeast cells, suggesting an interaction of p53 with endogenous proteins localized 
there (see Discussion). 
 
 
Once ascertained that the yeast copes well with the presence of the exogenous p53-ECFP 
fusion protein, that p53-ECFP exhibits a normal distribution in the cell and it does not get 
degraded when expressed alone, I went on testing whether Mdm2 was able to 
ubiquitylate itself, getting degraded by the proteosome.  
 
 
Mdm2-EYFP is degraded in yeast 
To look at Mdm2-EYFP fusion protein stability in yeast cells I used the same type 
of experiment performed with p53-ECFP. While in human cells the half life of Mdm2 is 
very short, ranging from 5 to 20 minutes, in yeast Mdm2 has a half life of about one hour 
(Figure 2.2.5). Considering that the average half life of a yeast protein is about 40 
minutes (Belle et al., 2006), we can conclude that Mdm2 is not as rapidly degraded in 
yeast as in human cells.   
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Figure 2.2.5 | Mdm2-EYFP is degraded in yeast. Cells were grown at 30°C and 
induced with 2% f.c. galactose once they reached exponential growth phase. To stop 
protein synthesis cycloheximide was added to 100 µg/ml f.c. Protein level was calculated 
using Adobe Photoshop as explained in Materials and Methods. Three independent 
experiments were used to calculate the average protein level for each time point. Inset: 
representative western blot to show the degradation of Mdm2-EYFP. Time course is as in 
the graph. Mdm2-EYFP reaches 50% of its initial level about one hour after protein 
synthesis is inhibited.  
 
 
Mechanisms underlying Mdm2-EYFP degradation 
From the previous experiment it is possible to conclude that Mdm2-EYFP fusion 
protein has a half-life of about one hour, but it is not possible to attribute this degradation 
solely to the autoubiquitylation activity of Mdm2. In fact, there could be four 
explanations:  
a) degradation is due only to Mdm2 autoubiquitylation 
b) degradation is only due to the action of some endogenous enzyme(s) 
c) degradation is due to both autoubiquitylation and ubiquitylation by some yeast 
enzyme(s) 
d) degradation is not ubiquitin dependent (it is vacuolar).  
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In order to shed some light on the mechanisms underlying Mdm2 degradation, I 
generated a mutant Mdm2, Mdm2H452A, which was shown not to ubiquitylate itself nor 
p53 in human cells, due to a mutation in its RING domain (Honda et al., 2000). If 
Mdm2H452A-EYFP is stable, we can conclude that Mdm2 degradation is due only to 
autoubiquitylation. Unfortunately, since the mutant protein appears to be degraded to the 
same extent – or more (Figure 2.2.6 and 2.2.7) – than wild type Mdm2 (Figure 2.2.6), we 
can only eliminate possibility a, but we cannot distinguish between cases b, c and d. This 
result, however, mirrors what happens in human cells, where Mdm2 lacking its RING 
domain, or harbouring a point mutation in the active site, is still capable of being 
degraded, suggesting the presence of other mechanisms for keeping Mdm2 half life short 
(Brooks et al., 2004). 
 
 
 
 
Figure 2.2.6 | Mdm2 carrying a mutation in its RING domain is degraded in yeast. 
Cells were grown at 30°C and induced with 2% f.c. galactose once they reached 
exponential growth phase. To stop protein synthesis cycloheximide was added to 100 
µg/ml f.c. Samples were collected every hour starting from the moment in which protein 
synthesis is inhibited. Mdm2H452A-EYFP fusion protein, carrying a point mutation in 
the RING domain which inhibits the E3 ubiquitin ligase function, is degraded in yeast 
like the wild type protein, indicating that autoubiquitylation is not – if at all – the cause of 
Mdm2 degradation.  
 
 
 
 
Chapter Two Results Part Two 
 64
Mdm2-EYFP degradation is proteasome-dependent 
To see whether Mdm2-EYFP degradation is mediated by ubiquitin, I used a yeast 
strain (pre1-1 pre2-2) for which proteasomal degradation is impaired (Heinemeyer et al., 
1993). When the protein is expressed in this mutant strain, we expect to see a slowing-
down in its degradation, provided it is proteasome-dependent. This is what we observe 
for both wild type and mutant Mdm2 (Figure 2.2.7).  
 
 
 
 
Figure 2.2.7 | Mdm2-EYFP degradation is proteasome-dependent. Plasmids 
containing Mdm2-EYFP and Mdm2H452A-EYFP genes under the GAL promoter were 
transformed (separately) in a wild type yeast strain and a mutant strain (pre1-1 pre2-2) 
impaired in proteasomal degradation. Induction was done with 0.5% f.c. galactose for 1 
hour. Expression from the GAL promoter was blocked adding 3% f.c. glucose to the 
same medium. Time 0’ corresponds to the moment in which protein synthesis is blocked. 
Samples are collected every hour, for a total of four hours. Degradation of both wild type 
and mutant Mdm2 proteins is slowed-down in the mutant strain, indicating that their 
degradation is proteasome-dependent. 
 
 
From these experiments we can conclude that Mdm2-EYFP degradation is proteosomal 
and to a large extent independent of any autoubiquitylation activity. 
 
 
Mdm2-EYFP localizes to the yeast nucleus and to one or several nuclear speckles   
Mdm2-EYFP localization was determined by fluorescence microscopy (Figure 
2.2.8) and indirect immunofluorescence (Figure 2.2.9). Both techniques reveal a nuclear 
localization, although only with fluorescence microscopy it is possible to detect one or 
more nuclear speckles in which Mdm2-EYFP accumulates.  
 
Chapter Two Results Part Two 
 65
 
 
Chapter Two Results Part Two 
 66
Figure 2.2.8 | Mdm2-EYFP fusion protein localizes to the yeast nucleus and to one 
or several nuclear speckles. In the merged image, the Höechst signal is shown in blue 
and the Mdm2 is shown in red. a, Cells were grown at 30°C and gene expression was 
triggered by the addition of 2% f.c. galactose in the exponentially growing culture. After 
1 hour of induction, the cells were imaged using excitation and emission filters for YFP 
(see Materials and Methods). Mdm2-EYFP shows no localization in the cytoplasm as 
compared to p53-ECFP. b, Höechst 33352 was added to the medium to stain the DNA. 
These cells also contain the p53-ECFP plasmid, but were imaged before p53 gene 
expression was triggered with galactose.   
 
 
 
 
 
 
Figure 2.2.9 | Indirect immunofluorescence of yeast cells expressing Mdm2-EYFP 
fusion protein. Cells were grown at 30°C and gene expression was triggered by the 
addition of 2% f.c. galactose in the exponentially growing culture. Immunofluorescence 
was performed as described in Materials and Methods. DNA was stained with Höechst 
33352 (shown in blue). Mdm2-EYFP was stained using the monoclonal SMP14 antibody 
(shown in red). Mdm2-EYFP localizes to the nucleus of yeast cells, sometimes 
accumulating in a round area at the tip of the Höechst signal (see red arrows and Figure 
2.2.8b).  
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Comparing figures 2.2.8 and 2.2.9, it is evident that while with fluorescence microscopy 
the discrete dots in which Mdm2-EYFP localizes are visible, with indirect 
immunofluorescence Mdm2-EYFP appears mostly evenly distributed in the cell nucleus 
or at maximum concentrated in a single spot at the extremity of the DNA signal. One 
explanation for this difference is that the antibody used to detect the protein in the 
immunofluorescence cannot access the structures in which the protein is found, or that it 
cannot access the epitope it recognizes when the protein is localized in these structures. 
The antibody, then, binds only to the nuclear fraction of the protein pool, resulting mainly 
in a homogenous nuclear staining. In fact, only perfect fixation would immobilize the 
antigens, while retaining authentic cellular and subcellular architecture and permitting 
unhindered access of antibodies to all cells and subcellular compartments. Cross-linking 
reagents (such as formaldehyde) in general preserve well cell structure, but may reduce 
the antigenicity of some cell components.   
 
 
 
Mdm2-EYFP localization is very dynamic 
In order to follow the localization of the protein through time, I also performed 
time-lapse microscopy. Mdm2-EYFP non-homogeneous nuclear distribution, 
characterized by several dots often at the nuclear periphery, is very dynamic, with dots 
appearing and disappearing, fusing and sometimes separating again into single dots 
(Figure 2.2.10).  
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Figure 2.2.10 | Mdm2-EYFP localization is very dynamic. Cells harbouring the 
Mdm2-EYFP plasmid were grown at 30°C until they reached exponential growth phase. 
Cells were then adhered to the bottom of a Petri dish for live imaging (see Materials and 
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Methods). Galactose was added directly into the Petri dish and time-lapse started at this 
point. Movies are shown from the moment in which the fluorescent signal starts rising. In 
most cells, Mdm2-EYFP first appears distributed into discrete loci, which tend to fuse 
into a single very bright dot. Sometimes several dots appear in other regions of the 
nucleus as compared to the bright bigger dot.    
 
 
In human cells, Mdm2 is mainly nuclear, (although it can shuttle between the nucleus and 
the cytoplasm), so the presence of Mdm2-EYFP in the yeast nucleus is not surprising. 
The dotty localization of the protein is instead very intriguing and does not have an 
immediate correspondent in human cells (see Discussion).  
 
 
The first two requirements for the successful construction of the synthetic oscillator are 
satisfied – p53-ECFP being stable in the absence of Mdm2-EYFP and Mdm2-EYFP 
being degraded when on its own. Also, the fusion proteins do not show abnormal 
distributions inside the yeast cells, which would have prevented the use of this model 
organism to host our synthetic circuit. Next, I needed to determine whether the Mdm2-
EYFP fusion protein is able to ubiquitylate p53-ECFP, targeting it for proteasomal 
degradation. 
 
 
p53-ECFP is not degraded in the presence of Mdm2-EYFP 
 To analyse Mdm2-dependent p53 degradation, I transformed yeast cells with two 
plasmids, one harbouring the Mdm2-EYFP fusion gene under the constitutive TEF 
promoter, and another carrying the p53-ECFP fusion protein under the inducible GAL 
promoter. In this way, the cells have a constant level of the E3 ubiquitin ligase Mdm2 
while p53 expression is given a pulse and then stopped. As previously mentioned, in this 
case gene expression from the GAL promoter is blocked by adding glucose to the 
medium. Notably, using the concentrations of galactose and glucose indicated in the 
literature (2% for both), the promoter was not completely shut off and protein 
degradation (in the case of Mdm2) was masked (data not shown). I found that inducing 
with 0.5% galactose and repressing with 3% glucose yielded the desired outcome. 
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Samples are collected as previously explained. To our great disappointment, the presence 
of Mdm2 does not affect p53 stability, leading us to conclude that Mdm2-EYFP is for 
some reason not able to ubiquitylate p53-ECFP under these conditions (Figure 2.2.11).  
 
 
 
Figure 2.2.11 | p53-ECFP is stable in the presence of Mdm2-EYFP. Cells containing 
both p53-ECFP and Mdm2-EYFP – respectively under the GAL and TEF promoters – 
were grown at 30°C until exponential growth phase. Gene expression from the GAL 
promoter was triggered by adding 0.5% f.c. galactose to the medium and was inhibited by 
adding 3% f.c. glucose to the same medium. An equal volume of sample (1 ml) was 
collected at every time point and an equal volume of treated sample was loaded in each 
lane of the gel. BI stands for Before Induction. p53-ECFP is not degraded in the presence 
of Mdm2-EYFP.  
 
 
p53-ECFP and Mdm2-EYFP interact and co-localize to a dot inside the yeast nucleus 
 Western blot analysis of cells expressing p53-ECFP and Mdm2-EYFP reveals that 
p53-ECFP is not degraded in the presence of Mdm2.  This could be due to the fact that 
the proteins do not interact in the yeast cells. Fluorescence microscopy of living cells, 
expressing both p53-ECFP and Mdm2-EYFP, demonstrates that the proteins always co-
localize to a dot, strongly suggesting that they do interact – directly or indirectly (Figure 
2.2.12). 
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Figure 2.2.12 | p53-ECFP and Mmd2-EYFP co-localize to a dot in yeast cells. Cells 
were grown at 30°C and gene expression was triggered by the addition of 2% f.c. 
galactose in the exponentially growing culture. After 1 hour of induction, the cells were 
imaged using excitation and emission filters for CFP and YFP (see Materials and 
Methods). Mdm2-EYFP is shown in red and p53-ECFP in green. Co-localization results 
in yellow colour for the dot. Whenever the two proteins are expressed in the same cell, 
they co-localize. 
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To understand whether the dot formed by p53-ECFP and Mdm2-EYFP lied inside or 
outside the nucleus, I performed indirect immunofluorescence and used Höechst 33352 as 
a dye to stain the DNA, while detecting the fusion proteins with antibodies against p53 
and Mdm2.  
Although in some cells the dot overlaps with the Höechst signal, in most cells the dot 
appears to be in contact with the nucleus, but in a Höechst-minus region (Figure 2.2.13). 
Considering that a similar pattern is observed when using the Nop1 antibody to detect the 
nucleolus (with the Nop1 signal being in a Höechst-minus region despite the location of 
the nucleolus inside the nucleus, Figure 2.2.36), we should not interpret the absence of 
overlap as a clear indication that the dot is cytoplasmic.  
Nonetheless, these results do not allow us to conclude that the dot resides inside the 
nucleus either. To clarify the localization of the dot in respect to the nucleus, we 
performed electron microscopy (see below) which showed unambiguously that the dot is 
indeed inside the nucleus.   
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Figure 2.2.13 | p53-ECFP and Mdm2-EYFP co-localization in respect to the yeast 
nucleus. Indirect immunofluorescence was performed as described in Materials and 
Methods using the mouse monoclonal PAb 1801 anti-p53 antibody and the mouse 
monoclonal SMP14 anti-Mdm2 antibody. The DNA is shown in blue, while the p53-
ECFP/Mdm2-EYFP complex in green. In most cells, the dot is detected at the edge of the 
nucleus, in a Höechst-minus region.  
 
 
When a mutant p53 (p53W23S-ECFP) which does not bind Mdm2 due to a point 
mutation in the Mdm2 binding domain (Inoue et al., 2001) is co-expressed with Mdm2-
EYFP in yeast cells, the dot is lost, suggesting that the binding of p53 to Mdm2 is 
required in order for the two proteins to co-localize (Figure 2.2.14). This result 
completely eliminates the possibility that p53-ECFP stability in the presence of Mdm2-
EYFP is due to the inability of the proteins to interact with each other.  
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Figure 2.2.14 | Binding of p53 to Mdm2 is required for their co-localization. Cells 
were grown at 30°C and gene expression was triggered by the addition of 2% f.c. 
galactose in the exponentially growing culture. After 1 hour of induction, the cells were 
imaged using excitation and emission filters for CFP and YFP (see Materials and 
Methods). Cells express Mdm2-EYFP and a mutant p53 which does not bind to Mdm2 
(p53W23S-ECFP). p53-ECFP is shown in blue, Mdm2-EYFP in green. In this case, the 
fluorescent signals in the CFP and YFP channels resemble those obtained with p53-ECFP 
alone and Mdm2-EYFP alone respectively.  
 
 
At this point it seemed that we could not build the synthetic p53-Mdm2 oscillator relying 
only on these two proteins. We therefore revised our design several times, adding to the 
circuit different components that we thought could allow p53 degradation to happen. 
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On the road to degradation, first attempt: adding the human ubiquitin chain 
elongation factor p300 to the network  
While this study was being done, a new type of enzyme in the ubiquitylation 
pathway was described: the E4, also called “chain elongation factor” due to its ability to 
ligate ubiquitin molecules to a nascent chain of ubiquitins on a substrate protein (see 
Introduction). Grossman et al. showed that the acetyltransferase p300 – previously 
known to acetylate and activate p53 after DNA damage – has also intrinsic E3 ligase 
activity and that together with Mdm2 it works as an E4 and targets p53 for proteasomal 
degradation catalysing p53 polyubiquitylation as opposed to monoubiquitylation 
catalysed by Mdm2 alone (Grossman et al., 2003). Using truncated versions of the 
protein, these authors could ascribe p300 catalytic activity to its N-terminus (a.a. 1-595).  
In light of these results, I interpreted the lack of p53 degradation to the fact that, without 
p300, Mdm2 can only monoubiquitylate p53, a signal which is not sufficient to target p53 
to the proteasome. I therefore cloned human p300 N-terminus (p300(CH1)), hoping that 
this would represent the solution to problem. Unfortunately, p53-ECFP is stable also 
when Mdm2-EYFP and p300(CH1) are co-expressed in the cell (Figure 2.2.15) 
 
 
Figure 2.2.15 | p53-ECFP is stable in the presence of Mdm2-EYFP and p300(CH1). 
Cells containing three plasmids, one carrying p53-ECFP under the GAL promoter, one 
carrying Mdm2-EYFP under the TEF promoter and one carrying p300(CH1) under the 
TEF promoter were grown at 30°C until exponential growth phase. Gene expression from 
the GAL promoter was triggered by adding 0.5% f.c. galactose to the medium and was 
inhibited by adding 3% f.c. glucose to the same medium. An equal volume of sample (1 
ml) was collected at every time point and an equal volume of treated sample was loaded 
in each lane of the gel. BI stands for Before Induction. p300(CH1) expression was not 
directly detected with an antibody, but the plasmid was sequenced to make sure that the 
gene sequence was correct and in the right frame. The same result was obtained using 
native p53 and Mdm2 and p300(CH1) fused to the FLAG tag (see Figure 2.2.18a), thus 
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we can conclude that Mdm2-EYFP and p300(CH1) do not suffice to trigger p53-ECFP 
degradation in yeast cells. 
 
 
On the road to degradation, second attempt: Removing the fluorescent proteins from 
p53 and Mdm2  
At this stage, we started wondering whether the presence of the fluorescent 
protein at the C-termini of p53 and Mdm2 could affect their proper folding, the 
accessibility of the residues to be modified (in the case of p53), or the enzymatic activity 
(in the case of Mdm2). Although we used exactly the same fusion proteins described in 
(Lahav et al., 2004), we thought that the degradation of p53 that they observed in their 
cell line could be due to the activity of other E3 ubiquitin ligases present in those cells, 
thus leaving the possibility that Mdm2-EYFP might be impaired in its function. Also, the 
tight co-localization of the proteins to the dot might be due to aggregation (see below and 
Discussion) and since it is well known that GFP tends to aggregate (Tsien, 1998) (unless 
the modified monomeric GFP version is used) and considering that p53 forms a tetramer, 
we believed that ECFP and EYFP might prevent ubiquitylation to occur. Furthermore, 
protein over-expression might as well be the cause of aggregation; I therefore decided to 
clone the p53 and Mdm2 wild type genes this time under the weaker inducible GALS 
promoter and – when expression ought to be constant – the constitutive weaker ADH 
promoter.  
Surprisingly, Mdm2 levels under the ADH promoter were not constant with time as it 
was supposed to be.  Since Mdm2 levels need to be reliably constant if we want to 
increase our chances to degrade p53, I cloned the mdm2 gene under the strong 
constitutive TEF promoter, the one used with the fusion protein Mdm2-EYFP. The 
choice of a strong promoter for the Mdm2 is also supported by the consideration that in 
the literature, for both in vitro and in vivo ubiquitylation assays, Mdm2 levels 
consistently appear to be at least twice those of p53 (see (Shimizu et al., 2002) for 
example).  
Figure 2.2.16 shows that the native proteins behave like the fusion proteins when 
expressed alone and also when co-expressed, leading to the conclusion that the fusion 
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proteins are functional – as was shown by (Lahav et al., 2004) – and that the failure of 
p53 degradation is not to be ascribed to the presence of the fluorescent proteins. 
 
 
 
Figure 2.2.16 | Stability of the p53, Mdm2 native proteins in yeast.  Cells were grown 
at 30°C until exponential growth phase. Gene expression from the GAL or the GALS 
promoter was triggered by adding 0.5% f.c. galactose to the medium and was inhibited by 
adding 3% f.c. glucose to the same medium. a, Samples were collected before adding the 
galactose (BI), when adding the glucose (0’), 3 hours (3h) and 5 hours (5h) after stopping 
induction. Mdm2 levels decrease at time point 5h independently of p53. p53 is stable 
regardless the presence of Mdm2. NC indicates the negative control. b, Mdm2 native 
protein is degraded fast, confirming what we observed with the fusion protein. BI refers 
to the sample collected before induction with galactose.  
 
 
Since tagging a protein with the fluorescent protein GFP can sometimes alter its 
localization (Huh et al., 2003), I took advantage of having both native and fusion proteins 
to check whether their showed different localizations. Indirect immunofluorescence 
reveals no difference in the localization of native versus fusion proteins (data not shown).   
 
 
On the road to degradation, third attempt: cloning the human E2, UbcH5B  
Our belief that the human E3 ligase Mdm2 could function in budding yeast was 
based on the consideration that the human E2 (UbcH5B) – known to catalyze the passage 
of ubiquitin onto p53 in interaction with Mdm2 (Saville et al., 2004) – and its yeast 
homologue (Ubc4) share a very high homology (79% identities, 90% conservative 
changes). The stability of p53 in the presence of its negative regulator Mdm2 led us to 
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think that this homology might not suffice for the yeast E2-human E3 interaction to be 
efficient. Indeed, there exist several E2s in a cell, each interacting with only a subset of 
E3s, thus indicating a certain degree of selectivity already at the level of the E2s. In an 
attempt to correct for what we thought had been a naïve assumption responsible for p53 
failed degradation, I cloned UbcH5B in a yeast expression plasmid and co-expressed it 
with only Mdm2 or with p53 and Mdm2 together. To our great surprise and 
disappointment, p53 was not degraded even under these conditions (Figure 2.2.17). 
 
 
 
 
Figure 2.2.17 | p53 is stable in the presence of Mdm2 and UbcH5B. Cells were grown 
at 30°C until exponential growth phase. Gene expression from the GAL promoter was 
triggered by adding 0.5% f.c. galactose to the medium and was inhibited by adding 3% 
f.c. glucose to the same medium. a, Western blot analysis using an antibody against 
UbcH5B confirms expression of the protein. b, p53 is not degraded by Mdm2 in the 
presence of its human E2 partner.   
 
 
 
On the road to degradation, fourth attempt: combining p300(CH1), UbcH5B and 
Mdm2  
The fact that p53 is not being degraded when Mdm2 and UbcH5B are present in 
the yeast cells does not exclude the possibility that p300 is needed to polyubiquitylate 
p53 and order its degradation through the proteasome. Consequently, I built a plasmid 
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containing UbcH5B and p300(CH1) both under the TEF promoter and co-transformed it 
into cells together with a plasmid carrying the p53 gene and a plasmid carrying the mdm2 
gene. As can be seen in Figure 2.2.18, p53 is still stable under these conditions.  
 
 
 
 
Figure 2.2.18 | p53 is stable in the presence of Mdm2, UbcH5B and p300(CH1). a, 
Western blot on cells containing p300(CH1)-FLAG to show that the protein is expressed. 
p300 is under the constitutive TEF promoter. b, In this experiment, cells were induced in 
the late exponential growth phase and last samples collected with the cells in stationary 
phase. Cell growth is thus limited and on the blot we do not see the accumulation of 
Mdm2 that we see in the other blots. I performed the same type of experiment later, this 
time under usual growth conditions and confirmed the result, eliminating the possibility 
that failed p53 degradation could be due to the cells being in stationary phase (data not 
shown).  
 
 
On the road to degradation, fifth attempt: lowering the expression levels of p53; 
doubling the amount of Mdm2   
Since little quantitative data are available for the p53 network, we don’t know 
what the relative concentrations of p53 and Mdm2 allowing ubiquitylation to occur are. 
One could speculate that too much substrate inhibits the reaction and that we must have 
an excess of E3 ligase. Otherwise, we might assume that the substrate, E2 and E3 need to 
be at equimolar ratios or even that, being ubiquitylation an enzymatic reaction, little 
amounts of Mdm2 are sufficient to ubiquitylate p53. In principle, we should explore 
many different expression levels for p53 and Mdm2. In practise, this is very time-
consuming, so we restricted ourselves to reducing p53 levels while keeping the same 
Mdm2 levels as we had before. In order to determine the minimal amount of galactose 
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that induces p53 to a level which is detectable on a western blot, I performed an induction 
curve of the p53 under the GALS promoter (Figure 2.2.19), and decided to use for further 
experiments galactose to a final concentration of 0.006%. It should be noted that the 
concentration of galactose had to be really low in order to have a non-saturated curve; in 
fact, when spanning concentrations ranging from 0.01% to 1%, p53 levels are already 
saturated (data not shown).   
 
 
Figure 2.2.19 | p53 induction curve. Cells carrying p53 were grown up to exponential 
phase, then the culture was split in different subcultures, each of which was induced 
using an increasing amount of galactose. Samples were collected immediately and three 
hours after stopping induction with 3% f.c. glucose. a, western blot showing p53 levels as 
a function of galactose concentration; b, the western blot data were quantified using 
Adobe Photoshop (Materials and Methods) and the induction curve drawn in Excel. In 
the graph, the data point corresponding to no galactose (0%) is put to zero and this value 
is subtracted to all other data points.  
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Figure 2.2.20 shows that even when p53 expression levels are reduced, while keeping 
Mdm2 levels as before, degradation does not occur.  
 
 
Figure 2.2.20 | Lowering expression levels of p53 does not bring degradation about. 
Cells were grown at 30°C until exponential growth phase. Gene expression from the 
GAL promoter was triggered by adding, respectively, 0.006% and 0.5% f.c. galactose to 
the medium and was inhibited by adding 3% f.c. glucose to the same medium. Samples 
were collected every hour, starting from the moment in which glucose was added to the 
medium, for a total amount of three hours. Lowering p53 expression level does not lead 
to its degradation.  
 
 
On the road to degradation, sixth attempt: using a p53 mutant (p53F270A) that is 
hyper-ubiquitylated in human cells 
Shimizu et al. have shown that mutating phenilalanine 270 to alanine renders the 
p53 hyper-susceptible to Mdm2-mediated ubiquitylation (Shimizu et al., 2002). I decided 
to generate the same mutant used in that study hoping that this would increase p53 
ubiquitylated species, and consequently our chances to detect some degradation. To our 
surprise, I found that this mutant p53 is very unstable on its own and therefore we cannot 
conclude that degradation is due to the action of Mdm2 (Figure 2.2.21). Moreover, this 
mutant is not a good candidate for the construction of the synthetic oscillator, since we 
need a p53 protein that is stable on its own and degraded in an Mdm2-dependent fashion.  
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Figure 2.2.21 | p53F270A is degraded regardless the presence of Mdm2. Cells were 
grown at 30°C until they reached exponential growth phase. Gene expression from the 
GAL promoter was triggered by addition of 0.006% galactose to the medium and was 
inhibited by addition of 3% f.c. glucose to the same medium. Samples were collected in 
the moment in which glucose was added to the medium and every hour afterwards, for a 
total amount of 3 hours. p53F270A is unstable in the absence or presence of Mdm2.  
 
  
Mdm2 is modified in yeast  
Mdm2 is known to be subject, in human cells, to almost as many post-
translational modifications as p53 itself. It is plausible, then, that Mdm2 is being 
modified in yeast in a way that affects its E3 ligase activity towards p53. One way to 
verify if this is happening is to compare Mdm2 status at different time points. To do this, 
we need Mdm2 to be under an inducible promoter, so that we can decide when the 
protein is made and follow it from that moment on.  
As inducible promoter I decided to use a p53 responsive one – so that Mdm2 expression 
is p53-dependent – because, on the one hand I can double-check the ability of my p53 
clone to activate transcription in yeast as previously described (Oliner et al., 1993) and, 
on the other hand, I can obtain information on the timings of Mdm2 expression in 
response to p53 induction, which can be useful for the construction of the synthetic 
oscillator (as well as for a mathematical model of the synthetic network). Remarkably, 
the P2 promoter that drives Mdm2 gene expression in human cells in response to p53 
binding does not work in budding yeast (data not shown). Only when I used the same 
promoter described in Oliner et al., which comprises several repeats of the p53 consensus 
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sequence, did I observe Mdm2 expression. From these results, we speculate that one or 
two repeats of the p53 consensus sequence do not suffice to start a p53 transcriptional 
response from such a promoter. Rather additional elements – such as enhancers and co-
factors – are needed. Figure 2.2.22 shows p53-dependent Mdm2 induction in yeast cells. 
From this experiment, it is evident that Mdm2 is modified in yeast as specific higher 
molecular weight bands are observed.                                                                                                                 
 
 
 
 
Figure 2.2.22 | p53-dependent Mdm2 induction in yeast. Cells carrying a plasmid with 
the p53 under the GAL promoter and a plasmid with Mdm2 under a p53-responsive 
promoter were grown up to exponential growth phase. Induction of p53 expression was 
done with 0.5% f.c. galactose. Glucose was not added to stop induction. The red stars 
indicate less mobile species which correspond to modified Mdm2.  
 
 
Since we know that Mdm2 is being degraded through the ubiquitin-proteasome pathway, 
it is likely that the bands are ubiquitylated forms of the protein. I tried to purify the 
protein (6xHIS-tagged), but the amount of protein obtained was not sufficient to detect a 
signal when probing with an antibody against ubiquitylated proteins. Therefore, we 
cannot be sure of the nature of these modifications and we also cannot conclude that they 
are the cause of failed p53 degradation.  
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On the road to degradation, last attempt: changing E3 ligase 
At this point, it was evident that, for some reason, the human E3 ligase Mdm2 
cannot ubiquitylate p53 in yeast, at least not to an extent sufficient to trigger its 
degradation (see Discussion for an analysis of the reasons why Mdm2 might not lead to 
p53 degradation in budding yeast). Since, as mentioned in the Introduction, Mdm2 is not 
the only E3 ubiquitin ligase responsible for p53 ubiquitylation in human cells, I decided 
to test the behaviour of two other E3 ligases for p53, COP1 and Pirh2.  
I first cloned the human COP1 into a yeast expression plasmid and analyzed p53 levels in 
its presence. Unfortunately, the COP1 antibody was extremely “noisy” and COP1 
expression cannot be detected unambiguously. Therefore it is possible that p53 is not 
degraded because COP1 is not expressed (although the sequences of both the ORF and 
the promoter were verified before transforming the construct in yeast cells). Surely, p53 
is not degraded when the E3 ligase Pirh2 (which I cloned introducing the 6xHIS tag and 
whose expression I could detect using an antibody against this tag) is used in place of 
Mmd2 (Figure 2.2.23).  
 
 
Figure 2.2.23 | p53 is not degraded in yeast by the human E3 ligase Pirh2. Cells 
carrying a plasmid with the p53 under the GAL promoter and a plasmid with the Pirh2 
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under the TEF promoter were grown up to exponential growth phase. Induction of p53 
expression was done with 0.006% f.c. galactose. 3% f.c. glucose was not added to stop 
induction. a, Western blot showing that Pirh2 is expressed. Due to space limitation on the 
gel, only samples 0’, 1h and 3h were run. b, Comparison between p53 levels in the 
absence (left) or presence (right) of the human E3 ubiquitin ligase Pirh2. p53 is stable in 
either case.    
 
 
In conclusion, p53 is not being degraded in the presence of any of the ubiquitin E3 
ligases tested in this study known to ubiquitylate p53 in human cells.  
 
 
 
p53 is modified in the presence of Mdm2  
Although p53 levels proved to be extremely stable under all the conditions I 
tested, I noticed that, when loading a sufficiently high amount of p53 on the gel, a less 
mobile p53 species appears on the western blot only in the presence of Mdm2 (Figure 
2.2.24).  
Since this band is about 8-10 KDa higher than wild type p53, we thought it might be a 
monoubiquitylated form of p53. In order to make sure that this band is not an artefact due 
to unspecific binding of the antibody, I used another antibody against a different epitope 
on p53 and obtained the same result (data not shown). 
 
 
Figure 2.2.24 | p53 is modified in yeast in the presence of Mdm2. Yeast cells carrying 
only p53 or p53 together with Mdm2 were grown at 30°C to exponential phase. The first 
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sample (BI) was collected when 0.5% f.c. galactose was added to the medium to induce 
expression of p53. One hour later, induction was stopped through the addition of 3% f.c. 
glucose and a sample (0’) was collected. Cells were grown for three hours before 
collecting the last sample (3h). The antibody against p53 recognizes an additional band 
(indicated by the red star) only in the samples obtained from cells expressing p53 and 
Mdm2.  
 
 
p53 is similarly modified when Mdm2 is expressed together with p300(CH1), UbcH5B 
or p300(CH1) and UbcH5B contemporarily (Figure 2.2.25). 
 
 
 
Figure 2.2.25 | p53 modification in the presence of p300(CH1) and UbcH5B. Yeast 
cells carrying the indicated constructs were grown at 30°C to exponential phase. The first 
sample (BI) was collected when 0.5% f.c. galactose was added to the medium to induce 
expression of p53. One hour later, induction was stopped through the addition of 3% f.c. 
glucose and a sample (0’) was collected. Cells were grown for three hours before 
collecting the last sample (3h). p300(CH1) and UbcH5B (whose expression was 
previously verified, see Figures 2.2.17a and 2.2.18a) do not appreciably affect the action 
of Mdm2 on p53.   
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Is p53 monoubiquitylated? 
There are several ways to understand what this modification is. The most elegant 
way is to use mass spectrometry, since this technique does not require any a priori 
knowledge on the nature of the modification and simply answers the question: “what is 
it?” Alternatively, one can use antibodies which can specifically recognize the modified 
version of the protein, such as antibodies against mono- and polyubiquitylated proteins. 
This method requires an a priori knowledge of the modification to select the right 
antibody. A third method is also an indirect one and it requires the generation of mutant 
proteins which are no longer modified. Again, we need to guess which is the modification 
and, if mutants have not been described before, one has to predict in silico which residues 
might affect the modification and then test the prediction experimentally.  
While the first two methods require some sort of purification of the protein (e.g. a pull-
down), the third one does not, since we simply need to see that the band disappears when 
using the mutant.  
For the p53, a mutant protein in which the C-terminal lysines are mutated to arginines or 
alanines has been described to no longer be ubiquitylated by Mdm2 in human cells 
(Nakamura et al., 2000; Rodriguez et al., 2000). I therefore generated a p53 mutant 
(which I called p53δ) in which lysines 372, 373, 382 and 383 are mutated to arginines. If 
the higher molecular p53 band is a monoubiquitylated form of the protein, we expect it to 
disappear when using p53δ.  
Strikingly, p53δ appears to be more modified than the wild type (Figure 2.2.26). 
 
 
 
Figure 2.2.26 | p53δ is modified more than wild type p53. Cells were grown at 30°C 
up to exponential growth phase. Induction was done using 0.006% f.c. galactose. To stop 
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induction, 1% glucose was added after one hour to the same medium, and the first 
samples collected (0’). The second samples were collected one and a half hours later 
(1h30’), and three and a half hours later (3h30’). Notably, while the modified p53 – in the 
presence of Mdm2 – is not visible under these conditions (too little amount of p53 on the 
gel, too short exposure time), the band is very dark on p53δ + Mdm2 samples. p53δ alone 
does not have any additional band (data not shown). 
 
 
Also, were the modification monoubiquitylation, the mutant Mdm2 carrying a mutation 
in its RING domain (Mdm2H452A) should not be able to modify p53. I find that, instead, 
the modification is present, and even somehow “stronger” than that obtained with wild 
type Mdm2 (Figure 2.2.27, compare the bands indicated by the red star in lanes 3 and 6).  
 
 
 
Figure 2.2.27 | Mdm2H452A retains its ability to modify p53 in yeast cells. Cells 
were grown at 30°C to exponential growth phase. The first sample (BI) was collected 
when 0.5% f.c. galactose was added to the medium to induce expression of p53. One 
hour later, induction was stopped through the addition of 3% f.c. glucose and a sample 
(0’) was collected. The last sample was collected three hours later (3h). The fact that 
Mdm2H452A, which does not ubiquitylate p53 in human cells, is able to modify p53 in 
yeast argues against p53 modification being monoubiquitylation. 
 
  
All the data collected were in contradiction with the hypothesis that the modification is 
ubiquitylation: a) Mdm2H452A, which should no longer function as a ubiquitin E3 
ligase, works even better than the wild type Mdm2; b) p53F270A, which should be more 
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heavily modified appears to be less modified than the wild type; c) p53δ, which should 
not be ubiquitylated, is more strongly modified.  
At this point, some pieces of evidence came that pointed towards the idea that the 
modification might be sumoylation, which is the only covalent protein modification that, 
like ubiquitin, leads to an increase in molecular weight of around 8 KDa.  
Specifically, in the attempt to purify p53 to probe with an antibody specific for mono- 
and polyubiquitylated proteins, I realized that the band corresponding to modified p53 
was being lost when lysing the cells under native conditions to perform an 
immunoprecipitation (IP) with low detergent concentration (i.e. a concentration that is 
used to immunoprecipitate soluble proteins, and not membrane proteins for instance) 
(Figure 2.2.28) 
 
 
 
Figure 2.2.28 | Modified p53 is lost when performing immunoprecipitation. Yeast 
cells carrying p53 and Mdm2 were grown to exponential growth phase, induced with 
0.5% f.c. galactose for two hours and then harvested. IP was performed using the DO-1 
anti-p53 antibody as described in Materials and Methods. LysateD stands for “lysate 
obtained under denaturing conditions”, while lysateN denotes “lysate obtained under 
native conditions”. FT indicates the flow through, and IP the immunoprecipitation. Upper 
and lower panel represent the same film with different exposure times. The band 
corresponding to modified p53 is lost when lysing the cells under native conditions.  
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When, instead, I purified p53 (6xHIS-tagged) under denaturing conditions using a Ni+-
NTA column, the band could be detected, although it represents a very small fraction of 
the total protein (less than 5%, data not shown).  
These results suggested that either this modified p53 is subject to de-modification in the 
cell lysate, or somehow the modified p53 protein is bound to something inside the cell, a 
membrane, a macromolecular complex or an organelle. From the microscopy studies, we 
knew that p53 co-localizes with Mdm2 in a very bright dot in the vicinity of the cell 
nucleus. Indeed, there seems to be a connection between the dot and the modification. 
Searching the literature for inspiration, I came across the work by Kim et al. in which 
they show that sumoylation of the human homeodomain-interacting protein kinase 2 
(HIPK2) correlates with its localization to nuclear dots (Kim et al., 1999). Finally, p53 is 
itself sumoylated in human cells by Mdm2 and its sumoylation seems to correlate with its 
association with nuclear bodies (Gostissa et al., 1999; Muller et al., 2001). All these 
considerations led me to the conclusion that p53 might be sumoylated in yeast and that 
sumoylation correlates with the localization of p53 in the nuclear dot.  
 
 
p53 is sumoylated in yeast by Mdm2 
Using Ni+-NTA columns, I purified p53 (6xHIS-tagged) from cells expressing 
only p53 or p53 together with Mdm2. I also included cells expressing either only p53δ or 
p53δ and Mdm2. This p53 mutant is more strongly modified than the wild type (Figure 
2.2.26), so I thought it would increase the chance to retain the modified p53 after the 
purification. To exclude the possibility that the band is Mdm2-specific but not a modified 
p53, I used as a control cells expressing only Mdm2 (6xHIS-tagged). Figure 2.2.29 shows 
that p53 is sumoylated in yeast in the presence of Mdm2 and, as expected, this is more 
evident with p53δ.  
 
Chapter Two Results Part Two 
 91
 
Figure 2.2.29 | p53 is sumoylated in yeast in the presence of Mdm2. Cells expressing 
only Mdm2-6xHIS (first lane starting from the left), only p53-6xHIS (second lane), p53-
6xHIS and Mdm2 (third lane), only p53δ-6xHIS (fourth lane) and p53δ-6xHIS and 
Mdm2 (fifth lane), were grown at 30°C and induced with 0.5% f.c. galactose for two 
hours, then harvested. Purification on Ni+-NTA columns was performed as described in 
Materials and Methods. Samples were run on a gel and sumoylated proteins were 
detected with western blot using the anti-Smt3 antibody. Only in the presence of Mdm2 it 
is possible to detect sumoylated p53 (indicated by red stars to the left of the 
corresponding band). As expected, p53δ is more strongly sumoylated than wild type p53 
(compare bands indicated by red stars in lanes 3 and 5). Finally, a degradation product of 
p53 which is sumoylated is detected.  
 
 
 
Direct binding of p53 to Mdm2 is necessary for sumoylation to occur. When p53W23S, 
which cannot bind Mdm2 due to a point mutation in the Mdm2 binding domain (Inoue et 
al., 2001), is expressed with Mdm2 in place of wild type p53, sumoylation is strongly 
reduced (Figure 2.2.30).   
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Figure 2.2.30 | Direct binding of p53 to Mdm2 is required for Mdm2-induced p53 
sumoylation in yeast. Cells carrying the wild type p53–ECFP fusion protein together 
with the Mdm2-EYFP fusion protein or the mutant p53W23S-ECFP fusion protein and 
the Mdm2-EYFP fusion protein were induced with 0.5% f.c. galactose and induction was 
inhibited using 3% f.c. glucose. Although the band corresponding to sumoylated p53 
(indicated by a red star) runs very close to the Mdm2-EYFP band, it is possible to see that 
the band is absent in the p53W23S-ECFP + Mdm2-EYFP samples.   
 
 
SUMO conjugation to p53 in yeast cells requires lysine 386  
In human cells, lysine 386 is known to be the major site for p53 sumoylation, 
since when this residue is mutated to arginine, p53 sumoylation is strongly impaired 
(Gostissa et al., 1999).  
To prove that this holds true in yeast as well, I generated the same mutant (p53K386R) 
and compared its sumoylation levels to those of wild type p53 (Figure 2.2.31).  
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Figure 2.2.31 | Mutation of lysine 386 abolishes p53 sumoylation in yeast. Cells were 
grown at 30°C and induced with 0.5% f.c. galactose. To stop induction from the GALS 
promoter, 3% f.c. glucose was added to the same medium at time point 0’. When lysine 
386 at the C-terminus of p53 is mutated to arginine, p53 sumoylation is abolished.   
 
 
 p14ARF enhances Mdm2-dependent p53 sumoylation  
Chen and Chen have shown that p14ARF enhances Mdm2-mediated p53 
sumoylation in human cells (Chen et al., 2003). I decided to see whether this would 
happen in yeast cells as well. To this purpose, I cloned the human p14ARF gene in a yeast 
expression plasmid and co-transformed cells with plasmids containing p53, Mdm2 and 
p14ARF. As it can be seen from Figure 2.2.32, p53 sumoylation is strongly enhanced in 
the presence of p14ARF. 
 
 
Figure 2.2.32 | p14ARF strongly enhances Mdm2-mediated p53 sumoylation in yeast 
cells. Cells were grown at 30°C and induced with 0.5% f.c. galactose. p53 is under the 
inducible GAL promoter, while Mdm2 and p14ARF are under the constitutive TEF 
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promoter. As in figure 2.2.26, while sumoylated p53 – in the presence of Mdm2 – is not 
visible under these conditions (too little amount of p53 on the gel, too short exposure 
time), sumoylated p53 can be detected in the presence of p14ARF. 
 
 
Sumoylation is responsible for p53 co-localization with Mdm2 to the nuclear dot 
Sumoylation is known to affect the cellular localization of substrate proteins, 
often correlating with their affiliation with nuclear bodies (Kim et al., 1999; Muller et al., 
2001). Since we find that p53 and Mdm2 co-localize to a specific cellular location in 
yeast and that p53 is sumoylated by Mdm2, I thought there might be a correlation 
between the modification and localization of p53 in yeast cells. This hypothesis is found 
to be true, since the co-localization of p53 and Mdm2 to the nuclear dot is lost when 
substituting wild type p53 with p53K386R which can no longer be sumoylated (Figure 
2.2.33).  
 
 
Figure 2.2.33 | p53K386R-ECFP does not co-localize with Mdm2-EYFP. Cells were 
grown at 30°C and gene expression was triggered by the addition of 2% f.c. galactose in 
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the exponentially growing culture. After 1 hour of induction, the cells were imaged using 
excitation and emission filters for CFP and YFP (see Materials and Methods). When p53 
sumoylation is abolished (mutating the major site for sumoylation from lysine to 
arginine), p53-ECFP does not co-localize with Mdm2 and shows a diffuse fluorescence, 
sometimes being localized to the tip of the cell.   
 
 
 
 
Aggresome or organelle? 
From the data collected up to this point it is unclear whether the dot in which p53 
and Mdm2 so tightly co-localize is an aggresome, i.e. a place in which the two proteins 
are confined because they are misfolded and not functional, or rather an organelle. 
Although I did not reach a clear-cut answer to this question, there are several evidences 
that discard the aggresome hypothesis in favour of the organelle one.  
 
Considering that lower temperatures facilitate protein folding, I grew yeast cells at 20°C, 
25°C and 30°C respectively and used fluorescence microscopy to see whether the dot 
would disappear at lower temperatures. Figure 2.2.34 shows that the dot is formed 
independently of the temperature at which the yeast cells are grown. Moreover, the dot is 
found also when p53 is expressed at very low levels (data not shown), which again argues 
against the aggresome hypothesis.  
 
 
 
Chapter Two Results Part Two 
 96
 
Chapter Two Results Part Two 
 97
Figure 2.2.34 | p53 and Mdm2 co-localize to the nuclear dot in yeast cells grown at 
different temperatures. Cells were grown at 20°C, 25°C and 30°C respectively. When  
cells reached exponential growth phase, p53 induction was trigger by adding 0.5% f.c. 
galactose to the medium (Mdm2 is constantly expressed). The first panel shows the signal 
obtained in the YFP channel, the second panel shows the phase-contrast image, the third 
panel shows the signal obtained in the CFP channel. The last panel shows the merged 
images for the CFP and YFP signals, where the CFP is pseudo-coloured in green and the 
YFP in red. Co-localization appears as a yellow signal. The dot is insensitive to the 
temperature at which the yeast cells are grown, arguing against the aggresome 
hypothesis.  
 
 
 
To gain a better understanding on the nature of this dot, Charlotta Funaya in the EMBL 
Electron Microscopy Core Facility performed electron microscopy on yeast cells  
expressing p53 and Mdm2. I previously mentioned that it was difficult for us to 
understand whether the dot resided inside or outside the nucleus looking at indirect 
immunofluorescence pictures. Electron microscopy analysis ensures us that the dot is 
inside the nucleus (Figure 2.2.35). 
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Figure 2.2.35 | Electron microscopy on a yeast cell expressing p53 and Mdm2. Cells 
were grown at 30°C and induced with 0.5% f.c. galactose when they reached exponential 
growth phase. Cells were then treated for electron microscopy as explained in Materials 
and Methods. The area where the gold particles are found is indicated by black arrows. 
The p53-Mdm2 complex is inside the yeast nucleus.  
 
 
The position of the p53-Mdm2 nuclear dot is not random and is related to the yeast 
nucleolus 
The electron microscopy pictures of cells expressing p53 and Mdm2 reveal that 
the nuclear dot formed by the two proteins is always adjacent to the yeast nucleolus (that 
can be recognized even without using a marker, due to its characteristic shape and its 
density compared to the rest of the nucleus). This is confirmed by indirect 
immunofluorescence, where using an antibody against the nucleolar protein Nop1 we 
find exactly the same pattern as in the electron microscopy pictures (Figure 2.2.36-37).  
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Figure 2.2.36 | Position of the p53-Mdm2 dot in respect to the yeast nucleolus. Cells 
were grown at 30°C and gene expression was triggered by the addition of 2% f.c. 
galactose in the exponentially growing culture. Immunofluorescence was performed as 
described in Materials and Methods. The DNA (stained with Höechst 33352) is shown in 
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blue, the nucleolus (stained with anti-Nop1 antibody) in red and the p53-Mdm2 complex 
(stained with anti-p53 and anti-Mdm2 antibodies) in green. The yellow circles 
surrounding the cells were inserted to highlight the typical disposition of the dot in 
respect to the DNA and the nucleolus.  
 
 
 
Figure 2.2.37 | The p53-Mdm2 dot is adjacent to the yeast nucleus. The same cell as 
in Figure 2.2.36 is shown here, but three different areas in the yeast nucleus are 
highlighted in colours: a light dense area corresponding to chromatin (blue), a denser area 
with no gold particles corresponding to the nucleolus (red) and a denser area with gold 
particles corresponding to the p53-Mdm2 dot (green). The p53-Mdm2 dot is found 
always in the proximity of the nucleus, confirming what we observe with 
immunofluorescence.    
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Considering that the vast majority of aggresomes described – until now – in human cells 
and in yeast are located in the cytoplasm (Corboy et al., 2005; Haslbeck et al., 2005), we 
consider this piece of information as another clue pointing towards the organelle 
hypothesis. Moreover, the distribution of the electron density over which the gold is 
found does not resemble that of aggregates and also the positioning of the gold particles 
is not that typical of aggregates (Prof. Ed Hurt, personal communication). 
Surprisingly, the donut shape of the p53-Mdm2 dot is reminiscent of the nuclear bodies 
in which the human promyelocytic leukemia protein (PML) accumulates (Figure 2.2.38). 
This is an intriguing finding, considering the strong correlation between p53, sumoylation 
and PML bodies in human cells (see Introduction) and our results on the inability of 
p53K386R to localize to the nuclear dot with Mdm2 (see Discussion).  
 
Figure 2.2.38 | The nuclear dot formed by p53 and Mdm2 is reminiscent of human 
PML bodies. a, Electron microscopy image of a PML body in Hela Cells (taken from 
(Weis et al., 1994)). b, Close-up on the p53-Mdm2 dot from the electron microscopy 
picture shown in Figure 2.2.35.  
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Dynamics of p53-Mdm2 nuclear dot formation 
The nuclear dot formed by p53 and Mdm2 is not static but rather dynamic as can 
be seen by the time-lapse microscopy sequence in Figure 2.2.39. Actually, while in the 
electron microscopy we only see a single big structure recognized by the anti-p53 and 
anti-Mdm2 antibodies, with fluorescence microscopy it becomes evident that there are 
several dots. A common observed pattern is the fusion of these smaller dots to form a 
bigger one (which is likely the structure identified by electron microscopy), although 
from the time-lapse movies it is possible to detect cells in which several smaller dots co-
exist with the bigger one (lower cell in Figure 2.2.39, for instance at the time-frames 
40min, 70min, 80min). We can therefore conclude that the p53-Mdm2 dot is very 
dynamic, with dots fusing and sometimes splitting again into several dots. This also 
argues against an aggregation type of complex, and suggests that whatever the nuclear 
region involved in the dot formation is, it is rather dynamic.  
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Figure 2.2.39 | Time-lapse microscopy on yeast cells expressing p53 and Mdm2. 
Cells harbouring the p53-ECFP and the Mdm2-EYFP plasmids were grown at 30°C until 
they reached exponential growth phase. Cells were then adhered to the bottom of a Petri 
dish for live imaging (see Materials and Methods). Galactose was added directly into the 
Petri dish and time-lapse started shortly after. Only Mdm2 position was tracked over time 
using the YFP filter to avoid bleaching the signals using also the CFP one. p53 
appearance in each cell is verified taking stacks before and after the time-lapse (data not 
shown). Mdm2 is shown in red, and the phase-contrast image of the cells in blue. In the 
cells in which p53 is made, the many small dots always get together to form a bigger one, 
which sometimes splits again into smaller ones. 
 
 
 
Mdm2 and the yeast nucleolus 
An intriguing result concerns the shape of the yeast nucleolus in the presence of 
Mdm2. When looking at the localization of Mdm2 alone or in the presence of p53 with 
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electron microscopy we observe a striking difference: the dense area corresponding to the 
nucleolus seems to be scattered through the nucleus when compared to cells expressing 
both Mdm2 and p53 (compare Figures 2.2.40 and 2.2.35 and see Table 2.2.1 for 
statistics). This could indicate that Mdm2 on its own produces a reorganization of the 
yeast nucleolus. Notably, for the statistics we analyzed only a small number of cells 
(thirty precisely) and since the thin sections that were cut through the yeast nucleus for 
electron microscopy analysis could either completely miss the nucleolus or cut it in a way 
that the typical shape is not visible, we should enlarge the data set in order to confirm 
these observation.  
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Figure 2.2.40 | Electron microscopy on a yeast cell expressing only Mdm2. Cells were 
grown at 30°C and induced with 0.5% f.c. galactose when they reached exponential 
growth phase. Cells were then treated for electron microscopy as explained in Materials 
and Methods. In twenty-nine out of thirty cells analyzed, the yeast nucleolus is not 
visible. Denser areas are scattered throughout the cell and the gold particles (indicating 
Mdm2) are mostly found on top of these dense areas (see black arrows).  
 
 
 
 p53 Mdm2 p53+Mdm2
% cells with 
a visible nucleolus
70% 3% 83% 
 
Table 2.2.1 | Statistics on yeast cells analyzed by electron microscopy. A set of thirty 
cells was analyzed and percentages of cells with a visible nucleolus calculated. 
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Discussion 
The aim of this study was to test the sufficiency of the p53-Mdm2 negative 
feedback for generating oscillations in the context of budding yeast Saccharomyces 
cerevisiae, while taking advantage of this minimalist approach to understand better the 
biological relevance of such dynamic interactions. This type of circuit differs from 
previously described synthetic oscillators in that the negative action of Mdm2 on p53 
does not occur at the level of transcription, but at the protein-protein interaction and post-
translational modification levels, with ubiquitylation playing a key role for the 
oscillations. The underlying assumption on which we relied for the successful 
construction of the synthetic p53 network in yeast was that, since targeted degradation by 
ubiquitylation is conserved in eukaryotes, Mdm2-dependent p53 degradation should 
occur in yeast cells, conformingly to what happens in human cells. To our great surprise, 
under all the conditions tested in the course of this study, we failed to detect p53 
degradation; even when UbcH5B – which is the human E2 that interacts with Mdm2 to 
ubiquitylate p53 – or p300 – the human E4 that was shown to transform 
monoubiquitylated into polyubiquitylated p53 – are expressed together with Mdm2, p53 
is not degraded.  
Remarkably, p53 is instead sumoylated by Mdm2 in yeast and we find that the residue 
which is the major target for this modification in human cells (lysine 386) is also 
responsible for p53 sumoylation in yeast. Furthemore we observe a strong enhancement 
of Mdm2-mediated p53 sumoylation in the presence of the human nucleolar protein 
p14ARF, scenario which mirrors what happens in human cells as well. Finally, we find a 
correlation between p53 sumoylation and the formation of nuclear bodies in yeast cells, 
which look like the nuclear bodies formed by the promyelocytic leukemia protein (PML) 
in human cells, where p53 and Mdm2 are also localized under certain circumstances.  
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Why is p53 not degraded in S. cerevisiae? 
There are several explanations which could account for the failure of Mdm2-
mediated p53 degradation in budding yeast. 
 
Mdm2 and p53 are not interacting in yeast 
In order for Mdm2 to ubiquitylate p53, the two proteins need to be in the same 
compartment (Xirodimas et al., 2001). If in yeast p53 and Mdm2 are localized to 
different cellular addresses, ubiquitylation and subsequent p53 degradation cannot occur. 
Our data on p53 and Mdm2 localization (when each is expressed alone or when they are 
expressed together), using both the fusion p53-ECFP and Mdm2-EYFP proteins and the 
native ones, exclude this possibility (see Figures 2.2.3, 2.2.8 and 2.2.12 in Results Part 
Two). As a matter of fact, p53 and Mdm2 always co-localize to a dot inside the yeast 
nucleus (see Figure 2.2.37 in Results Part Two), and this co-localization is lost when 
using a mutant p53 protein for which binding to Mdm2 is disrupted (see Figure 2.2.14 in 
Results Part Two). Hence, we can discard the possibility that Mdm2 cannot ubiquitylate 
p53 because the two proteins are far from each other.  
 
p53 and Mdm2 aggregate 
Even though we are sure that p53 and Mdm2 interact in yeast, the proteins could 
be forming a non-functional aggregate. The first, instinctive reaction one has looking at 
the p53-Mdm2 dot, in fact, is that it is an aggregate caused by the over-expression of 
exogenous proteins in the host organism. Although we still don’t have a clear answer to 
the question “aggresome or organelle?” (see Conclusions and future plans), there are 
several observations that favour the latter hypothesis.  
First of all, the dot is inside the nucleus and, although recently nuclear aggresomes have 
been described (Fu et al., 2005), aggregates have been generally identified as cytosolic 
deposits of misfolded proteins (Markossian et al., 2004).  
p53 being transcriptionally active in the presence of Mdm2 (see Figure 2.2.22 in Results 
Part Two) and Mdm2 being active as SUMO ligase for p53 (see Figures 2.2.29 and 
2.2.31 in Results Part Two) also argue against the idea that p53 and Mdm2 are 
aggregating, as well as the fact that the dot is visible also with cells grown at 20°C (see 
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Figure 2.2.34 in Results Part Two) or when p53 expression levels are lowered (data not 
shown). In an attempt to better understand the internal arrangement of the p53-Mdm2 
dot, we performed immunogold labelling on thin sections of high pressure frozen, 
lowicryl embedded yeast cells expressing only Mdm2 or p53 together with Mdm2. The 
electron dense region on top of which the gold particles are found does not resemble a 
typical aggregate (as assessed by comparing our images to published electron microscopy 
images of aggregates); rather, we find a strong similitude between the dot formed by p53 
and Mdm2 in yeast and the nuclear bodies formed by the promyelocytic leukemia protein 
(PML) in human cells, in which p53 and Mdm2 are also recruited under certain 
circumstances (see Figure 2.2.38 in Results Part Two) (Pearson et al., 2000; Kurki et al., 
2003). Furthermore, aggresomes are known to recruit components of the ubiquitin-
proteasome pathway (Fu et al., 2005) and proteins therein are usually ubiquitylated 
(Johnston et al., 1998). We do not detect, instead, any ubiquitylation of p53, on the 
opposite we find that p53 is sumoylated and sumoylation is involved in the association of 
proteins with nuclear (functional) bodies.  
 
Mdm2, p53 or both are post-translationally modified in a way that prevents 
ubiquitylation to occur 
We know that p53 and Mdm2 are subject, in human cells, to a series of post-
translational modifications (phosphorylation, acetylation, etc.) which modulate their 
interaction as well as their localization or interaction with other proteins (see 
Introduction). We cannot exclude that p53, Mdm2 or both are modified in yeast in a way 
that prevents Mdm2-mediated p53 ubiquitylation. For instance, it has been shown that 
p53 acetylation inhibits Mdm2-mediated ubiquitylation in human cells with mechanisms 
that go beyond simple competition for the lysine residues to be modified (Li et al., 2002). 
Recently, it has been reported that phosphorylation inhibits sumoylation of c-Fos (Bossis 
et al., 2005), showing that two modifications occurring on different residues and in 
different domains on a protein substrate can also interfere with each other . It is possible, 
therefore, that p53 is post-translationally modified in yeast (e.g. acetylated) and that this 
modification keeps p53 from being ubiquitylated by Mdm2 (although mass spectrometry 
analysis did not identify any such modification). 
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Also, Mdm2 can be modified in a way that is consequential to its E3 ligase activity. From 
the results obtained in this study, it is in fact clear that Mdm2 is modified; with higher 
molecular weight bands becoming more detectable at later time points with respect to 
Mdm2 expression (see Figure 2.2.22 in Results Part Two). Since Mdm2 is degraded in 
yeast, these higher molecular weight species could be ubiquitylated forms of the protein 
(although I failed to detect them when probing Mdm2 purification with an antibody 
specific for mono- and polyubiquitylated proteins – data not shown). Mdm2 degradation 
is known to be subject to regulation in various ways, since Mdm2 stabilization leads to 
enhanced p53 degradation (Sharp et al., 1999; Zeng et al., 2003; Feng et al., 2004). It 
would be intriguing, therefore, to attribute Mdm2 incapability to ubiquitylate p53 to the 
fact that the enzyme is busy with its own ubiquitylation. To test this hypothesis, I 
generated a mutant Mdm2 in which lysine 446 was exchanged for arginine, following the 
data published by Buschmann et al. which indicated residue 446 as the major site for 
Mdm2 autoubiquitylation (Buschmann et al., 2000). Preliminary results with this mutant 
show that p53 is stable (data not shown), although it is difficult to interpret them since I 
realized that the paper in which the mutation was described has been retracted (Fuchs et 
al., 2002), making it arguable whether lysine 446 is indeed the major site for Mdm2 
autoubiquitylation.  
 
Post-translational modifications on p53 or Mdm2 required for efficient Mdm2-
mediated ubiquitylation do not take place in yeast 
The opposite situation could also be the cause for the failure of p53 ubiquitylation 
in yeast. In the literature, in fact, we find few examples of post-translational 
modifications which are required for effective p53 degradation in human cells (Chernov 
et al., 2001; Zhou et al., 2001). Were this the case, we should conclude that yeast is not 
an adequate model organism to study p53 ubiquitylation, unless we identified the 
required modifications and were able to either mimic or  force them to happen. 
 
Something is missing 
When I started this project, Mdm2 was thought to be sufficient to polyubiquitylate 
p53 in the presence of ubiquitin, E1 and E2, both in vitro and in vivo. During the course 
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of this study, however, there has been a shift in paradigm: Mdm2 is now believed to 
catalyze only p53 monoubiquitylation, which is not sufficient to target p53 to the 
proteasome, whereas p300 – an acetyltransferase known to acetylate p53 thus enhancing 
p53 transcriptional activity – is the enzyme responsible for the conversion of 
monoubiquitylated species into polyubiquitylated ones (Grossman et al., 2003). This and 
other findings, which highlight the need for additional proteins in order for efficient 
Mdm2-dependent p53 degradation to take place (Gu et al., 2002; Gronroos et al., 2004), 
raise the possibility that Mdm2 alone is not enough to trigger p53 degradation., Some 
essential component(s) seems to be missing, although known candidates like p300 do not 
change p53 stability when expressed in yeast (see Figures 2.2.15 and 2.2.18 in Results 
Part Two), Most studies on p53 degradation are carried on in human cell lines expressing 
endogenous proteins which might be essential for p53 degradation without being 
identified as such. For years Mdm2 has been considered as the only E3 ligase for p53, so 
when researchers were performing in vivo ubiquitylation assays on human cells, they 
were not considering the fact that those cells have additional ligases which might account 
for the observed p53 degradation. In this respect, the use of yeast instead of human cells 
should facilitate the search for the minimal network able to support p53 degradation, 
being much more likely in this synthetic context the absence of additional proteins acting 
in the background (we confide that this would have some biological meaning and not be 
an artefact caused by the difference between human and yeast cells).  
 
Yeast and human ubiquitylation pathways are incompatible 
Although the ubiquitylation pathway is considered to be conserved in eukaryotes, 
it is possible that a human E3 ligase – like Mdm2 – cannot interact with the yeast 
homologue (Ubc4) of its interacting human E2 (UbcH5B), or that a human E2 cannot 
interact with a yeast E1. To discard the possibility that the failure of p53 degradation 
were caused by incompatibility between Mdm2 and Ubc4, I expressed in yeast UbcH5B 
and saw no change in p53 stability (see Figure 2.2.17 in Results Part Two).  
We cannot discard the hypothesis that the human E1 is needed as well, since the classical 
view that there is no selectivity at the level of the E1 is changing. It is in fact being 
suggested that different members of the E1 enzyme family may have specialized 
Chapter Three Discussion 
 112
functions (perhaps preferentially transferring ubiquitin or ubiquitin-like proteins to 
particular E2 enzymes or directly to certain substrate proteins) and may be assigned to 
distinct cellular compartments (Hochstrasser, 1996). 
 
p53 is ubiquitylated to an extent which is insufficient to signal its degradation 
The fact that I never detected p53 degradation does not exclude that p53 is being 
(mono)ubiquitylated by Mdm2, but that the amount of ubiquitylated molecules is below 
detection on a western blot. Actually, the detection of protein ubiquitylation requires a 
careful methodological approach, because ubiquitination is a dynamic process that 
involves both ubiquitinating and deubiquitinating enzymes – and deubiquitinating 
enzymes are known to be very active in cellular extracts (Rajapurohitam et al., 2002). 
Consequently, only a small fraction of the cellular pool of a protein that is destined for 
proteasomal degradation is modified by ubiquitin at any given time. As an example of the 
difficulty in detecting ubiquitylated p53 species, in the paper published by Krummel et 
al., the authors mention that attempts to detect endogenous ubiquitylation on wild type 
p53 failed even when exogenous Mdm2 was expressed and proteasome inhibitors used. 
To be able to detect p53 ubiquitylation, the authors had to transfect cells with exogenous 
p53, Mdm2 and ubiquitin (Krummel et al., 2005).  
In this study, I tried various expression levels for p53, ranging from over-expression 
(using 2% galactose) to lower levels (down to 0.006% galactose), so one could argue that 
at least when over-expressing p53 in the presence of Mdm2, I should be able to detect 
some ubiquitylation. Instead, not even when pulling p53 down with an antibody or when 
purifying a 6xHIS-tagged version of the protein on columns, did I detect a signal using an 
antibody again mono- and polyubiquitylated proteins (data not shown). Considering that 
Mdm2 sumoylates p53 and that, despite the fact that the sumoylated fraction constitute 
less than 5% of the total protein pool, it is possible to detect this modification on a 
western blot using crude yeast lysates, I am prone to conclude that ubiquitylation is not 
happening at all, for some of the other reasons discussed here.    
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Mdm2 is after all not responsible for p53 degradation in normal cells  
Although Mdm2 was the only known ligase to be in charge of p53 degradation 
when this study started, many additional ligases have been recently described (see 
Introduction). It is interesting that, for each of these newly discovered ligases, the 
respective authors claim a central role in p53 degradation, which is not confirmed by the 
data found in the other papers; for instance, in the work published by Dornan et al., 
showing that COP1 is an E3 ligase specific for p53, the authors perform RNAi on U2OS 
cell lines to show the effect on p53 levels of knocking down COP1, Mdm2 and Pirh2, 
singularly or in combination (Dornan et al., 2004). Looking at their data, p53 levels 
strongly increase with RNAi against COP1 or Mdm2. In the recently published paper by 
Chen et al., which identifies ARF-BP1 as the ligase responsible for p53 turnover in 
unstressed cells, the authors show similar RNAi experiments on U2OS cell lines, but this 
time the effect on p53 levels of RNAi against COP1 is much weaker (Chen et al., 2005). 
In light of these considerations, I decided to test other E3 ligases for p53, namely Pirh2 
and COP1, trying to find the one which was able to catalyze p53 ubiquitylation in my 
yeast system. Unfortunately, none was successful (I also tried to combine two of them, 
like Mdm2 and COP1, Mdm2 and Pirh2, but failed to observe any change – data not 
shown).  
 
 
Sumoylation wins over ubiquitylation 
Our discovery of Mdm2-dependent p53 sumoylation in yeast brought the hope that 
this might represent the reason for failed degradation. In the literature, in fact, it has been 
proposed that sumoylation inhibits degradation of IkappaBalpha (Desterro et al., 1998), 
while the role of sumoylation in contrasting p53 ubiquitylation is subject to debate 
(Gostissa et al., 1999; Muller et al., 2000; Rodriguez et al., 1999). We found that the non-
sumoylatable mutant of p53 (p53K386R) is as stable as wild type p53. This suggests that 
sumoylation is not impeding p53 ubiquitylation.  Another possibility is that the affinity of 
Mdm2 for Ubc9 is much higher than that for Ubc4 – the yeast homologue of the human 
E2 (UbcH5) which pairs with Mdm2 to ubiquitylate p53 – resulting in p53 being 
preferentially sumoylated and not ubiquitylated (small amounts of the protein might be 
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ubiquitylated, but again this could be below detection). This hypothesis is supported by 
the observation that Ubc9 has a remarkable ability to interact with other proteins, likely 
consequence of the distinct electrostatic potential distribution that characterizes Ubc9 as 
compared to other E2s (Tong et al., 1997). 
 
 
p53 is sumoylated and not ubiquitinated in yeast 
p53 sumoylation by Mdm2 in budding yeast came as a surprise, expecting as we 
were that Mdm2 would function as a ubiquitin E3 ligase, since this is well established in 
the literature. Mdm2 promoting p53 sumoylation is instead a rather recent finding, and 
the consequences of sumoylation on p53 await further studies (Chen et al., 2003). Not 
only did we find that p53 is sumoylated by Mdm2 (see Figure 2.2.29 in Results Part 
Two), we also found that the lysine which is the major site for sumoylation in human 
cells (lysine 386) is also responsible for p53 sumoylation in yeast (see Figure 2.2.31 in 
Results Part Two). Even more intriguing is the finding that yeast cells co-expressing 
Mdm2 and p14ARF show enhancement in p53 sumoylation (see Figure 2.2.32 in Results 
Part Two). This is in perfect agreement with results obtained using human cell lines, 
where Mdm2 and p14ARF co-ordinately sumoylate p53 targeting it to the nucleolus (Chen 
et al., 2003) 
 
Functional role of p53 sumoylation 
The role of sumoylation in p53 transcriptional activity is at the moment unclear, 
since results obtained up to now claim either its enhancement (Gostissa et al., 1999; 
Rodriguez et al., 1999) or its inhibition (Schmidt et al., 2002) or no effect at all (Kwek et 
al., 2001). On the other hand, sumoylation has been reported to activate other 
transcription factors such as the heat shock transcription factor 2 (HSF2) (Goodson et al., 
2001).  Although we have not done yet extensive studies on this topic, our preliminary 
data suggest that sumoylation does not inhibit drastically transcription activity of p53 (see 
Figure 2.2.22 in Results Part Two), but further studies are needed to elucidate this point.  
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Sumoylated p53 exhibits different localization than non-sumoylated one 
Our results indicate that sumoylation is necessary for the co-localization of p53 
with Mdm2 to the nuclear dot, since when Mdm2 is co-expressed with the non-
sumoytable mutant of p53 (p53K386R) the dot is not detected (see Figure 2.2.33 in 
Results Part Two). Looking at the distribution of p53K386R-ECFP in the cell, we notice 
that it is diffuse throughout the entire cell, but does not show a stronger staining into the 
nucleus like wild type p53 (compare Figures 2.2.3 and 2.2.33 in Results Part Two). If this 
on the one hand suggests that the nuclear levels of p53K386R are lower than those of the 
wild type p53, on the other hand we do not see an exclusion of p53K386R from the 
nucleus, therefore we believe that the failed co-localization with Mdm2 to the dot is not 
due to a failed interaction with Mdm2. This idea is supported by preliminary data of a 
cytoplasmic p53 mutant (which carries a mutation on lysine 305 which is essential for 
p53 nuclear import (Liang et al., 1998)) which is found to co-localize to the dot with 
Mdm2 (data not shown). This result suggests that even if p53K386R is mostly 
cytoplasmic, Mdm2 could still interact and co-localize with it to the nuclear dot 
seemingly to what happens with cytoplasmic p53. 
We suggest that sumoylation is the tag that re-directs p53 to the nuclear dot, in the same 
way in which sumoylation of the homeodomain-interacting protein kinase 2 (HIPK2) 
correlates with its localization to nuclear dots (Kim et al., 1999) and sumoylation of the 
PML protein is required for its localization into PML bodies (Muller et al., 1998).  
According to the western blot data, the fraction of p53 which is sumoylated is less than 
5% of the total protein amount (which is in accordance with what was reported for other 
sumoylated proteins (Johnson et al., 1999)), yet light microscopy on living cells shows 
that p53 is all concentrated in the dot with Mdm2, which we believe is made of 
sumoylated p53. This contradiction could either reflect an artefact of the microscopy set-
up, in that p53 molecules are also somewhere else in the cell but the fluorescence in the 
dot is so high that the remaining fluorescence is undetectable, or it could be explained by 
a model in which sumoylation is required to target p53 to the nuclear dot, but once the 
protein is there, it gets rapidly desumoylated, so that the fraction of sumoylated p53 at 
any given time is very low.  
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What is the p53-Mdm2 nuclear dot? 
From our indirect immunofluorescence analysis we notice a non-random positioning of 
the p53-Mdm2 dot in respect to the nucleolus (see Figures 2.2.36 and 2.2.37 in Results 
Part Two), so we suspect some sort of relation between the two. In fact, even if in the 
majority of the cells there is no overlap between the nucleolus (detected using an 
antibody against Nop1) and the p53-Mdm2 signals, this could reflect a limited 
accessibility to the antibody of the dense nucleolar structure (similar antibody 
accessibility problem has been reported for other nucleolar proteins (Wansink et al., 
1993) and for p53 itself (Rubbi et al., 2000). Moreover, Nop1 resides in the dense 
fibrillar component (DFC) of the nucleolus and the p53-Mdm2 complex could be located 
in another area of the nucleolus not stained by an antibody against Nop1.  
Indeed there is a strong relation between p53, Mdm2 and the nucleolus in human cells 
(see Introduction) and moreover Mdm2 carries a cryptic nucleolar localization signal 
(NoLS) (Lohrum et al., 2000) and it is found in human nucleoli under different 
circumstances (Kurki et al., 2003; Bernardi et al., 2004). It would therefore not be 
surprising if there were a connection between the nucleolus and the p53-Mdm2 cellular 
location.  
Another intriguing possibility is that p53 and Mdm2 are triggering in yeast the formation 
of PML body-like structures, given the resemblance of the p53-Mdm2 dot to a PML body 
in human cells (see Figure 2.2.38 in Results Part Two). Actually, PML bodies are 
suspected to play some role in RNA-processing events (Borden, 2002), and in human 
cells are often found close to other nuclear bodies like the Cajal bodies (Borden, 2002), 
which in turn are related to the nucleolus (Gall, 2000).   
 
Who brings whom to the dot? 
An important aspect to be clarified is whether Mdm2 is simply mediating p53 
sumoylation and localizes to the dot because of this function, or if Mdm2 itself is 
dictating the cellular address to which p53 has to go. Fluorescence microscopy on yeast 
cells expressing p53 and Mdm2 shows that, when p53 expression is low, the two proteins 
co-exist in several small dots, which resemble Mdm2 foci (data not shown). Since I 
performed time-lapse microscopy following only Mdm2 (I used only YFP excitation 
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since using also the CFP one would lead to bleaching of the signal), it is unclear whether 
p53 is recruited to sites in which Mdm2 is already present or if the two proteins go 
together somewhere else. Although Mdm2 foci are also dynamic and move towards each 
other to fuse into a brighter bigger dot, their behaviour is different from that observed in 
the presence of p53, which always lead to the (rapid) formation of the bigger dot. 
Electron microscopy images seem to confirm that the distribution of Mdm2 when alone is 
different from that in the presence of p53, and that the two proteins accumulate in a 
single donut-shape structure rather than in many smaller areas, but this could also reflect 
a detection limit of the immunogold labelling.  
 
 
Mdm2 localization in yeast  
Mdm2 localization is per se fascinating. Light microscopy clearly shows that the 
protein is distributed in several nuclear – very dynamic – dots, often at the periphery of 
the nucleus (see Figures 2.2.8 and 2.2.10 in Results Part Two). Sometimes, Mdm2 
appears as a half-moon that resembles the nucleolus (see Figure 2.2.8 in Results Part 
Two). Considering that, as mentioned above, Mdm2 carries a cryptic NoLS, it could be 
that the protein localizes to the nucleolus or to some extra-nucleolar region at least during 
some stages of the cell cycle. Moreover, when expressing Mdm2 together with p14ARF, a 
human nucleolar protein, Mdm2 localization does not change, or rather, the nuclear 
speckles become more evident (data not shown). Although I did not detect directly 
p14ARF localization in yeast, there is in principle no reason for its NoLS not to be 
recognized in this organism, living the question whether Mdm2 is nucleolar very much 
open.  
More promising is the finding that the yeast telomere-binding protein Rap1 has a 
cellular distribution strikingly similar to that of Mdm2 (Figure 3.3). The resemblance is 
so remarkable that we are prone to believe that Mdm2 also binds telomeres in yeast.  
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Figure 3.3 | Comparison between GFP-Rap1 and Mdm2-EYFP localization in 
budding yeast. GFP-Rap1 localization has been adapted from (Laroche et al., 2000). The 
left panel shows the merged image between phase-contrast and the fluorescent image. 
The right panel shows the GFP and YFP channel alone, respectively.  
 
 
Mdm2 binding to telomeres has never been described in the literature, while the  ability 
of Mdm2 to bind to DNA (Zhao et al., 2005) and RNA in general (Elenbaas et al., 1996), 
as well as p53-depedent Mdm2 association with chromatin (White et al., 2006), have 
been documented. Mdm2 putative nucleolar localization and association with yeast 
telomeres do not exclude each other, since in the literature we find examples of proteins 
which localize to the nucleolus and to telomeric foci (Gotta et al., 1997).  
 
Re-shaping the nucleolus? 
While looking at the electron microscopy pictures of a yeast cell expressing only 
Mdm2 and a cell expressing p53 and Mdm2, we noticed that only in the latter case it was 
possible to visually detect a darker (denser) region which we identified as the nucleolus 
(compare Figures 2.2.35 and 2.2.40 in Results Part Two). A statistical analysis on a small 
set of cells confirmed the observation that around 97% of the cells expressing only Mdm2 
have a dispersed nucleolus, while circa 80% of the cells expressing p53 and Mdm2 have 
a visually detectable nucleolus. We could speculate that the presence of Mdm2 somehow 
inhibits the proper assembly of the yeast nucleolus or re-organizes it in a way that 
prevents us to detect the nucleolus in the electron microscopy pictures. Typical nucleolar 
shape is restored in the presence of p53.  
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These are, though, only speculations and more experiments are necessary to clarify this 
point. For instance, for the statistics we analyzed only a small number of cells and since 
the thin sections that were cut through the yeast nucleus for electron microscopy analysis 
could either completely miss the nucleolus or cut it in a way that the typical shape is not 
visible, we should enlarge the data set in order to confirm these observation.  
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Conclusions  
The secrets of nature lie very well hidden from the grasp of our senses. We try 
through a continuous cycle of observations/experiments and theories/models to approach 
the truth as much as possible, though the depths of knowledge we can reach are 
unambiguously limited by the tools we use in our quest. This iterative process also 
dictates that we must accept parts of previous knowledge as true, even temporarily, and 
use them as working hypotheses to move forward. Sometimes such hypotheses lurk 
unquestioned for so long that we tend to confuse them with solid facts. Fortunately for 
science (and maybe unfortunately for the frustrated researcher) new tools and new 
approaches sometimes give results which shake the very foundations of these hypotheses. 
The p53-Mdm2 module could not have escaped such fate, since its extreme biological 
significance has been an irresistible temptation for a plethora of scientists, generating 
huge amounts of data at an amazing rate. However, one could argue that the countdown 
for bringing down such dogmas in this field started about one year ago when Krummel 
and colleagues published a paper which has important consequences on our 
understanding of p53 function (Krummel et al., 2005). With their work on transgenic 
mice, these authors showed that the C-terminal lysines believed to be critical to p53 
regulation are instead dispensable, since homozygous mutant mice where the seven C-
terminal lysines were changed to arginines (Trp-53(7KR)) are surprisingly viable and 
phenotypically normal. Their explanation for the discrepancy between their results and 
previous ones is that usually studies on p53 are carried out either in vitro or over-
expressing the protein, therefore in conditions of perturbed stoichiometries between p53 
and its regulators. The work by Krummel and colleagues is not alone in its provocative 
appeal for revisiting the knowledge that has been accumulated over the years on p53 and 
its negative regulator Mdm2 (Brooks et al., 2006). 
In this study we tried an approach which combines advantages of the previous in vivo and 
in vitro studies; a synthetic p53-Mdm2 module was implanted in a eukaryotic organism 
to which it was completely foreign. Thus, the system was allowed to operate “in 
isolation” from other characterized or unknown components, like in vitro, while it 
enjoyed all other luxuries, provisions, but also limitations,  of its more “natural” 
environment, the eukaryotic cell.  The emergent properties of the synthetic network in 
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this context should be affected from the properties of each component much more than in 
the wild type system, since there are no other components or putative alternative 
pathways to buffer the effect. Taking this into consideration, it is not surprising that our 
first attempts were unfruitful, since they were based on previous “facts” about the 
properties of p53 and Mdm2 which are now in question.  
Nonetheless this synthetic approach proved to be a powerful tool since studying the 
properties of the proteins in such isolation emphasized some of their underestimated 
previously described properties (like the sumoylation of p53 by Mdm2) and paves the 
way to clarify certain ambiguities like the effect of sumoylation on p53 degradation or 
localization.  
Furthermore the synthetic system gives rise to a whole new set of issues which might or 
might not be specific for the yeast background. For instance, “is Mdm2 binding to 
telomeres?”, “are p53 and Mdm2 able to trigger the formation of nuclear bodies (NBs) in 
yeast?”, “what is the functional significance of such NBs?”, “is p53 interacting with yeast 
septins?”  
The localization of p53 to the yeast septin ring is an exciting discovery that deserves 
further investigation. Indeed, the fact that SUMO and sumoylated proteins are found at 
the bud neck and that p53 is itself a SUMO substrate, suggests that p53 may directly 
interact with SUMO or with SUMO substrates. Since the localization of sumoylated 
septins to the ring is cell cycle dependent (Johnson et al., 1999), it would be interesting to 
see whether p53 localization to the septin ring follows a similar temporal pattern. It is 
also intriguing to investigate the relation between Mdm2 and the yeast nucleolus 
structure, to assess whether Mdm2 is effectively re-shaping it.  
 
We therefore believe that the synthetic biology approach used in this study provides a 
different but complementary framework that not only helps in re-evaluating the 
relationship between p53 and its regulators, but also unlocks completely new areas of 
research. 
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Strains 
 
Bacterial strains 
All yeast plasmids used in this study can be propagated in E. coli to facilitate cloning. For 
manipulation of constructs until final version – to be transformed in yeast – I used any of 
the following E. coli strains: 
   
XL1-Blue ( recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB lacI
q
Z∆M15 
Tn10(Tet
r
)], stratagene) 
BL21(DE3) (E.coli B F
- 
dcm ompT hsdS(r
B
- 
m
B
-
) gal λ(DE3), stratagene) 
TOP10 (F
- 
mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 deoR recA1 araD139 
∆(ara-leu)7697 galU galK rpsL (Str
R
) endA1 nupG, invitrogen) 
 
Yeast strains 
For the analysis of Mdm2 proteasome-dependent degradation I used the following strains 
(kind gift of Dr. Dieter H. Wolf):  
 
YWO 0607  Mata ura3 leu2-3,112 his3-11,15 Cans Gal+ 
YWO 0612   Mata pre1-1 pre2-2 ura3 leu2-3,112 his3-11,15 Cans Gal+ 
 
For all other experiments described in this thesis I used the strain ESM356-1 (Mata ura3-
53 leu2∆1 his3∆200 trp1∆63, kind gift of Dr. Michael Knop) 
 
Plasmids 
The plasmid pRS314-SN containing wild type p53 gene was a kind gift of Prof. Bert 
Vogelstein. For all experiments with the fusion protein I used this plasmid, in which I 
substituted the original p53 gene with the p53-ECFP fusion gene. For all experiments 
with native p53, I used the pRS314-SN plasmid as a template from which to amplify the 
p53 gene, which I cloned into the yeast vectors p413-GAL/GALS (kind gift of Dr. 
Michael Knop). 
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Mdm2 was amplified using pCDNA3.1-Mdm2 as a template (kind gift of Dr. Gaetano 
Gonzales). I then inserted the mdm2 gene into the yeast vectors p416-GALS/TEF. 
All the p53 and Mdm2 mutants (performed as indicated in the respective references) were 
obtained with the PCR mutagenesis protocol (see below) and therefore remained in the 
same plasmids. 
The plasmid pLPC containing P14ARF was a kind gift of Dr. Gaetano Gonzales. I 
restricted the gene out of this plasmid (BamHI-XhoI) and ligated it into the yeast vector 
p413-TEF. 
Plasmids pEYFP-N1 and pECFP-N1 were a kind gift of Dr. Philippe Bastiaens. I used 
these vectors as templates from which I amplified the ecfp and eyfp genes respectively. 
The plasmid pFLAG-CMV containing the cop1 gene was a kind gift of Dr. Elisabetta 
Bianchi. I restricted the gene out of this plasmid and ligated it into p416-TEF. 
For subcloning I used the plasmids pQE-30, PCM252 and PBluescriptII(+). 
 
Growth media 
The media used to grow E. coli (LB, SOC) were supplied by the European Molecular 
Biology Laboratory. S. cerevisiae cultures were grown in synthetic complete (SC) media, 
lacking one or more amino acids for maintenance of plasmids, with 2% raffinose in order 
to have a full response when adding galactose for gene expression induction. The 
materials and the recipe to prepare the SC medium are the following:  
 
Materials  
Yeast nitrogen base without amino acids but with ammonium sulfate (YNB) 
Drop out powder 
 
Protocol 
For 1 L of medium, mix 6.7 g of YNB and 2 g of drop out powder in 700 ml of water. 
Stir for 20 min. Sterilize, add 100 ml of 20% raffinose (filter-sterile), top up to 1 L with 
water, filter again.   
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Yeast transformants were plated on SC plates with 2% glucose, which I prepared 
according to the following recipe:  
 
Materials 
YNB 
Drop out powder  
Agar 
 
Protocol 
For 1 L, mix 6.7 g of YNB with 2 g of drop put powder in 400 ml of water. Stir for 20 
min. At the same time, add 20 g of Agar to 500 ml of water and stir for 20 min. 
Autoclave, then mix the two solutions, add 100 ml of 20% glucose, add water to reach 1 
L final volume, mix well and pour plates.  
 
Cultivation conditions 
E. coli 
E. coli strains were cultivated in LB medium at 37°C. Recombinant clones were selected 
in LB plates supplied with 100µg/ml Ampicilline.  
 
S. cerevisiae 
Wild type S. cerevisiae strains were grown in YEPD medium or plates at 30°C. 
Transformants were grown in SC + 2% raffinose medium or SC plates + 2% glucose. For 
pre-cultures, a medium size yeast colony was picked and transferred to 50 ml medium 
and grown at 30°C overnight. Cultures were grown on shakers at 230 rpm.  
 
Freezing and storage of yeast strains 
Yeast cells were scraped from a plate and were suspended into 1 ml of (sterile) 15% 
glycerol in water. The suspension was vortexed, immerged into liquid nitrogen and then 
stored at -80°C.  
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Galactose induction of protein expression 
Strains carrying plasmids were cultivated at 30°C on a shaker at 230 rpm O.N. Cultures 
were diluted in the morning to an OD600 of 0.5. When the cells reached an OD600 of about 
1.5, galactose was added to a final concentration of 0.006%, 0.5% or 2% depending on 
the downstream application. Cells were incubated typically for 1-2 hours before glucose 
to a final concentration of 3% was added to stop gene expression from the Gal promoter. 
Alternatively, cycloheximide was added to the medium to a final concentration of 100 
µg/ml. 
 
DNA and RNA isolation 
Small scale plasmid DNA isolation from E. coli strains (minipreps) 
5 ml of LB culture were grown O.N. at 37°C. Cells were harvested and minipreps were 
performed using the Qiagen MiniPrep Kit following the manufacturer’s 
recommendations, with the following differences:  
-the optional wash with PB was always done;  
-the DNA was always eluted adding 40 µl of water to the column, waiting 5 minutes 
and finally centrifuging at top speed.  
 
Isolation of RNA from S. cerevisiae 
 
Total RNA extraction was performed according to the following protocol: 
 
Materials  
Citrate buffer 
1.2 M sorbitol, 20 mM K2HPO4, 1 mM EDTA; pH 5.8 
Denaturing solution 
250g Guanidinthiocyanate, 293 ml DEPC-water, 24,6 ml 10% Sarkosyl, 17,6 ml 0,75 M 
sodium citrate, pH 7,0; heated at 65°C for dissolving 
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Protocol 
O.N. cultures were harvested at 3-5K rpm for 5 min at 4°C and put on ice. Cells were 
resuspended in 10 ml citrate buffer, incubated with 1-5 mg/ml of Lytic enzyme (ISN) for 
20-30 min at 37°C, and spun down at 5K rpm for 5 min at 4°C. Secondly, the cell were 
broken by suspending in 5 ml of denaturing solution and 5 ml of DEPC water, vortex for 
1 min. Then 0.5 ml of 2M Na-acetate (pH 4,0), 5 ml phenol, and 1ml 44 
CHCl3/Isoamylalcohol (24:1) were added, this solution was vortex vigorously for 10 sec 
and placed on ice for 15 min. After centrifugation at 10K rpm for 20 min at 4°C the 
aqueous phase was pulled off to a fresh tube and precipitated with 5 ml of Isopropanol at 
–20 °C overnight. On the next day, the nucleic acids were centrifuged at 10K rpm for 20 
min at 4°C. The pellet was washed with 80 % Ethanol, spun down at 10K rpm for 5 min, 
dried in a Speed-Vac as short as possible and dissolved in 300 µl of DEPC-water.  
 
Isolation of DNA from Agarose gels 
DNA was extracted from agarose gels cutting the band(s) at the appropriate size(s) and 
Qiagen Gel Extraction Kit was used to purify the DNA. Sometimes, to obtain purer 
DNA, ethanol precipitation was also used (see below). 
 
Ethanol precipitation to purify DNA 
The volume was adjusted to 100 µl in water. 1 µl glycogen (1µg) and 10 µl 3M NaAcO 
pH 5.5 were added and the solution vortex to mix well. 330 µl of pure EtOH were added, 
the solution vortex and then was frozen in liquid nitrogen. After spinning for 10 min at 
maximal speed (in a table-top centrifuge), the supernatant was carefully removed and 
washed once with 600 µl of 70% EtOH, which was completely removed. The pellet was 
finally resuspended in 10 µl of water.  
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DNA in vitro recombination methods 
Restriction Enzyme Digestions of plasmids and PCR products 
Purified plasmids or PCR products were digested with restriction enzymes to create 
appropriate cohesive ends for DNA ligation. Restriction enzymes were used in the 
appropriate salt buffers and under the conditions recommended by the manufacturers. 
The total reaction volume was always 50 µl and 2 µl of enzyme was used (total amount of 
glycerol in the reaction was always kept below 5% of final volume) when digestion was 
needed for further cloning or 0.5 µl when digestion was used to check for positive clones 
after ligation. Whenever possible, double digestions were performed (for this purpose, the 
NEB catalogue was consulted for compatibility of restriction enzymes), otherwise 
sequential digestions were performed according to the NEB recommendations. 
Incubations were generally carried out at 37˚C for 3 hours (for 1 hour when digestion was 
used to check positive clones after ligation). Digested species were purified either by 
agarose gel electrophoresis or by using the Qiagen PCR purification kit to remove small 
cleaved DNA fragments (see below). Plasmid dephosphorylation was avoided to increase 
efficiency of ligation when the restriction enzymes used produced non-compatible sticky 
ends (therefore likelihood of plasmid self-ligation is low).  
 
Plasmid-insert ligations 
During the course of this study, I tried many different protocols for ligations, eventually 
settling for O.N. ligation at 16°C (using a PCR machine). The final reaction volume was 
always 20 µl and contained 2 µl of ligase buffer (supplied with the enzyme), 1 µl of 
bacteriophage T4 DNA ligase (Roche), 2 µl of cut vector, 5 µl of cut insert and 10 µl of 
water.  The following day, 10 µl of this reaction mixture were transformed using 20 µl of 
E. coli competent cells (to increase ligation efficiency, sometimes ethanol precipitation to 
purify the DNA was used prior to transformation, see above).  The control ligation of the 
vector without the insert was always performed as an indication of restriction efficiency 
(the vector was not dephosphorylated whenever the used restriction enzymes produced 
incompatible sticky ends).   
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Enzymatic reaction clean-up  
Products of restriction reactions were purified using the Qiaquick PCR purification kit, 
following the manufacturer’s protocol for enzymatic reaction clean-up, when the 
restriction yielded undesirable fragments smaller than 80 bp. When the undesired 
products were higher than 80 bp the desired products were separated by preparative 
agarose gels and purified with the Qiagen gel-extraction kit.  
 
 
Polymerase chain reaction (PCR) (Kleppe et al., 1971; Saiki et al., 1985) 
The Polymerase Chain Reation (PCR) was used for amplifying DNA fragments, creating 
fusion genes, screening bacterial colonies for constructs and for mutagenesis. In all 
applications the final volume of the reaction mixture was 50 µl, containing 3 µl of 10 
mM solution of each primer and 1µl of 10 mM dNTP mix. PCR screening was carried 
out using 0.2 units of Taq polymerase, whereas for the remaining applications 1-2 units 
of Pwo polymerase were used.  
 
DNA amplification  
The desired DNA fragments were amplified using 10-50 ng of template, for plasmid-
borne templates, or by lysing a single bacterial colony, by boiling at 98°C for 5 min in 
water, for genomic templates. When the primers in use introduce a restriction site, extra 
bases are added to the 5’ end of the primer to facilitate restriction. The exact number of 
these bases is specified for each restriction enzyme by its manufacturer (NEB). The 
procedure followed was:  
• Heating at 97°C for 2 min (the polymerase is added at the end of these 2 min 
when hot-start is needed) ; 
• Denaturation at 97°C for 30 sec; 
• Annealing at 2°C below the lowest melting temperature of the primers, as 
calculated by the manufacturer (Sigma); 
• Elongation at 72°C for X min where X is the size of the desired fragment in kb. 
For fragments smaller than 1 kb the time used was 1 min.  
• Final elongation at 72°C for 8 min.  
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• Cooling at 4°C 
 
The number of denaturation-annealing-elongation cycles was between 20 and 30 (the 
number of cycles was kept low to avoid introducing mutations and increased only when 
the PCR yield was insufficient for cloning purposes).  
 
Fusion gene construction 
Constructs which are the fusion of two DNA fragments were built as follows:  
Each fragment was amplified for 10 cycles (if it was plasmid-borne) or for 30 cycles (if it 
came from genomic DNA). The primers used were such that the 3’ reverse primer of the 
first fragment contained a complementary sequence to the 5’ forward primer of the 
second fragment, marking the fusion of the two fragments (Figure 5.1). The overlap was 
such that the melting temperature was quite high (above 63°C).  
 
 
 
Figure 5.1 | Fusion of two genes by PCR. The two genes are amplified by using a 3’ 
primer for the first gene and a 5’ primer for the second one that contain the sequence at 
the fusion point and are complementary to each other. When the products of the two PCR 
reactions are mixed, under PCR conditions, the top strand of the first reaction will 
hybridize to the bottom strand of the second and the gaps will be filled-in by the 
polymerase leading to the full-length desired product. Including the external 5’ and 3’ 
primers (single colour rectangles) results in amplification of the latter product. Adapted 
from (Michalodimitrakis, 2005) 
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Aliquots from both reaction mixtures were directly mixed in a new tube, with fresh 
dNTPs, polymerase and the 5’ forward primer of the first fragment and the 3’ reverse 
primer of the second. The aliquots were such that the ratio of the aliquots’ volume was 
roughly within the range of the ratio of the sizes of the two fragments.  
 
In all applications PCR products were cleaned using the Qiaquick PCR purification kit 
(Qiagen), except when there were by-products. In those cases the desired product was 
purified by gel-extraction, after agarose gel electrophoresis, using the Gel-Extraction kit 
(Qiagen).  
 
Mutagenesis 
To create all point mutations used in this study I used the Quickchange site-directed 
mutagenesis (Stratagene). The reactions were always carried as indicated by the 
manufacturer.   
  
 
DNA sequencing of PCR products 
Once positive clones for ligation were obtained, constructs were sequenced by the EMBL 
Genomics Core Facility to make sure that the sequence of the insert was correct.   
 
Agarose gel electrophoresis 
Agarose gels were made with 0.8% - 2% (w/v) agarose in 25-50 ml TBE buffer. The 
percentage of agarose used depended on the size of the DNA fragments, although for 
preparative gels, 0.7% agarose was preferred in order to minimize the amount of agarose 
in the sample during the gel-extraction procedure. 2.5 µl of ethidium bromide solution 
(10 mg/ml) were added per 50 ml agarose gel. DNA samples were loaded with 6 µl non-
denaturing DNA loading buffer. Gels were run at a constant current of 60 mA, in TBE 
buffer, for between 40 minutes and 1.5 hours. DNA was visualised by ethidium bromide 
fluorescence under ultraviolet (UV) illumination at 260 nm.  
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Transformation methods 
 
Transformation of E. coli 
Tubes were pre-chilled on ice for 20 min. The appropriate number of aliquots of 
competent cells was thawed on ice for 15 min. When the cells were thawed, few 
microliters of plasmid(s) were added to the cells and the tubes were left on ice for 30 min. 
Heat-shock was performed for 45 sec in a pre-warmed bath at 42°C. Tubes were put back 
on ice for 2 min. 1 ml of warm SOC medium was added to each tube and the culture 
grown for maximum 1h at 37°C. Finally, cells were plated on appropriate selection 
plates. When transforming a ligation product, cells were spun down (at maximal speed) 
so to remove 800 µl circa of supernatant. The remaining 200 µl were plated.  
 
Transformation of S. cerevisiae 
If aliquots of competent cells were not available, I first made fresh aliquots using the 
following protocol:  
 
Heat-shock competent S. cerevisiae cells 
 
Materials 
LiSorb 
100 mM LiOAc, 10 mM TRIS pH 8, 1 mM EDTA pH 8, 1 M Sorbitol (MERCK). Filter-
sterilize 
Carried DNA (Salmon Sperm) 
 
Protocol 
5 ml of YPD were inoculated with a single colony and incubated at 30°C on a shaker for 
12 to 16 hours. This pre-culture was then diluted to a final concentration of OD600 0.15 
in a final volume of 100 ml. The cells were grown at 30°C until OD600 was 0.5-0.7. 
They were then harvested at RT for 3 min at 2200 rpm, washed once with 0.1-0.5 volume 
of sterile water and once with 0.1-0.2 volume of LiSorb (always at RT). Supernatant was 
completely removed (to get rid of the LiSorb) and the pellet resuspended in a total 
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volume of 360 µl of LiSorb and 40 µl of carrier DNA (previously denaturated for 10 min 
at 99°C and cooled on ice for 3 min). The cell suspension was aliquoted in 50-100 µl 
fractions and directly stored at -80°C (knop et al., 1999). 
 
Transformation 
 
Materials  
LiPEG 
100 mM LiOAc, 10 mM TRIS pH 8, 1 mM EDTA pH 8, 40% PEG 3350. Filter-sterilize 
 
Protocol 
Competent cells in 50 µl aliquots were thawed on ice and typically 2 µl of DNA were 
added mixing well (snipping the tube). After waiting 2-3 min with the cells on ice, a 6 
fold volume of LiPEG was added and the cells were well mixed and let incubate at RT 
for 30 min. The heat shock was performed in a water bath at 42C for 15 min. The cells 
were then washed once with water (spinning for 3 min at 2000 rpm at RT), sedimented 
with centrifugation, resuspended in 200 µl of water and plated on plates with SC-media 
lacking the appropriate amino acid or base. Plates were incubated at 30°C for two days, 
and transformants streaked out as single colonies. After two days one single, well 
growing colony was streaked out as a patch, frozen and stored at -80°C.  
 
 
Protein analyses  
 
Poly-Acrylamide Gel Electrophoresis under denaturing conditions (SDS-PAGE)  
 
Materials  
Loading buffer 2x (8ml)  
100 mM NaPi pH 6.8, 6M Urea, 5% SDS, 1 mM EDTA, Bromphenol Blue (a dash), 1.5 
% (w/v) DTT was freshly added prior to use 
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Running Buffer 10x (1L)  
Tris 30.2 g, glycine 188 g, SDS 10g, H
2
O up to 1L 
 
Protocol 
Criterion pre-cast gels (Biorad) Tris-HCl (7.5% or 15%, dependently on the size of the 
proteins) were loaded with the samples, then run at constant 170 V for approximately 1h.  
Visualization of the proteins was done with Western Blotting.  
 
 
Western Blotting  
 
Materials  
Transfer buffer 10x without EtOH (1L)  
Trizma 30 g, glycine 144 g 
Transfer buffer 1x +EtOH (1L)  
Transfer buffer 10x 100 ml, EtOH 200 ml, H
2
O up to 1L 
PBS (obtained from the European Molecular Biology Laboratory) 
PBST(1L)  
PBS 1L, Tween 20 50 µl (0.05%) 
 
Protocol  
Western Blots were performed using the Criterion Blotter system from Biorad, according 
to the manufacturer’s instructions. However, optimal transfer conditions were constant 
current at 380 mA for 30 min. After the transfer, the nitrocellulose membrane was 
washed with water and stained with Ponceau S Solution (Sigma), in order to visualise the 
total amount of protein in each lane. Background staining was removed by washing with 
de-ionised water. The membrane was then scanned with an Agfa Duoscan f40 scanner or 
a photocopy was made. The stain was subsequently removed by washing with PBS. The 
membrane was blocked at RT for 1h with 5% milk in PBST and then exposed to the 
primary antibody for 1h at RT and to the secondary antibody, which is for 45 min. Each 
step with an antibody was followed by four 10 min washes with PBST. After the final 
wash, GFP bands were visualised with the ECL Western blotting analysis kit from 
Amersham Biosciences and the exposed films were scanned.  
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Blots quantification 
Using Adobe Photoshop, a rectangular area was define into each band to quantify and the 
corresponding mean intensity obtained through the function “Histogram”. To this number 
the background – calculated in the same way – was subtracted.  
 
Stripping blots 
 
Materials 
Stripping buffer 
100 mM TRIS/HCl pH 6.8, 2% SDS, βME 0.007 v.v or 143x 
 
Protocol 
Antibodies were stripped from the membranes through incubation of the latter ones in 
stripping buffer, at 60°C for 30 min. The membranes were then washed 6 times with PBS 
1x to get rid of the stripping buffer. At this point, normal western blot procedure was 
carried on, starting from the blocking step (see western blot procedure paragraph in this 
chapter) 
 
Analysis of protein turnover in yeast cells  
 
Material 
HU buffer 
100 mM NaPi pH 6.8, 6M Urea, 5% SDS, 1 mM EDTA, Bromphenol Blue (a dash), 1.5 
% (w/v) DTT was freshly added prior to use 
 
Protocol 
Cells were grown and induced following the previously described procedures. Samples 
were collected at different time points (typically, one sample right before addition of 
galactose – referred to as BI – one sample when glucose is added to stop induction – 
referred to as time 0’ since from this moment on the protein’s levels are followed – and 
once every hour, for up to 3-6 hours). Sample collection was done adding 150 µl of 1.85 
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M NaOH + 7.5 % βME to 1 ml of culture and throwing the tube into liquid nitrogen. 
When all samples were collected, they were thawed on ice. To precipitate proteins, 150 
µl of 55% TCA were added to each sample and tubes were kept on ice for 10 min. They 
were then spun down for 5 min at maximal speed in a cold centrifuge and the supernatant 
completely removed. Pellets were resuspended in HU buffer, heated at 65C for 10 min, 
spun down 5 min at RT. Equal amounts of samples were analysed by SDS-PAGE 
followed by Western Blotting.  Remaining volumes of samples were stored at -20°C for 
at least one repetition of the western blotting analysis.  
 
Purification of 6xHIS-tagged proteins 
 
Materials 
 
Binding Buffer 
50 mM TRIS/HCl, 100 mM NaCl, 20 mM imidazole, 1 mM DTT, (8M urea if purifying 
under denaturing conditions), pH 8.0 
Washing Buffer 
50 mM TRIS/HCl, 100 mM NaCl, 50 mM imidazole, 1 mM DTT, (8M urea if purifying 
under denaturing conditions), pH 8.0 
Elution Buffer 
50 mM TRIS/HCl, 100 mM NaCl, 300 mM imidazole, 1 mM DTT, (8M urea if purifying 
under denaturing conditions), pH 8.0 
 
Depending on whether the buffers contained or not 8M urea, the purification was done 
under denaturing or native conditions respectively. 
 
Protocol 
2 L yeast culture was grown and induced as previously described (see normal growth and 
galactose induction of proteins paragraphs in this chapter), except that induction was 
carried on for 3 hours in order to have more protein for the purification step. Cells were 
then centrifuged at 4000 rpm for 10 min, washed with PBS + 0.5 mM PMSF at RT and 
Chapter Five Materials and Methods 
 138
transferred to a 50 ml Falcon tube. Lysis buffer was added to have a final volume of 25 
ml to which an equal volume of glass beads was added. The suspension was poured into a 
planet mill beaker and cells were spun at 350 rpm 3 times, each time for 3 min. The cell 
lysate was then first centrifuged in a 50 ml Falcon tube at 4000 rpm for 10 min, then the 
supernatant was poured into an ultracentrifuge tube and ultracentrifuged for 1 h at 33.500 
rpm. For the purification, the lysate was filtered through a 0.22 µm filter, then loaded on 
a Ni-NTA column, which was pre-equilibrated with 5 volumes (respect to the column 
volume) of Binding Buffer. The column was washed with 10 volumes of Washing Buffer 
and elution was done with Elution Buffer. Protein concentration was estimated by the 
Bradford method using BSA as a standard and a gel was run with the elution fractions to 
analyse the purification result.  
 
 
Immunofluorescence  
 
Materials 
KPi buffer 
1M KPi pH 6.5, 0.5 mM MgCl2 
SP buffer 
3M Sorbitol, 100 mM KPi pH 6.5, 0.5 mM MgCl2 
SPβ buffer 
SP with 14 µl βME for 10 ml of SP (added fresh) 
Mounting medium 
55% Glycerol in PBS with 0.5 µg/ml of DAPI or Hoechst 
 
Protocol 
Cells were grown O.N.. When OD600 reached 0.5-1, induction of proteins was triggered 
adding galactose to a final concentration of 2%. Induction was done for 1 or 2 hours. 40 
ml of cells were fixed at RT for 90 minutes (with occasional inversions of the tubes) 
adding 5 ml of KPi buffer and 5 ml of 37% Formaldehyde (Sigma). Cells were 
subsequently washed 3 times in 1 ml of SP buffer (cells were transferred to 1.5 ml tubes 
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after the first wash). Centrifugations were carried out at 1500 RPM for 3-5 min. Cells 
were always resuspended by spinning the tube. Cells were then digested for 75 min at 
30°C on a roller in 1 ml of SPβ buffer with 200 µg/ml of Zymolyase 100 T (added from 
stock: 10 mg/ml in SP, stored at -20C). To recognize properly digested cells, 5 µl of 
sample were observed under the microscope to see whether more than 80% of the cells 
no longer showed phase contrast. Cells were washed 3 times in SP buffer and finally 
resuspended in 0.5 ml SP buffer with 2 mM PMSF (from stock: 200 mM in DMSO). 
Slides were prepared coating each well with ca. 100 µl of Polylysine 0.1% for 5 min 
followed by 5 washes with water. 35-50 µl of cells were added to each well and let settle 
for 20 min in a humid chamber in the cold. Cells are then aspirated using a 0.2 ml tipp 
and a vacuum pump. 10-15 µl of PBS-1%TX100 are added to each well and let incubate 
for 1 min. This step was repeated once. Cells were washed 3-5 times with PBS-1%BSA. 
Cells were incubated in PBS-1%BSA for 40 min at RT, followed by incubation with the 
primary antibodies (diluted in PBS-1%BSA) for 2 hours in a humid chamber. Cells were 
then washed 5 times with PBS. Incubation with secondary antibodies (always diluted in 
PBS-1%BSA) was performed for 1 hour in a humid chamber. Cells were washed 5 times 
with PBS-1%SBA, 3 times with PBS (letting two of the three washing solutions for 5 min 
on the wells). PBS was carefully aspirated from the wells and 3.5 µl of mounting medium 
were added to wells, after letting them dry for 3 min. A coverslip was glued to the slide 
using nail polish and slides were stored at -20°C for successive analysis.  
 
In vivo staining of the yeast nucleus 
 
Materials 
Höechst 33352 (5 ng/ml) 
 
Protocol 
Höechst 33352 was added directly into the cell culture and incubated for 5 min before 
imaging the cells. 
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Microscopic techniques 
For live cells imaging, cells were adhered with Concavalin A on small glass bottom Petri 
dishes (MaTek). All live cell experiments were performed at RT. Live cell imaging was 
performed on an imaging system (DeltaVision Spectris; Applied Precision) equipped 
with CFP, YFP, Cy3 filters (Chroma Technology Corp.), a 10x NA 1.4 oil immersion 
objective (plan Apo, IX70; Olympus), softWorRx software (Applied Precision), and a 
CoolSNAP HQ camera. ImageJ software was used to mount the images and to produce 
merged colour images. No image manipulations other than brightness adjustment were 
used. For certain fluorescence images, always stacks encompassing at least the thickness 
of the cell nucleus were recorded (spacing 0.5 µm). Maximum projections of the 
fluorescence images were generated, coloured and sometimes superimposed with the 
phase-contrast image using ImageJ software. 
 
 
Electron microscopy 
 
Immunolabelling  
 
Materials  
Blocking buffer 
1.5% BSA + 0.1% Fish skin gelatin in PBS 
Antibodies 
rabbit polyclonal Mdm2 (H-221), mouse anti-rabbit linker antibody 
Protein A Gold 10nm 
 
Protocol 
Yeast cells were high pressure frozen, lowicryl embedded and sections prepared. Non-
specific binding sites were blocked by incubating sections with blocking buffer for 15 
min. Sections were then rinsed in blocking buffer 3x 10 min each. Incubation with 
primary antibody went on for 30 min, then non-reacted primary antibody was removed 
with 10 min washes with PBS. Sections were then incubated on mouse anti-rabbit 
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antibody for 20 min.  Sections were washed with PBS for 10 min with PBS. Sections 
were then incubated with Protein A Gold 10nm for 20 min and then rinsed in blocking 
buffer and PBS for 1 h total. Sections were fixed in 1% glutaraldehyde in PBS for 5 min, 
rinsed with water and stained with UAc, PbCi. Grids were placed section down onto 
droplets of 1 part 1% (v}v) aqueous uranyl acetate and 9 parts 2% (v}v) aqueous olyvinyl 
alcohol (MW 10000, Sigma) solution for 10 min on parafilm and air dried after removal 
of excess solution. Sections were then viewed and photographed with a transmission 
electron microscope. 
 
 
Antibodies 
All the antibodies used in this study are listed here: 
 
Primary Antibodies 
Mono- and poly ubiquitylated proteins, multi ubiquitin chains, mouse mAb (clone FK2), 
BIOMOL international, LP 
p53 (FL-393), agarose conjugated, rabbit polyclonal, Santa Cruz biotech 
p53 (DO-1), mouse monoclonal, Santa Cruz biotech  
p53 (Pab 1801), mouse monoclonal, Santa Cruz biotech 
p53 (N-19), goat polyclonal, Santa Cruz biotech 
Mdm2 (H-221), rabbit polyclonal, Santa Cruz biotech 
Mdm2 (SMP14), mouse monoclonal, Santa Cruz biotech 
PCAF (H-369), rabbit polyclonal, Santa Cruz biotech 
COP1, rabbit polyclonal, BIOMOL 
P14ARF (ab3642), rabbit polyclonal, abcam  
UbcH5, rabbit polyclonal, BostonBiochem 
Anti-HIS antibody, kind gift of Dr. Elena Conti 
Anti-FLAG M2 antibody, mouse monoclonal, Sigma 
NOP1, mouse monoclonal, kind gift of Dr. Michael Knop 
Cdc14, rabbit polyclonal, kind gift of Dr. Michael Knop 
tubulin, rabbit polyclonal, kind gift of Dr. Michael Knop 
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PGK, mouse monoclonal, kind gift of Dr. Michael Knop 
Secondary antibodies 
peroxidase-conjugated donkey anti-mouse, Jackson Immuno Reasearch Laboratories 
CY3-conjugated donkey anti-mouse, kind gift of Dr. Michael Knop 
 
 
Reaction network and parameters for the simulation of the models discussed in 
Results Part One 
 
Figure 2.1.1 
In all three cases considered, rates corresponding to reactions of the same type were 
given identical values, such that the same parameter set was used each time, specifying 
constants for all four reaction types (counting forward and reverse reactions). 
 
Parameters: 
Dimerization rate: kon=1e09 M-1s-1 
Dissociation rate: koff=1 s-1  
Monomer modification rate: ka=1e-02 s-1 
Monomer demodification rate: ka=1e-02 s-1 
 
Initial conditions: 600 M molecules, 0 molecules all remaining species.   
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Figure 2.1.2 
Reaction Network for model simulated deterministically (c) and stochastically (e) in 
which B represses its transcription by binding to its own transcription activator AP.  
 
Parameters used for simulation: 
k1=0.1 s-1 (B_mRNA production) 
k2=0.5 s-1 (B production) 
kon=1e09 M-1 s-1 (complex formation) 
koff=0.01 s-1 
kdeg=log(2)/80 s-1 
Initial conditions: 100 AP molecules, 0 molecules for remaining species 
 
Reaction Network for model simulated deterministically (d), stochastically (f) in the case 
in which B oligomerization is considered. B octamer is now the species that binds to the 
transcription factor AP, repressing B transcription.   
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Parameters used for simulation: 
k1=0.1 s-1 (B_mRNA production) 
k2=0.5 s-1 (B production) 
kdeg=log(2)/80 s-1 
kon=1e09 M-1 s-1 (complex formation between B8 and AP) 
koff=0.01 s-1 
kon2=1e06 M-1 s-1 (dimer formation) 
koff2=0.01 s-1 
kon4=1e06 M-1 s-1 (tetramer formation) 
koff4=0.01 s-1 
kon8=1e09 M-1 s-1 (octamer formation) 
koff8=0.1 s-1 
Initial conditions: 100 AP molecules, 0 molecules for remaining species 
 
 
Figure 2.1.3 
 
Reactions considered for the simulation 
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Parameters used for simulation: 
D= 0.8 µm2 s-1 
kon=1e07 M-1 s-1 
koff=1 s-1 
kcat=1 s-1 
kpA=1 s-1 (protein A production) 
kd=1e06 M-1 s-1 (proteins A and B degradation) 
kpB=7e-04 M-1 s-1 (protein B production) 
 
Initial conditions: TF=200 molecules, TFP=TF•Kn=TFP•Ph=A=0 molecules, Kn=Ph=60 
molecules, B=250 molecules 
 
Figure 2.1.4 
Scheme of the model: B can form a complex with its promoter prom, giving B_prom. 
B_prom catalyses the production of B. B degradation occurs by first order decay. 
 
 
Parameter values used for the simulations of the HIGH and LOW cases: 
 
Reactions constants (units) HIGH LOW 
k_on (M-1 s-1) 108 108 
k_off (s-1) 8.3 1.66 
k_prod (s-1) 1 0.2 
k_deg (s-1) 10-2 10-2 
 
 References 
 146
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
 
 References 
 147
 
Kobayashi, K., et al. (2003). Essential Bacillus subtilis genes, Proc Natl Acad Sci U S A, 
100, 4678-83 
 
Smith, H. O., et al. (2003). Generating a synthetic genome by whole genome assembly: 
phiX174 bacteriophage from synthetic oligonucleotides, Proc Natl Acad Sci U S A, 100, 
15440-5 
 
Noireaux, V. and Libchaber, A. (2004). A vesicle bioreactor as a step toward an artificial 
cell assembly, Proc Natl Acad Sci U S A, 101, 17669-74 
 
Martin, V. J., et al. (2003). Engineering a mevalonate pathway in Escherichia coli for 
production of terpenoids, Nat Biotechnol, 21, 796-802 
 
Herrera, S. (2005). Synthetic biology offers alternative pathways to natural products, Nat 
Biotechnol, 23, 270-1 
 
Gilbert, E. S., et al. (2003). A constructed microbial consortium for biodegradation of the 
organophosphorus insecticide parathion, Appl Microbiol Biotechnol, 61, 77-81 
 
Benner, S. A., et al. (2003). Synthetic biology with artificially expanded genetic 
information systems. From personalized medicine to extraterrestrial life, Nucleic Acids 
Res Suppl, 125-6 
 
Hutter, D., et al. (2002). From phosphate to bis(methylene) sulfone: Non-ionic backbone 
linkers in DNA, Helv. Chim. Acta, 85, 27777-2806 
 
Geyer, C. R., et al. (2003). Nucleobase pairing in expanded Watson-Crick-like genetic 
information systems, Structure, 11, 1485-98 
 
Yeger-Lotem, E., et al. (2004). Network motifs in integrated cellular networks of 
transcription-regulation and protein-protein interaction, Proc Natl Acad Sci U S A, 101, 
5934-9 
 
Hartwell, L. H., et al. (1999). From molecular to modular cell biology, Nature, 402, C47-
52 
 
Kashtan, N. and Alon, U. (2005). Spontaneous evolution of modularity and network 
motifs, Proc Natl Acad Sci U S A, 102, 13773-8 
 
Becskei, A. and Serrano, L. (2000). Engineering stability in gene networks by 
autoregulation, Nature, 405, 590-3 
 
Gardner, T. S., et al. (2000). Construction of a genetic toggle switch in Escherichia coli, 
Nature, 403, 339-42 
 
 References 
 148
Becskei, A., et al. (2001). Positive feedback in eukaryotic gene networks: cell 
differentiation by graded to binary response conversion, Embo J, 20, 2528-35 
 
Kobayashi, H., et al. (2004). Programmable cells: interfacing natural and engineered gene 
networks, Proc Natl Acad Sci U S A, 101, 8414-9 
 
Kramer, B. P., et al. (2004). An engineered epigenetic transgene switch in mammalian 
cells, Nat Biotechnol, 22, 867-70 
 
Pourquie, O. (2003). The segmentation clock: converting embryonic time into spatial 
pattern, Science, 301, 328-30 
 
Blatten, C. (2004). Preliminary designs for synthetic chemotactic oscillators, MIT 
Summer Synthetic Biology Competition,  
 
Guido, N. J., et al. (2006). A bottom-up approach to gene regulation, Nature, 439, 856-60 
 
Hooshangi, S., et al. (2005). Ultrasensitivity and noise propagation in a synthetic 
transcriptional cascade, Proc Natl Acad Sci U S A, 102, 3581-6 
 
Pedraza, J. M. and van Oudenaarden, A. (2005). Noise propagation in gene networks, 
Science, 307, 1965-9 
 
Rosenfeld, N., et al. (2005). Gene regulation at the single-cell level, Science, 307, 1962-5 
 
Dublanche, Y., et al. (2006). Noise in transcription negative feedback loops: simulation 
and experimental analysis, Mol Syst Biol, 2, 41 
 
Hooshangi, S. and Weiss, R. (2006). The effect of negative feedback on noise 
propagation in transcriptional gene networks, Chaos, 16, 26108 
 
Elowitz, M. B. and Leibler, S. (2000). A synthetic oscillatory network of transcriptional 
regulators, Nature, 403, 335-8 
 
Atkinson, M. R., et al. (2003). Development of genetic circuitry exhibiting toggle switch 
or oscillatory behavior in Escherichia coli, Cell, 113, 597-607 
 
Fung, E., et al. (2005). A synthetic gene-metabolic oscillator, Nature, 435, 118-22 
 
Chen, M. T. and Weiss, R. (2005). Artificial cell-cell communication in yeast 
Saccharomyces cerevisiae using signaling elements from Arabidopsis thaliana, Nat 
Biotechnol, 23, 1551-5 
 
Ball, P. (2004). Synthetic biology: starting from scratch, Nature, 431, 624-6 
 
 References 
 149
Pomerening, J. R., et al. (2005). Systems-level dissection of the cell-cycle oscillator: 
bypassing positive feedback produces damped oscillations, Cell, 122, 565-78 
 
Naef, F. (2005). Circadian clocks go in vitro: purely post-translational oscillators in 
cyanobacteria, Mol Syst Biol, 1, 2005 0019 
 
Hoffmann, A., et al. (2002). The IkappaB-NF-kappaB signaling module: temporal 
control and selective gene activation, Science, 298, 1241-5 
 
Lewis, J. (2003). Autoinhibition with transcriptional delay: a simple mechanism for the 
zebrafish somitogenesis oscillator, Curr Biol, 13, 1398-408 
 
Takigawa-Imamura, H. and Mochizuki, A. (2006). Predicting Regulation of the 
Phosphorylation Cycle of KaiC Clock Protein Using Mathematical Analysis, J Biol 
Rhythms, 21, 405-16 
 
Tomita, J., et al. (2005). No transcription-translation feedback in circadian rhythm of 
KaiC phosphorylation, Science, 307, 251-4 
 
Guantes, R. and Poyatos, J. F. (2006). Dynamical principles of two-component genetic 
oscillators, PLoS Comput Biol, 2, e30 
 
Wong, W. W. and Liao, J. C. (2006). The design of intracellular oscillators that interact 
with metabolism, Cell Mol Life Sci, 63, 1215-20 
 
Slee, E. A., et al. (2004). To die or not to die: how does p53 decide?, Oncogene, 23, 
2809-18 
 
Sharpless, N. E. and DePinho, R. A. (2002). p53: good cop/bad cop, Cell, 110, 9-12 
 
Kohn, K. W. and Pommier, Y. (2005). Molecular interaction map of the p53 and Mdm2 
logic elements, which control the Off-On switch of p53 in response to DNA damage, 
Biochem Biophys Res Commun, 331, 816-27 
 
Lu, X. (2005). p53: a heavily dictated dictator of life and death, Curr Opin Genet Dev, 
15, 27-33 
 
Liu, G. and Chen, X. (2006). Regulation of the p53 transcriptional activity, J Cell 
Biochem, 97, 448-58 
 
Matoba, S., et al. (2006). p53 regulates mitochondrial respiration, Science, 312, 1650-3 
 
Roger, L., et al. (2006). Control of cell migration: a tumour suppressor function for p53?, 
Biol Cell, 98, 141-52 
 
 References 
 150
Scoumanne, A. and Chen, X. (2006). The epithelial cell transforming sequence 2, a 
guanine nucleotide exchange factor for Rho GTPases, is repressed by p53 via protein 
methyltransferases and is required for G1-S transition, Cancer Res, 66, 6271-9 
 
Jung, E. J., et al. (2006). Myosin VI is a mediator of the p53-dependent cell survival 
pathway, Mol Cell Biol, 26, 2175-86 
 
Lengner, C. J., et al. (2006). Osteoblast differentiation and skeletal development are 
regulated by Mdm2-p53 signaling, J Cell Biol, 172, 909-21 
 
Yu, X., et al. (2006). The regulation of exosome secretion: a novel function of the p53 
protein, Cancer Res, 66, 4795-801 
 
Momand, J., et al. (1992). The mdm-2 oncogene product forms a complex with the p53 
protein and inhibits p53-mediated transactivation, Cell, 69, 1237-45 
 
Fuchs, S. Y., et al. (1998). Mdm2 association with p53 targets its ubiquitination, 
Oncogene, 17, 2543-7 
 
Fuchs, S. Y., et al. (1998). JNK targets p53 ubiquitination and degradation in nonstressed 
cells, Genes Dev, 12, 2658-63 
 
Ganguli, G. and Wasylyk, B. (2003). p53-independent functions of MDM2, Mol Cancer 
Res, 1, 1027-35 
 
Meek, D. W. and Knippschild, U. (2003). Posttranslational modification of MDM2, Mol 
Cancer Res, 1, 1017-26 
 
Leng, R. P., et al. (2003). Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 
degradation, Cell, 112, 779-91 
 
Corcoran, C. A., et al. (2004). The p53 paddy wagon: COP1, Pirh2 and MDM2 are found 
resisting apoptosis and growth arrest, Cancer Biol Ther, 3, 721-5 
 
Dornan, D., et al. (2004). The ubiquitin ligase COP1 is a critical negative regulator of 
p53, Nature, 429, 86-92 
 
Bratsun, D., et al. (2005). Delay-induced stochastic oscillations in gene regulation, Proc 
Natl Acad Sci U S A, 102, 14593-8 
 
Perry, M. E., et al. (1993). The mdm-2 gene is induced in response to UV light in a p53-
dependent manner, Proc Natl Acad Sci U S A, 90, 11623-7 
 
Knippschild, U., et al. (1995). Cell-specific transcriptional activation of the mdm2-gene 
by ectopically expressed wild-type form of a temperature-sensitive mutant p53, 
Oncogene, 11, 683-90 
 References 
 151
 
Lahav, G., et al. (2004). Dynamics of the p53-Mdm2 feedback loop in individual cells, 
Nat Genet, 36, 147-50 
 
Geva-Zatorsky, N., et al. (2006). Oscillations and variability in the p53 system, Mol Syst 
Biol, 2, 2006 0033 
 
Gohler, T., et al. (2002). Specific interaction of p53 with target binding sites is 
determined by DNA conformation and is regulated by the C-terminal domain, J Biol 
Chem, 277, 41192-203 
 
Espinosa, J. M., et al. (2003). p53 functions through stress- and promoter-specific 
recruitment of transcription initiation components before and after DNA damage, Mol 
Cell, 12, 1015-27 
 
Nayak, B. K. and Das, B. R. (1999). Differential binding of NF1 transcription factor to 
P53 gene promoter and its depletion in human breast tumours, Mol Biol Rep, 26, 223-30 
 
Reisman, D., et al. (1993). c-Myc trans-activates the p53 promoter through a required 
downstream CACGTG motif, Cell Growth Differ, 4, 57-65 
 
Boggs, K. and Reisman, D. (2006). Increased p53 transcription prior to DNA synthesis is 
regulated through a novel regulatory element within the p53 promoter, Oncogene, 25, 
555-65 
 
Oda, K., et al. (2000). p53AIP1, a potential mediator of p53-dependent apoptosis, and its 
regulation by Ser-46-phosphorylated p53, Cell, 102, 849-62 
 
Appella, A. a. (2003). Handbook of Cell Signaling, Academic Press,  
 
Jones, S. N., et al. (1995). Rescue of embryonic lethality in Mdm2-deficient mice by 
absence of p53, Nature, 378, 206-8 
 
Montes de Oca Luna, R., et al. (1995). Rescue of early embryonic lethality in mdm2-
deficient mice by deletion of p53, Nature, 378, 203-6 
 
Iwakuma, T. and Lozano, G. (2003). MDM2, an introduction, Mol Cancer Res, 1, 993-
1000 
 
Freedman, D. A. and Levine, A. J. (1998). Nuclear export is required for degradation of 
endogenous p53 by MDM2 and human papillomavirus E6, Mol Cell Biol, 18, 7288-93 
 
Geyer, R. K., et al. (2000). The MDM2 RING-finger domain is required to promote p53 
nuclear export, Nat Cell Biol, 2, 569-73 
 
 References 
 152
Joseph, T. W., et al. (2003). Nuclear and cytoplasmic degradation of endogenous p53 and 
HDM2 occurs during down-regulation of the p53 response after multiple types of DNA 
damage, Faseb J, 17, 1622-30 
 
Lohrum, M. A., et al. (2000). Identification of a cryptic nucleolar-localization signal in 
MDM2, Nat Cell Biol, 2, 179-81 
 
Moll, U. M., et al. (2005). Transcription-independent pro-apoptotic functions of p53, 
Curr Opin Cell Biol, 17, 631-6 
 
Li, M., et al. (2003). Mono- versus polyubiquitination: differential control of p53 fate by 
Mdm2, Science, 302, 1972-5 
 
Liu, L., et al. (1999). p53 sites acetylated in vitro by PCAF and p300 are acetylated in 
vivo in response to DNA damage, Mol Cell Biol, 19, 1202-9 
 
Zhu, Q., et al. (2001). Mdm2 mutant defective in binding p300 promotes ubiquitination 
but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and 
proteolysis, J Biol Chem, 276, 29695-701 
 
Grossman, S. R., et al. (2003). Polyubiquitination of p53 by a ubiquitin ligase activity of 
p300, Science, 300, 342-4 
 
Feng, L., et al. (2005). Functional analysis of the roles of posttranslational modifications 
at the p53 C terminus in regulating p53 stability and activity, Mol Cell Biol, 25, 5389-95 
 
Krummel, K. A., et al. (2005). The C-terminal lysines fine-tune P53 stress responses in a 
mouse model but are not required for stability control or transactivation, Proc Natl Acad 
Sci U S A, 102, 10188-93 
 
Dai, M. S., et al. (2006). Balance of Yin and Yang: ubiquitylation-mediated regulation of 
p53 and c-Myc, Neoplasia, 8, 630-44 
 
Chen, D., et al. (2005). ARF-BP1/Mule is a critical mediator of the ARF tumor 
suppressor, Cell, 121, 1071-83 
 
Brooks, C. L. and Gu, W. (2006). p53 ubiquitination: Mdm2 and beyond, Mol Cell, 21, 
307-15 
 
Li, M., et al. (2004). A dynamic role of HAUSP in the p53-Mdm2 pathway, Mol Cell, 13, 
879-86 
 
Shvarts, A., et al. (1996). MDMX: a novel p53-binding protein with some functional 
properties of MDM2, Embo J, 15, 5349-57 
 
 References 
 153
Stad, R., et al. (2001). Mdmx stabilizes p53 and Mdm2 via two distinct mechanisms, 
EMBO Rep, 2, 1029-34 
 
Badciong, J. C. and Haas, A. L. (2002). MdmX is a RING finger ubiquitin ligase capable 
of synergistically enhancing Mdm2 ubiquitination, J Biol Chem, 277, 49668-75 
 
Sherr, C. J., et al. (2005). p53-Dependent and -independent functions of the Arf tumor 
suppressor, Cold Spring Harb Symp Quant Biol, 70, 129-37 
 
Zhang, Y., et al. (1998). ARF promotes MDM2 degradation and stabilizes p53: ARF-
INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways, Cell, 92, 
725-34 
 
Tao, W. and Levine, A. J. (1999). P19(ARF) stabilizes p53 by blocking nucleo-
cytoplasmic shuttling of Mdm2, Proc Natl Acad Sci U S A, 96, 6937-41 
 
Stott, F. J., et al. (1998). The alternative product from the human CDKN2A locus, 
p14(ARF), participates in a regulatory feedback loop with p53 and MDM2, Embo J, 17, 
5001-14 
 
Dai, M. S. and Lu, H. (2004). Inhibition of MDM2-mediated p53 ubiquitination and 
degradation by ribosomal protein L5, J Biol Chem, 279, 44475-82 
 
Dai, M. S., et al. (2004). Ribosomal protein L23 activates p53 by inhibiting MDM2 
function in response to ribosomal perturbation but not to translation inhibition, Mol Cell 
Biol, 24, 7654-68 
 
Dai, M. S., et al. (2006). Regulation of the MDM2-p53 pathway by ribosomal protein 
L11 involves a post-ubiquitination mechanism, J Biol Chem, 281, 24304-13 
 
Argentini, M., et al. (2001). The contribution of the acidic domain of MDM2 to p53 and 
MDM2 stability, Oncogene, 20, 1267-75 
 
Kawai, H., et al. (2003). Critical contribution of the MDM2 acidic domain to p53 
ubiquitination, Mol Cell Biol, 23, 4939-47 
 
Meulmeester, E., et al. (2003). Critical role for a central part of Mdm2 in the 
ubiquitylation of p53, Mol Cell Biol, 23, 4929-38 
 
Zhang, Y., et al. (2003). Ribosomal protein L11 negatively regulates oncoprotein MDM2 
and mediates a p53-dependent ribosomal-stress checkpoint pathway, Mol Cell Biol, 23, 
8902-12 
 
Takagi, M., et al. (2005). Regulation of p53 translation and induction after DNA damage 
by ribosomal protein L26 and nucleolin, Cell, 123, 49-63 
 
 References 
 154
Gostissa, M., et al. (1999). Activation of p53 by conjugation to the ubiquitin-like protein 
SUMO-1, Embo J, 18, 6462-71 
 
Rodriguez, M. S., et al. (1999). SUMO-1 modification activates the transcriptional 
response of p53, Embo J, 18, 6455-61 
 
Watson, I. R. and Irwin, M. S. (2006). Ubiquitin and ubiquitin-like modifications of the 
p53 family, Neoplasia, 8, 655-66 
 
Fogal, V., et al. (2000). Regulation of p53 activity in nuclear bodies by a specific PML 
isoform, Embo J, 19, 6185-95 
 
Kwek, S. S., et al. (2001). Functional analysis and intracellular localization of p53 
modified by SUMO-1, Oncogene, 20, 2587-99 
 
Muller, S., et al. (2001). SUMO, ubiquitin's mysterious cousin, Nat Rev Mol Cell Biol, 2, 
202-10 
 
Chen, L. and Chen, J. (2003). MDM2-ARF complex regulates p53 sumoylation, 
Oncogene, 22, 5348-57 
 
Gostissa, M., et al. (2003). Regulation of p53 functions: let's meet at the nuclear bodies, 
Curr Opin Cell Biol, 15, 351-7 
 
Jackson, P. K. (2001). A new RING for SUMO: wrestling transcriptional responses into 
nuclear bodies with PIAS family E3 SUMO ligases, Genes Dev, 15, 3053-8 
 
Seeler, J. S. and Dejean, A. (2001). SUMO: of branched proteins and nuclear bodies, 
Oncogene, 20, 7243-9 
 
Minty, A., et al. (2000). Covalent modification of p73alpha by SUMO-1. Two-hybrid 
screening with p73 identifies novel SUMO-1-interacting proteins and a SUMO-1 
interaction motif, J Biol Chem, 275, 36316-23 
 
Seet, B. T., et al. (2006). Reading protein modifications with interaction domains, Nat 
Rev Mol Cell Biol, 7, 473-83 
 
Krek, W. (1998). Proteolysis and the G1-S transition: the SCF connection, Curr Opin 
Genet Dev, 8, 36-42 
 
Liu, Y. C. (2004). Ubiquitin ligases and the immune response, Annu Rev Immunol, 22, 
81-127 
 
Banerjee, A., et al. (1993). The bacterially expressed yeast CDC34 gene product can 
undergo autoubiquitination to form a multiubiquitin chain-linked protein, J Biol Chem, 
268, 5668-75 
 References 
 155
 
d'Azzo, A., et al. (2005). E3 ubiquitin ligases as regulators of membrane protein 
trafficking and degradation, Traffic, 6, 429-41 
 
Dhananjayan, S. C., et al. (2005). Ubiquitin and control of transcription, Essays Biochem, 
41, 69-80 
 
Rotin, D., et al. (2000). Ubiquitination and endocytosis of plasma membrane proteins: 
role of Nedd4/Rsp5p family of ubiquitin-protein ligases, J Membr Biol, 176, 1-17 
 
Panasenko, O., et al. (2006). The yeast CCR4-not complex controls ubiquitination of the 
nascent associated polypeptide complex, J Biol Chem,  
 
Baarends, W. M., et al. (2000). Specific aspects of the ubiquitin system in 
spermatogenesis, J Endocrinol Invest, 23, 597-604 
 
Kikonyogo, A., et al. (2001). Proteins related to the Nedd4 family of ubiquitin protein 
ligases interact with the L domain of Rous sarcoma virus and are required for gag 
budding from cells, Proc Natl Acad Sci U S A, 98, 11199-204 
 
Thrower, J. S., et al. (2000). Recognition of the polyubiquitin proteolytic signal, Embo J, 
19, 94-102 
 
Haglund, K. and Dikic, I. (2005). Ubiquitylation and cell signaling, Embo J, 24, 3353-9 
 
Hochstrasser, M. (2006). Lingering mysteries of ubiquitin-chain assembly, Cell, 124, 27-
34 
 
Eletr, Z. M., et al. (2005). E2 conjugating enzymes must disengage from their E1 
enzymes before E3-dependent ubiquitin and ubiquitin-like transfer, Nat Struct Mol Biol, 
12, 933-4 
 
Reiss, Y., et al. (1989). Binding sites of ubiquitin-protein ligase. Binding of ubiquitin-
protein conjugates and of ubiquitin-carrier protein, J Biol Chem, 264, 10378-83 
 
Rape, M., et al. (2006). The processivity of multiubiquitination by the APC determines 
the order of substrate degradation, Cell, 124, 89-103 
 
Pickart, C. M. (2001). Mechanisms underlying ubiquitination, Annu Rev Biochem, 70, 
503-33 
 
van Nocker, S. and Vierstra, R. D. (1993). Multiubiquitin chains linked through lysine 48 
are abundant in vivo and are competent intermediates in the ubiquitin proteolytic 
pathway, J Biol Chem, 268, 24766-73 
 
 References 
 156
Gumbart, E. C.-C. a. J. (2006). 
http://www.ks.uiuc.edu/Training/CaseStudies/pdfs/ubq.pdf,  
 
Begley, T. P., et al. (1999). Thiamin biosynthesis in prokaryotes, Arch Microbiol, 171, 
293-300 
 
Unkles, S. E., et al. (1999). Eukaryotic molybdopterin synthase. Biochemical and 
molecular studies of Aspergillus nidulans cnxG and cnxH mutants, J Biol Chem, 274, 
19286-93 
 
Huang, D. T., et al. (2004). Ubiquitin-like protein activation, Oncogene, 23, 1958-71 
 
Scheel, H. (2005). Comparative Analysis of the ubiquitin-proteasome system in Homo 
sapiens and Saccharomyces cerevisiae, dissertation,  
 
Szczepanowski, R. H., et al. (2005). Crystal structure of a fragment of mouse ubiquitin-
activating enzyme, J Biol Chem, 280, 22006-11 
 
VanDemark, A. P. and Hill, C. P. (2002). Structural basis of ubiquitylation, Curr Opin 
Struct Biol, 12, 822-30 
 
Jiang, Y. H. and Beaudet, A. L. (2004). Human disorders of ubiquitination and 
proteasomal degradation, Curr Opin Pediatr, 16, 419-26 
 
Dominguez, C., et al. (2004). Structural model of the UbcH5B/CNOT4 complex revealed 
by combining NMR, mutagenesis, and docking approaches, Structure, 12, 633-44 
 
Saville, M. K., et al. (2004). Regulation of p53 by the ubiquitin-conjugating enzymes 
UbcH5B/C in vivo, J Biol Chem, 279, 42169-81 
 
Hoppe, T. (2005). Multiubiquitylation by E4 enzymes: 'one size' doesn't fit all, Trends 
Biochem Sci, 30, 183-7 
 
Hochstrasser, M. (2001). SP-RING for SUMO: new functions bloom for a ubiquitin-like 
protein, Cell, 107, 5-8 
 
Seeler, J. S. and Dejean, A. (2003). Nuclear and unclear functions of SUMO, Nat Rev 
Mol Cell Biol, 4, 690-9 
 
Muller, S., et al. (1998). Conjugation with the ubiquitin-related modifier SUMO-1 
regulates the partitioning of PML within the nucleus, Embo J, 17, 61-70 
 
Johnson, E. S. and Blobel, G. (1999). Cell cycle-regulated attachment of the ubiquitin-
related protein SUMO to the yeast septins, J Cell Biol, 147, 981-94 
 
 References 
 157
Guet, C. C., et al. (2002). Combinatorial synthesis of genetic networks, Science, 296, 
1466-70 
 
Ronen, M., et al. (2002). Assigning numbers to the arrows: parameterizing a gene 
regulation network by using accurate expression kinetics, Proc Natl Acad Sci U S A, 99, 
10555-60 
 
Batt, G., et al. (2005). Validation of qualitative models of genetic regulatory networks by 
model checking: analysis of the nutritional stress response in Escherichia coli, 
Bioinformatics, 21 Suppl 1, i19-28 
 
King, R. D., et al. (2005). On the use of qualitative reasoning to simulate and identify 
metabolic pathways, Bioinformatics, 21, 2017-26 
 
Fall, C. P., et al. (2002). Computational Cell Biology, Springer Verlag, 1st edition, 
Hardcover: 488 pages 
 
Liu, Q. and Jia, Y. (2004). Fluctuations-induced switch in the gene transcriptional 
regulatory system, Phys Rev E Stat Nonlin Soft Matter Phys, 70, 041907 
 
Thattai, M. and van Oudenaarden, A. (2004). Stochastic gene expression in fluctuating 
environments, Genetics, 167, 523-30 
 
Hanggi, P. (2002). Stochastic resonance in biology. How noise can enhance detection of 
weak signals and help improve biological information processing, Chemphyschem, 3, 
285-90 
 
Gillespie, D. T. (1976). General method for numerically simulating the stochastic time 
evolution of coupled chemical reactions, Journal of Computational Physics, 22,  
 
Gillespie, D. T. (1977). Exact stochastic simulation of coupled chemical reactions., J. 
Phys. Chem., 81,  
 
Haseltine, E. L. and Rawlings, J. B. (2002). Approximate simulation of coupled fast and 
slow reactions for stochastic chemical kinetics, J Chem Phys, 117, 6959-6969 
 
Rao, C. V. and Arkin, A. P. (2003). Stochastic chemical kinetics and the quasi-steady-
state assumption: Application to the Gillespie algorithm, J Chem Phys, 118, 4999-5010 
 
Rathinam, M., et al. (2003). Stiffness in stochastic chemically reaction systems: the 
implicit tau-leaping method, J Chem Phys, 119, 12784-12794 
 
Stundzia, A. B., Lumsden, C.J. (1996). Stochastic simulation of coupled reaction-
diffusion processes, J. Comput. Phys., 196–207 
 
 References 
 158
Ander, M., P. Beltrao, B. Di Ventura, J. Ferkinghoff-Borg, M. Foglierini, A. Kaplan, C. 
Lemerle, I. Tomás-Oliveira and L. Serrano (2004). SmartCell, a framework to simulate 
cellular processes that combines stochastic approximation with diffusion and localisation: 
analysis of simple networks, Syst. Biol., 1, 129-138 
 
Alfonsi, A., et al. (2005). Adaptive simulation of hybrid stochastic and deterministic 
models for biochemical systems, CEMRACS 2004, ESAIM Proceedings 2005,  
 
Salis, H. and Kaznessis, Y. (2005). Accurate hybrid stochastic simulation of a system of 
coupled chemical or biochemical reactions, J Chem Phys, 122, 54103 
 
Gitai, Z. (2005). The new bacterial cell biology: moving parts and subcellular 
architecture, Cell, 120, 577-86 
 
Gorlich, D., et al. (2003). Characterization of Ran-driven cargo transport and the 
RanGTPase system by kinetic measurements and computer simulation, Embo J, 22, 
1088-100 
 
Nedelec, F., et al. (2003). Self-organisation and forces in the microtubule cytoskeleton, 
Curr Opin Cell Biol, 15, 118-24 
 
Sawai, S., et al. (2005). An autoregulatory circuit for long-range self-organization in 
Dictyostelium cell populations, Nature, 433, 323-6 
 
Collier, J. R., et al. (1996). Pattern formation by lateral inhibition with feedback: a 
mathematical model of delta-notch intercellular signalling, J Theor Biol, 183, 429-46 
 
Dens, E. J., et al. (2005). Cell division theory and individual-based modeling of microbial 
lag Part I. The theory of cell division, Int J Food Microbiol, 101, 303-18 
 
Wu, D., et al. (2005). Phase synchronization and coherence resonance of stochastic 
calcium oscillations in coupled hepatocytes, Biophys Chem, 115, 37-47 
 
Lemerle, C., et al. (2005). Space as the final frontier in stochastic simulations of 
biological systems, FEBS Lett, 579, 1789-94 
 
Oliner, J. D., et al. (1993). Oncoprotein MDM2 conceals the activation domain of tumour 
suppressor p53, Nature, 362, 857-60 
 
Emmerich, B., et al. (1975). [Proceedings: Susceptibility of endogenous mRNA 
translation to emetine and cycloheximide in cell free systems from plasma cell tumors, 
reticulocytes and liver], Hoppe Seylers Z Physiol Chem, 356, 228 
 
Liang, S. H. and Clarke, M. F. (2001). Regulation of p53 localization, Eur J Biochem, 
268, 2779-83 
 
 References 
 159
Belle, A., et al. (2006). Quantification of protein half-lives in the budding yeast 
proteome, Proc Natl Acad Sci U S A, 103, 13004-9 
 
Honda, R. and Yasuda, H. (2000). Activity of MDM2, a ubiquitin ligase, toward p53 or 
itself is dependent on the RING finger domain of the ligase, Oncogene, 19, 1473-6 
 
Brooks, C. L. and Gu, W. (2004). Dynamics in the p53-Mdm2 ubiquitination pathway, 
Cell Cycle, 3, 895-9 
 
Heinemeyer, W., et al. (1993). PRE2, highly homologous to the human major 
histocompatibility complex-linked RING10 gene, codes for a yeast proteasome subunit 
necessary for chrymotryptic activity and degradation of ubiquitinated proteins, J Biol 
Chem, 268, 5115-20 
 
Inoue, T., et al. (2001). MDM2 can promote the ubiquitination, nuclear export, and 
degradation of p53 in the absence of direct binding, J Biol Chem, 276, 45255-60 
 
Tsien, R. Y. (1998). The green fluorescent protein, Annu Rev Biochem, 67, 509-44 
 
Shimizu, H., et al. (2002). The conformationally flexible S9-S10 linker region in the core 
domain of p53 contains a novel MDM2 binding site whose mutation increases 
ubiquitination of p53 in vivo, J Biol Chem, 277, 28446-58 
 
Huh, W. K., et al. (2003). Global analysis of protein localization in budding yeast, 
Nature, 425, 686-91 
 
Nakamura, S., et al. (2000). Multiple lysine mutations in the C-terminal domain of p53 
interfere with MDM2-dependent protein degradation and ubiquitination, Mol Cell Biol, 
20, 9391-8 
 
Rodriguez, M. S., et al. (2000). Multiple C-terminal lysine residues target p53 for 
ubiquitin-proteasome-mediated degradation, Mol Cell Biol, 20, 8458-67 
 
Kim, Y. H., et al. (1999). Covalent modification of the homeodomain-interacting protein 
kinase 2 (HIPK2) by the ubiquitin-like protein SUMO-1, Proc Natl Acad Sci U S A, 96, 
12350-5 
 
Corboy, M. J., et al. (2005). Aggresome formation, Methods Mol Biol, 301, 305-27 
 
Haslbeck, M., et al. (2005). Disassembling protein aggregates in the yeast cytosol. The 
cooperation of Hsp26 with Ssa1 and Hsp104, J Biol Chem, 280, 23861-8 
 
Weis, K., et al. (1994). Retinoic acid regulates aberrant nuclear localization of PML-
RAR alpha in acute promyelocytic leukemia cells, Cell, 76, 345-56 
 
 References 
 160
Xirodimas, D. P., et al. (2001). Cocompartmentalization of p53 and Mdm2 is a major 
determinant for Mdm2-mediated degradation of p53, Exp Cell Res, 270, 66-77 
 
Fu, L., et al. (2005). Nuclear aggresomes form by fusion of PML-associated aggregates, 
Mol Biol Cell, 16, 4905-17 
 
Markossian, K. A. and Kurganov, B. I. (2004). Protein folding, misfolding, and 
aggregation. Formation of inclusion bodies and aggresomes, Biochemistry (Mosc), 69, 
971-84 
 
Pearson, M., et al. (2000). PML regulates p53 acetylation and premature senescence 
induced by oncogenic Ras, Nature, 406, 207-10 
 
Kurki, S., et al. (2003). Cellular stress and DNA damage invoke temporally distinct 
Mdm2, p53 and PML complexes and damage-specific nuclear relocalization, J Cell Sci, 
116, 3917-25 
 
Johnston, J. A., et al. (1998). Aggresomes: a cellular response to misfolded proteins, J 
Cell Biol, 143, 1883-98 
 
Li, M., et al. (2002). Acetylation of p53 inhibits its ubiquitination by Mdm2, J Biol 
Chem, 277, 50607-11 
 
Bossis, G., et al. (2005). Down-regulation of c-Fos/c-Jun AP-1 dimer activity by 
sumoylation, Mol Cell Biol, 25, 6964-79 
 
Sharp, D. A., et al. (1999). Stabilization of the MDM2 oncoprotein by interaction with 
the structurally related MDMX protein, J Biol Chem, 274, 38189-96 
 
Zeng, S. X., et al. (2003). The acetylase activity of p300 is dispensable for MDM2 
stabilization, J Biol Chem, 278, 7453-8 
 
Feng, J., et al. (2004). Stabilization of Mdm2 via decreased ubiquitination is mediated by 
protein kinase B/Akt-dependent phosphorylation, J Biol Chem, 279, 35510-7 
 
Buschmann, T., et al. (2000). SUMO-1 modification of Mdm2 prevents its self-
ubiquitination and increases Mdm2 ability to ubiquitinate p53, Cell, 101, 753-62 
 
Fuchs, S. Y., et al. (2002). SUMO-1 modification of Mdm2 prevents its self-
ubiquitination and increases Mdm2 ability to ubiquitinate p53, Cell, 110, 531 
 
Chernov, M. V., et al. (2001). Regulation of ubiquitination and degradation of p53 in 
unstressed cells through C-terminal phosphorylation, J Biol Chem, 276, 31819-24 
 
Zhou, B. P., et al. (2001). HER-2/neu induces p53 ubiquitination via Akt-mediated 
MDM2 phosphorylation, Nat Cell Biol, 3, 973-82 
 References 
 161
 
Gu, J., et al. (2002). Mutual dependence of MDM2 and MDMX in their functional 
inactivation of p53, J Biol Chem, 277, 19251-4 
 
Gronroos, E., et al. (2004). YY1 inhibits the activation of the p53 tumor suppressor in 
response to genotoxic stress, Proc Natl Acad Sci U S A, 101, 12165-70 
 
Hochstrasser, M. (1996). Ubiquitin-dependent protein degradation, Annu Rev Genet, 30, 
405-39 
 
Rajapurohitam, V., et al. (2002). Control of ubiquitination of proteins in rat tissues by 
ubiquitin conjugating enzymes and isopeptidases, Am J Physiol Endocrinol Metab, 282, 
E739-45 
 
Desterro, J. M., et al. (1998). SUMO-1 modification of IkappaBalpha inhibits NF-
kappaB activation, Mol Cell, 2, 233-9 
 
Tong, H., et al. (1997). Crystal structure of murine/human Ubc9 provides insight into the 
variability of the ubiquitin-conjugating system, J Biol Chem, 272, 21381-7 
 
Schmidt, D. and Muller, S. (2002). Members of the PIAS family act as SUMO ligases for 
c-Jun and p53 and repress p53 activity, Proc Natl Acad Sci U S A, 99, 2872-7 
 
Goodson, M. L., et al. (2001). Sumo-1 modification regulates the DNA binding activity 
of heat shock transcription factor 2, a promyelocytic leukemia nuclear body associated 
transcription factor, J Biol Chem, 276, 18513-8 
 
Liang, S. H., et al. (1998). Cooperation of a single lysine mutation and a C-terminal 
domain in the cytoplasmic sequestration of the p53 protein, J Biol Chem, 273, 19817-21 
 
Wansink, D. G., et al. (1993). Fluorescent labeling of nascent RNA reveals transcription 
by RNA polymerase II in domains scattered throughout the nucleus, J Cell Biol, 122, 
283-93 
 
Rubbi, C. P. and Milner, J. (2000). Non-activated p53 co-localizes with sites of 
transcription within both the nucleoplasm and the nucleolus, Oncogene, 19, 85-96 
 
Bernardi, R., et al. (2004). PML regulates p53 stability by sequestering Mdm2 to the 
nucleolus, Nat Cell Biol, 6, 665-72 
 
Borden, K. L. (2002). Pondering the promyelocytic leukemia protein (PML) puzzle: 
possible functions for PML nuclear bodies, Mol Cell Biol, 22, 5259-69 
 
Gall, J. G. (2000). Cajal bodies: the first 100 years, Annu Rev Cell Dev Biol, 16, 273-300 
 
 References 
 162
Laroche, T., et al. (2000). The dynamics of yeast telomeres and silencing proteins 
through the cell cycle, J Struct Biol, 129, 159-74 
 
Zhao, J., et al. (2005). MDM2 negatively regulates the human telomerase RNA gene 
promoter, BMC Cancer, 5, 6 
 
Elenbaas, B., et al. (1996). The MDM2 oncoprotein binds specifically to RNA through its 
RING finger domain, Mol Med, 2, 439-51 
 
White, D. E., et al. (2006). Mouse double minute 2 associates with chromatin in the 
presence of p53 and is released to facilitate activation of transcription, Cancer Res, 66, 
3463-70 
 
Gotta, M., et al. (1997). Localization of Sir2p: the nucleolus as a compartment for silent 
information regulators, Embo J, 16, 3243-55 
 
 Original Publications 
 163
Original publications 
 
From in vivo to in silico biology and back 
Barbara Di Ventura*, Caroline Lemerle*, Konstantinos Michalodimitrakis and Luis 
Serrano, Nature 443, 527-533(5 October 2006) 
* these authors contributed equally to this work 
 
Adaptive simulation of hybrid stochastic and deterministic models for biochemical 
systems 
Aurélien Alfonsi, Eric Cancès, Gabriel Turinici, Barbara Di Ventura and Wilhelm 
Huisinga, ESAIM Proceedings 2005 Sept; 14:1-13 
 
Space as the final frontier in stochastic simulations of biological systems 
Lemerle, C., Di Ventura, B. & Serrano, L., FEBS Lett 2005 Mar 21;579(8):1789-94 
 
SmartCell: a framework to simulate cellular processes that combines stochastic 
approximation with diffusion and localisation: analysis of simple gene networks 
Ander, M., Beltrao, P., Di Ventura, B., Ferkinghoff-Borg, J., Foglierini, M., Kaplan, A., 
Lemerle, C., Tomas-Oliveira, I. & Serrano, L., Systems Biology 2004 1 129-139 
 
p53 sumoylation is conserved in budding yeast and correlates with its localization to 
nuclear bodies reminiscent of human PML bodies, manuscript in preparation 
 
